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THESIS ABSTRACT  
Background  
Amongst patients who have chronic disease, the majority have multiple chronic 
diseases (multimorbidity). Because medical evidence and guidelines are structured 
around single diseases, multimorbidity can lead to problems for general practitioners 
(GPs) when prescribing medications. The overarching aim of this thesis is to develop an 
intervention to support patient-centred prescribing in the context of multimorbidity in 
primary care. 
 
Methods 
A range of research methods were used to address different components of the 
Medical Research Council, UK (MRC) guidance on the development and evaluation of 
complex interventions in health care. The existing evidence on GPs’ perceptions of the 
management of multimorbidity was systematically reviewed and synthesized. This was 
supplemented with new evidence by conducting a qualitative interview study and a 
cross-sectional study. In qualitative interviews, chart-stimulated recall was used to 
explore the challenges experienced by GPs when prescribing for multimorbid patients. 
The utility of chart-stimulated recall as a clinical research method was also 
systematically reviewed. In the cross-sectional study, data from the Mitchelstown 
Cohort Study was used to understand the psychosocial issues that can occur with and 
complicate the management of multimorbidity. To develop the complex intervention, 
the Behaviour Change Wheel (BCW) was used to integrate behavioural theory with the 
findings of the systematic review, qualitative interviews and cross-sectional study. A 
feasibility study of the new intervention was then conducted with GPs.  
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Results 
The systematic review revealed GPs’ isolation in decision-making for multimorbid 
patients, which resulted from difficulties in four areas: disorganization and 
fragmentation of health care; inadequacy of guidelines and medical evidence; 
challenges delivering patient-centred care; and barriers to shared decision-making. The 
qualitative interview study showed that GPs responded to these difficulties by 
‘satisficing’: accepting care that they deemed satisfactory and sufficient for a particular 
patient. In multimorbid patients perceived as stable, GPs preferred to ‘maintain the 
status quo’ rather than actively change medications. In the cross-sectional study, the 
significant association between multimorbidity and a range of negative psychosocial 
factors was shown. The findings of these three studies were used to guide the 
development of the ‘Multimorbidity Collaborative Medication Review and Decision-
making’ (MY COMRADE) intervention. This intervention primarily involves peer 
support: two GPs review the medications prescribed to a complex multimorbid patient 
together. In the feasibility study, pairs of GPs reviewed medications using the MY 
COMRADE approach. They reported that the intervention was appropriate for the 
context of general practice; was widely applicable to their patients with multimorbidity; 
and recommendations for optimising medications arose from all collaborative reviews. 
 
Conclusion 
This work responds to the call for interventions to improve patient-centred medication 
management in multimorbidity. Applying theory to empirical data has led to an 
intervention that fits well into clinical practice, and has the potential to positively 
change GPs’ behaviour to support the conduct of medication review for patients with 
multimorbidity.  
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CHAPTER 1. INTRODUCTION 
1.1. Introduction  
Multimorbidity is the co-occurrence of two or more chronic medical conditions in one 
person. In general practice, individual chronic conditions are common: approximately 
one third of Irish adults have a chronic condition such as hypertension, cardiovascular 
disease, diabetes or stroke (1). However, more patients have multimorbidity than even 
the most common individual chronic condition (2, 3). Healthcare systems and clinical 
evidence remain overwhelmingly orientated towards the management of individual 
conditions with relatively few initiatives addressing the reality that the majority of 
people with chronic disease have multimorbidity (4).  
This mismatch can lead to problems in the management of patients with 
multimorbidity in general practice, especially in the management of medications. 
Combining clinical practice guidelines in the treatment of patients with multimorbidity 
can lead to burdensome and even harmful polypharmacy (5). Individual medications 
may be effective for a specific condition, but higher numbers of medications are 
associated with adverse effects, interactions and poor adherence (6).  
Therefore, there is a need for new patient-centred approaches to chronic disease 
management that acknowledge the predominance of multimorbidity. Rather than 
considering diseases in isolation, a patient-centred approach advocates consideration 
of the patient’s illnesses in a whole-person, biopsychosocial context (7). Regarding 
medication management, interventions that support proactive chronic disease care 
while avoiding medication-related harm are required. The question is how to develop 
an intervention which facilitates care that is consistent with the best available evidence 
and tailored to the needs and preferences of the individual patient.  
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The Medical Research Council, UK (MRC) has issued a widely used framework for the 
development of interventions in healthcare (8). This framework advocates using the 
best available (and if necessary, new) evidence and appropriate theory to develop 
interventions. It states that a thorough understanding of existing practice is required 
prior to intervention development and implementation, as inadequate consideration of 
participants’ perspectives or context can diminish an intervention’s clinical impact. If 
information on existing practice is lacking, primary research should be conducted.  
This framework provides a useful starting point for developing interventions to improve 
medication management in multimorbidity because, despite the high prevalence of 
multimorbidity, the specific challenges experienced by general practitioners (GPs) in 
relation to prescribing for these patients, and their responses to those challenges, have 
been poorly described. 
 
1.2. Aim 
The overarching aim of this thesis is to develop an intervention to support patient-
centred prescribing for patients with multimorbidity in general practice. Broadly, this 
involves gaining insights into GPs’ current practice, and then integrating these insights 
with behavioural theory to develop a behaviour change intervention to support and 
improve prescribing.  
 
1.3. Objectives 
Adhering to the phases outlined in the MRC guidance on the development of 
interventions in health care, the specific objectives of this thesis are:  
1. To identify and review the existing evidence on the challenges experienced by GPs 
in the management of patients with multimorbidity.  
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2. To generate new information on the complexities of clinical decision-making for 
patients with multimorbidity in primary care by 
a. exploring the challenges experienced by GPs when prescribing for these 
patients, using case-based data. 
b. examining the social, behavioural and psychological factors that can occur 
with, and complicate the management of, patients with multimorbidity. 
3. To develop an intervention targeted at GPs, by combining behavioural theory with 
evidence gained from objectives 1 and 2, and using the input of an expert panel.  
4. To evaluate the feasibility and implementation of the new intervention in a study 
with GPs. 
 
1.4. Thesis outline 
This thesis contains eleven chapters, six of which are studies that address the aims and 
objectives (Figure 1).  
In Chapter 2, the context for this research, including the role of general practice in the 
Irish healthcare system and recent changes to the landscape of Irish general practice 
are described. 
Chapter 3 provides an introduction to the problem of multimorbidity, and the related 
issues of polypharmacy and clinical practice guidelines. Existing approaches to improve 
medication management in primary care are reviewed.  
Chapter 4 gives an overview of the research methods used in this thesis to address 
different phases of the MRC guidance on the development and evaluation of complex 
interventions in health care. 
Chapters 5, 6, 8, 9 and 10 represent phases of the MRC framework. In Chapter 5, the 
existing evidence on GPs’ perceptions of the management of multimorbidity is 
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systematically reviewed and synthesized. This evidence had not been systematically 
collated prior to this thesis. Chapter 6 describes qualitative research on the 
complexities of clinical decision-making for patients with multimorbidity. Chapter 8 
details new findings on the negative psychosocial factors which can occur with and may 
complicate the management of multimorbidity, and therefore warrant consideration in 
the development of patient-centred interventions. In Chapter 9, the process of 
developing a theory-based intervention is described. Chapter 10 is the feasibility study 
of the new theory-based intervention, which was conducted with GPs. 
Chapter 7 details a scoping review of chart-stimulated recall. This method was used in 
the qualitative interviews in Chapter 6, and its application to clinical research had not 
been systematically reviewed prior to this thesis. 
Chapter 11 provides an overall discussion of the research, including strengths and 
limitations, and makes suggestions for future research and policy implications.
24 
 
  
Figure 1. Thesis outline 
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o Expertise on behavioural science and intervention design, and member of 
expert panel (Chapter 9); second coder for evaluation interviews in feasibility 
study (Chapter 10) 
 Professor Stewart Mercer, Chair in Primary Care Research, University of Glasgow, 
Scotland 
o Expertise on intervention development in multimorbidity and member of 
expert panel (Chapter 9)  
 Dr Martin Duerden, Senior Clinical Lecturer in Health Technology Assessment, 
Centre for Health Economics and Medicines Evaluation, Bangor University, Wales 
o Expertise on clinical pharmacology and prescribing in multimorbidity and 
member of expert panel (Chapter 9)  
 Dr Rupert Payne, Clinical Lecturer in General Practice, University of Cambridge 
o Expertise on clinical pharmacology and prescribing in multimorbidity and 
member of expert panel (Chapter 9) 
 
1.6. Author’s professional role  
I conducted the research for this thesis in tandem with GP training, as a fellow on the 
National Specialist Registrar Academic Fellowship Programme (NSAFP). The fellowship 
spanned five years during which I completed my final two years of GP training (on a 
part-time basis over four years) while simultaneously gaining training in and conducting 
27 
 
research for a PhD degree. As a GP trainee, my GP training practices were Killenaule 
Family Practice, Co. Tipperary (three days a week over six months); Ardmore Health 
Centre, Co. Waterford (three days a week over one year); and the Rowe Creavin 
General Practice, Waterford city (two days a week over two years). When not in 
practice, I was based in the Department of General Practice, University College Cork. I 
conducted the qualitative interview study and the feasibility study in GP practices in 
Cork and surrounding counties between 2013 and 2015. Overall, twenty seven 
practices and thirty five GPs participated. I used data from the Mitchelstown Cohort 
Study for the cross-sectional paper. This study recruited a representative sample of 
over two thousand middle-aged adults from a single large primary care centre in 2010.  
The funders of the NSAFP (the Health Service Executive and the Health Research Board 
of Ireland) and the funders of the Mitchelstown Cohort Study (the Health Research 
Board of Ireland) had no influence or input into the conduct of the research or study 
findings. 
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CHAPTER 2. MAPPING THE TERRAIN: THE CONTEXT FOR THIS RESEARCH  
This research is based in primary care, specifically the setting of general practice. 
Healthcare systems with strong primary care have better health outcomes for patients 
with chronic illness, at a lower cost and with less health inequality (9). There are 
multiple professionals involved in medication management (e.g. GPs, pharmacists, 
specialists, practice nurses etc.), but as GPs are the most commonly seen physician for 
patients with multimorbidity (9), I focus on the perspective and role of the GP.  
In this chapter, I describe briefly the context for the research that follows: the role of 
primary care and general practice in the Irish healthcare system, and changes that have 
occurred in the landscape of Irish general practice since I commenced this thesis in 
2012. 
 
2.1. Government policy on primary care in the Irish health system 
In 2001, the Irish government publication “Primary Care: A New Direction” 
acknowledged the central role of primary care in the Irish health service (10). It 
outlined a vision for primary care services whereby the health of the population is 
managed, as far as possible, within a primary care setting. In 2013, the government’s 
framework for achieving a “Healthy Ireland” was also aligned with this approach (11).  
Current government strategies promote the expansion of chronic disease prevention 
and management in primary care, with a specific emphasis on diabetes, chronic 
respiratory disease and heart failure. These strategies include the recent launch of 
integrated care programmes for chronic disease, implementation plans for activity 
based funding and the establishment of a Medicines Management programme to 
promote cost-effective prescribing, especially for long-term medications (12).  
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2.2. Structure of Irish general practice 
Although primary care is the location of choice for the management of chronic disease, 
Ireland is unique in being the only health system in the European Union that does not 
offer patients universal coverage for primary care at the point of access (13). GPs play a 
central role in the delivery of primary care services. The majority of GPs are self-
employed private practitioners but a large proportion also provide free GP care at the 
point of access through the state-funded General Medical Services (GMS) programme 
(14). Approximately 40% of the population is covered by the GMS, and the remainder 
generally pay their GP an out-of-pocket fee of approximately €50 per consultation (13). 
Individual patients are means tested to determine their eligibility for the GMS 
programme; if eligible, they are given either a Medical Card or a GP Visit Card. Medical 
Cards may also be granted on a discretionary basis in the case of serious illness. 
Medical Card and GP Visit Card holders are entitled to free GP care at the point of 
access, for which the GP is paid annual capitation of the order of €43 to €270, 
depending on the age and gender of the patient (15). In 2015, free GP care at the point 
of access was extended to all people aged over 70 regardless of income and all children 
aged under six years, with further expansion of coverage planned for 2016. 
As gatekeepers to hospital services, GPs play an important role in controlling costs at 
secondary and tertiary level. The Irish College of General Practitioners (ICGP) reports 
that 95% of patients are managed solely in general practice with only a 5% referral rate 
(16). However, recent figures show that only 2.3% of the total health budget is 
allocated to general practice (17).  
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2.3. The impact of austerity  
In 2008, Ireland faced an economic crisis caused by a combination of international 
factors, poor national fiscal and public policy choices (18). In December 2010, Ireland 
entered into an international bailout worth €85 billion. In response to this crisis, there 
were a series of austerity budgets which led to public expenditure on health falling by 
9% (19).  
The budgetary responses included the Financial Emergency Measures in the Public 
Interest (FEMPI) Act 2009. This act allowed the then Minister for Health, Mary Harney 
to reduce government payments to GPs (19). The first reductions were of the order of 
8%, and affected GMS services such as capitation, care of temporary residents, out of 
hour’s care, special items of service, distance allowances, immunisation and nursing 
home care, dispensing fees, and practice management expenses. In 2010, Minster 
Harney announced further reductions in GMS payments to GPs of between 8-15%. In 
July 2013, the new Minister for Health, Dr James O Reilly (also a GP), reduced payments 
to GPs by a further 7.5%. 
Simultaneously, as personal incomes fell with the recession, there was a 70% increase 
in the numbers of people eligible for state-provided GP care (13).  
The impact of increasing demand in the face of reduced payments has challenged the 
financial viability of many general practices. Some practices have closed, while others 
have struggled to find young GPs to take over practices on the retirement of GP 
principals. As of May 2015, there were 21 general practice lists in Ireland without a GP 
(16).  
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2.4. Withdrawal of the ICGP from Clinical Care Programmes 
In July 2013, in response to the diminishing resources available to general practice, the 
ICGP withdrew from the National Clinical Care Programmes (20). The Clinical Care 
Programmes were established by the Health Service Executive (HSE) to streamline the 
management of chronic conditions. One of the aims of the programmes was to develop 
more effective shared care of patients between hospitals and GPs. However, in the face 
of increasing workload and on-going cuts to funding, the ICGP stated that GPs were not 
in a position to offer structured chronic disease care unless funding was diverted from 
secondary to primary care (20). 
 
2.5. New contract and cycle of diabetes care 
The contract currently held by GPs for the provision of GMS care was written in 1989, 
and was originally designed for acute medical care without mention of chronic disease 
(21). From the perspective of GPs and the Department of Health, there has long been a 
need to revise the terms of this contract (22). In January 2014, the government 
released a draft contract for the provision of free GP care at the point of access without 
any prior consultation with the ICGP or medical unions. The contract was received 
unfavourably by GPs, and the ICGP’s formal response branded it “deficient in areas of 
clinical appropriateness, patient-centredness, quality and safety of care, evidence 
based care, outcomes focussed care, patient privacy, the clinical independence of 
doctors and ultimately the viability or sustainability of a general practice service”(23). 
Contract negotiations ensued and a revised contract was announced in July 2015. In 
addition to detailing the capitation payments and requirements of GPs in the provision 
of care to all children aged under six years, it includes a new cycle of care for patients 
with diabetes. GPs are paid a once-off registration fee of €30 per registered patient 
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with diabetes who holds a Medical Card, and receive enhanced capitation payments of 
€100 per registered patient for two annual reviews. Despite the fierce early opposition, 
this initiative seems to have been welcomed by GPs as the first step in adequately 
resourcing primary care to provide high quality chronic disease management.  
Figure 2 outlines the temporal relationship between some of these events and the 
qualitative research described in this thesis.  
 
 
Figure 2. Notable events in Irish general practice during this thesis. 
  
•FEMPI cut 1: 8 % reductions in captitation payments 
to GPsDec 2009
•FEMPI cut 2: 8-15% reductions in range of payments, 
including capitation, to GPsDec 2010
•FEMPI cut 3: 7.5% reduction in capitation payments to 
GPsJuly 2013
•ICGP withdraw from the National Clinical Care 
ProgrammesJuly 2013
•Draft contract for the provision of free GP care 
leaked. GPs respond negatively.Feb 2014
•The new under-six and diabetes cycle of care contract 
is released.July 2015
Feb-Nov 
2013: 
Qualitative 
interviews 
with GPs 
(Chapter 6) 
Dec 14-July 
2015: 
Feasibility 
study with 
GPs  
(Chapter 10) 
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CHAPTER 3. A REVIEW OF THE LITERATURE  
3.1. Introduction  
This chapter provides an overview of the literature which has informed my work. I 
begin by describing the problem of multimorbidity: its definition, epidemiology, short 
and long term health consequences, and wider economic costs. Then I review the 
related issues of polypharmacy and the influence of clinical practice guidelines. Lastly, I 
describe existing interventions to improve multimorbidity care, their limitations and 
lessons that can be learned from interventions in related fields.  
  
3.2. Multimorbidity: what’s in a word? 
The basic definition of multimorbidity is the co-occurrence of multiple chronic 
conditions within the one person without any reference to an index condition (24). This 
is conceptually different to comorbidity, which refers to any additional condition in a 
patient who has an index condition (25). The term multimorbidity tends to be used in a 
generalist context (i.e. by GPs and geriatricians) where the identification of an index 
condition may not be obvious or useful. Comorbidity better captures the views of 
specialists and what is designated as the index condition depends on the speciality in 
question (26). Starfield et al. suggested that acute conditions, some of which persist or 
recur over time, be included in the definition of multimorbidity but this application is 
not widespread (26, 27).  
 
3.3. Measures of multimorbidity 
Patients with multimorbidity are a heterogeneous group. Some have co-occurring but 
otherwise uncomplicated conditions while others, for a range of biopsychosocial 
reasons, are more difficult to manage. Numerous operational measures of 
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multimorbidity have been used in research. Some are broad and inclusive, while others 
try to capture the more complicated multimorbid patients that most need intervention.  
 
3.3.1. Counts of conditions  
In two separate systematic reviews, the most commonly used measure of 
multimorbidity was the presence of two or more chronic conditions (28, 29). While this 
measure appears to be straightforward, what constitutes a condition varies between 
studies. Fortin et al. have suggested that the term “condition” is more encompassing 
than “disease” (which denotes a condition with signs and symptoms) or “illness” (which 
refers to a person’s perception of their health) (30). Some researchers count anything 
that is listed as a chronic condition in a patient’s medical record (31) or coded as a 
chronic condition in a recognised classification system (such as the International 
Classification of Primary Care) (32, 33). Others use lists or indices of pre-specified 
conditions. In 2011, Diederichs et al. reviewed 39 such indices (34). On average, there 
were 18 conditions listed per index. The rationale for including conditions in an index 
varied from high prevalence, to inclusion in other indices of multimorbidity, or 
association with mortality, physical function, or other health outcomes. In the majority 
of indices (59%), there was no rationale given for the selection of conditions. 
Diederichs et al. recommended four criteria to govern the inclusion of conditions in 
indices of multimorbidity: conditions of long duration, a need for continuous medical 
treatment, severe impact on affected people, and high prevalence. They suggested 
eleven conditions that they believe should be included as a minimum: cancer, diabetes, 
hypertension, myocardial infarction, chronic ischaemic heart disease, cardiac 
arrhythmias, cardiac insufficiency, stroke, chronic obstructive airways disease, 
depression and arthritis (34). Fortin et al. (28) have suggested that indices should 
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include the twelve most prevalent chronic conditions at a minimum, as there is less 
variation in prevalence estimates using at least this number of conditions. 
While two or more conditions is the most commonly used measure of multimorbidity, 
Harrison et al. (35) compared this to three or more conditions, and found the latter had 
greater specificity for identifying patients with substantial health needs.  
When counting conditions, the source of the data (i.e. patient-reported, administrative 
data or medical records) is an important consideration. Diederichs et al. suggested that 
patient-reported data is better for establishing the effects of multimorbidity because it 
reduces the impact of excessive labelling of disease (34). Fortin and others have 
proposed that using a combination of sources gives more reliable estimates than 
relying on one source alone (28, 35, 36). 
 
3.3.2. Weighted classification systems  
More elaborate systems try to account for severity or the complexity that can occur 
due to non-biomedical factors. These systems attach weights to different conditions 
using mortality risk, presence of complications, or impact on physical function or 
quality of life (29, 34). They allow calculation of summary measures for the combined 
burden of a patient’s conditions. Examples include the Charlson Comorbidity Index, the 
Cumulative Illness Rating Scale, the Index of Coexisting Disease, the Kaplan–Feinstein 
Index and the Duke Severity of Illness Checklist (26, 37). Other systems combine the 
type and severity of diseases with age and gender to classify patients into groups that 
signify expected healthcare need (e.g. Adjusted Clinical Groups) (38).  
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3.3.3. Measures that use medications 
Given the lack of consensus on what constitutes a chronic condition, the number of 
long-term medications prescribed to an individual has been suggested as an alternative 
proxy measure of multimorbidity (39). This may involve simply counting the subclasses 
of medications prescribed to a patient or may be weighted by age, gender and the 
severity of conditions the medications are used to treat, as in the Chronic Disease Score 
(40). While these measures are useful for predicting outcomes like hospitalisation and 
mortality (39), medications cannot capture function or quality of life, or the presence of 
disease that is not being pharmacologically treated. Therefore, these measures may 
under-estimate morbidity burden in samples of older, frailer and cognitively impaired 
people where less active disease management is pursued (41).  
 
3.3.4. The concept of complex multimorbidity 
In 2014, Harrison et al. proposed the concept of "complex multimorbidity" for 
identifying high-need individuals who would benefit from more intensive intervention 
(35). They defined complex multimorbidity as the co-occurrence of three or more 
chronic conditions affecting three or more different body systems within one person 
without defining an index chronic condition. This “stepped care” approach is promising: 
targeting interventions at patients by profiling their level of complexity has led to 
improvements in the management of individual chronic conditions, and it is not a 
difficult measure to replicate or interpret (42, 43).  
 
3.3.5. Which measure to choose? 
Although different measures lead to different prevalence estimates of multimorbidity 
(discussed further below), the predictive validity of different measures for the same 
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outcome (e.g. hospitalisation or mortality) differ only slightly, and simple counts of 
conditions or medications perform almost as well as complex measures in predicting 
most outcomes (35, 36).  
In this thesis, the term multimorbidity is used to represent the co-occurrence of two or 
more chronic conditions. There are two exceptions. In the qualitative interview study 
(Chapter 6), I asked participating GPs to discuss multimorbid patients with at least 
three chronic conditions in order to get cases where difficult decisions, particularly 
those regarding medications, were more likely to arise. In the feasibility study (Chapter 
10), I asked GPs to choose multimorbid patients prescribed ten or more medications or 
five or more medications with another complicating factor, in order to get cases where 
recommendations for changes in medications were more likely to emerge.  
The concepts of patient complexity and frailty are more common in and complicate the 
management of patients of multimorbidity, but are distinct from multimorbidity as it is 
defined in this thesis (30). Patient complexity acknowledges that morbidity burden is 
influenced not only by health-related characteristics, but also by socioeconomic, 
cultural, environmental, and patient behaviour characteristics. These interactions 
between disease factors and socio-economic factors can make the clinical management 
of multimorbidity more or less challenging, time-consuming, and resource intensive. 
However, approaches to capturing and measuring complexity are lacking. Frailty 
represents a state of increased vulnerability to physical stressors that results from 
decreased physiologic reserves of multiple physiological systems (44). It has been 
estimated that frailty affects 46% of patients with multimorbidity, and substantially 
increases the risk of falls, disability, long-term care, and death in this population. 
However, 26% of patients with frailty do not have co-existing multimorbidity, which 
highlights the distinction between the concepts (45).  
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3.4. How common is multimorbidity? 
Unsurprisingly, estimates for the prevalence of multimorbidity vary according to the 
age and location of the study population, the data source and the measure of 
multimorbidity used. This variation has been demonstrated in three systematic 
reviews. The first review, published in 2011, included twelve prevalence studies, and 
showed multimorbidity affected 20-30% of all adults and 55-98% of older adults (46). 
The second review, published a year later, included 21 prevalence studies with 
estimates ranging from 3% to 98% (28). Three years on, a third review found double 
the number of studies (reflecting the interest in the topic) and found consistent 
variation in prevalence estimates (47).  
In all three reviews, the majority of included studies defined multimorbidity as two or 
more conditions. The main source of variation between studies was the total number 
of conditions considered. For example, a Dutch study used data on only five conditions 
to show a prevalence of multimorbidity of 15% in patients aged over 65 years (48), but 
another Dutch study considered 335 conditions and found a prevalence of over 60% in 
the same age group (33).  
Comparing population level data to primary care data, prevalence estimates are 
generally the same for people aged up to 60 years; after this, prevalence estimates are 
10 to 20 points higher in primary care data (29).  
In studies using similar measures of multimorbidity (i.e. two or more conditions), 
prevalence estimates for adults in high-incomes countries are similar e.g. 48% in Spain 
(47), and 46% to 52% in Canada (2). In Ireland, it is estimated that multimorbidity 
affects two thirds of patients aged over 50 years attending primary care (3).  
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Low and middle income countries (LMICs) appear to have lower rates of 
multimorbidity. In a pooled analysis of data on adults from China, Ghana, India, Mexico, 
Russia, and South Africa, the overall prevalence of multimorbidity was 22%; the highest 
rates were in Russia (35%) and the lowest rates were in China (20%) (49). The lower 
prevalence may be explained by a higher burden of infectious diseases and lower life 
expectancy in these countries. Alternatively, prevalence estimates may be biased by 
limitations in the data available, and under diagnosis of chronic disease (50). 
 
3.4.1. Association with age 
All studies included in the three systematic reviews show a significant positive 
association between age and multimorbidity, but the relationship is s-shaped rather 
than linear, plateauing after 70 years at around 75% (28, 29, 46).  
The association with age explains in part the increasing burden of multimorbidity, and 
the need for interventions to improve medication management for these patients. 
Nevertheless, the absolute number of people with multimorbidity is higher in those 
younger than 65 years (51). This places additional demands on GPs: whereas patients 
aged 65 and over can be referred to geriatricians, sub-specialisation of physicians in 
secondary care has led to a situation where generalist services seldom exist for the 
increasing number of multimorbid patients aged less than 65 years (52). 
 
3.4.2. Association with gender 
Studies from high income countries show that the prevalence of multimorbidity is 
higher in women than in men of a similar age, with an odds ratios of 1.12 (1.07-1.17) in 
the Netherlands (33), 1.23 (1.06-1.42) in Ireland (3), and 1.41 (1.4-1.42) in Scotland 
(51). This has been explained by women’s greater longevity, because men who survive 
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longer are healthier than women, and because women are more affected by non-fatal 
conditions (i.e. osteoarthritis) than men (46). It may also relate to reporting differences 
between the genders. However, to appropriately tailor interventions to patients’ 
needs, more research into the risk factors for, mechanisms of and natural history of 
multimorbidity between genders is warranted (46). 
 
3.4.3. Association with socio-economic status 
In high income countries, socio-economic status (measured using deprivation scores, 
health insurance status or lower educational attainment) is inversely associated with 
multimorbidity (29). This was most strikingly shown in a Scottish study where the onset 
of multimorbidity occurred on average ten years earlier in deprived areas than in more 
affluent areas (51). This is important because people living in areas of deprivation tend 
to experience more social problems and have more complex health needs that those in 
affluent areas.  
In low or middle income countries, this association between multimorbidity and socio-
economic status is inconsistent or inverted (49, 53). In lower income countries, affluent 
individuals tend to have higher levels of health risks like high body mass index and 
reduced physical activity, which can lead to higher levels of chronic disease in these 
groups. Additionally, under-diagnosed disease and relatively shorter life-expectancy 
with less opportunity to develop chronic disease disproportionately affects lower social 
classes in lower-income countries (54). 
 
3.5. Patterns of multimorbidity 
The level of difficulty associated with medication management in multimorbidity is 
influenced by the combination of conditions involved. Conditions can co-occur for 
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reasons of chance, detection bias, or common pathology (26, 46). Common pathology 
includes shared risk factors (e.g. smoking as a cause for lung disease and vascular 
disease), co-occurring risk factors (e.g. smoking and alcohol can lead to lung disease 
and hepatic disease in the one person), or one condition or its treatment causing 
another condition (e.g. inflammatory arthritis or non-steroidal anti-inflammatories 
leading to chronic kidney disease) (55).  
More generally, conditions may be described as “concordant” if they share the same 
overall pathophysiological risk profile or management (i.e. diabetes and hypertension); 
or “discordant” if not directly related in either pathogenesis, management or 
predisposing factors (i.e. diabetes and irritable bowel syndrome) (56). Discordant 
conditions cause more problems for medication management than concordant 
conditions, due to the risk of interactions between agents indicated for individual 
conditions, lack of synergies in management, and the additional time required to 
manage each distinct condition (57, 58).  
In their 2014 systematic review of prevalence studies, Violan et al. also examined the 
patterns of co-occurring conditions. The most frequently observed dyad of conditions 
was hypertension and osteoarthritis, followed by different combinations of 
cardiovascular conditions (29). Using cluster or factor analysis to group conditions in a 
meaningful way, the most commonly observed groupings were 1) cardio-metabolic 
conditions, 2) anxiety, depression and other psychiatric conditions and 3) painful 
conditions (including mechanical pain). Since that review, others groups have published 
similar findings (59, 60). The consistency of these patterns suggests that they should be 
accounted for in relevant clinical practice guidelines (61), especially the common 
synergies or interactions that may occur.  
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Guidelines aside, the importance of disease patterns should not be over-emphasized 
(62). In a study of patients with hypertension, only one third of their consultations were 
for that diagnosis. The next most common reason for consultation was their diabetes 
but this accounted for only 3% of consultations. Thus, almost two thirds of 
consultations were for a wide variety of reasons, with no one of them accounting for 
more than 1% of visits (63). 
 
3.5.1. Co-occurring physical and mental health conditions 
There is a unique relationship between physical and mental health conditions in 
multimorbidity, particularly in areas of deprivation (51, 64). It has been estimated that 
approximately one third of people with multimorbidity have both a physical and a 
mental health disorder, with the odds of a mental health condition increasing as the 
number of physical morbidities increase (51). Furthermore, serious mental illness is 
associated with elevated mortality compared to the general population; the majority of 
this excess is attributable to co-occurring common physical health conditions (65). It 
has been suggested that worse outcomes ensue for those with serious mental illness 
and co-occurring physical disease due to adverse health behaviours of patients with 
serious mental illness, suboptimal access to and utilisation of healthcare by this patient 
group, and the delivery of inferior healthcare to those that do. 
The relationship between physical and mental health conditions may be causal, with 
physical conditions contributing to the development of mental health conditions or 
vice-versa. Medications, and their side effects, may also be implicated (e.g. medications 
for psychiatric conditions contributing to cardiovascular disease or medications for 
epilepsy or hypertension leading to depression). Multimorbid patients with mental 
health issues have poorer health outcomes and greater functional deterioration than 
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those with mental health conditions or physical multimorbidity alone (43). However, 
ensuring that both the physical and the mental health conditions receive adequate 
attention can be a challenge in consultations in general practice, and highlights why 
interventions that aim for whole-person care are needed in this field (64).  
 
 
3.6. The impact of multimorbidity 
Interventions are needed to reduce the negative effects exerted by multimorbidity on 
patients and on healthcare systems. The degree to which individuals are affected by 
multimorbidity depends on the diseases involved, and the patient’s personal, physical 
and social resources (66). Health system effects are seen to vary by the relative 
strength of and accessibility to continuous, generalist primary care (9).  
 
3.6.1. Quality of life and function 
Quality of life declines with increasing numbers of and severity of chronic conditions 
(46, 67-69). This association persists even after controlling for confounders such as 
education, self-perception of economic status, and social support (70). Depression and 
chronic pain are associated with the greatest reductions in quality of life in 
multimorbidity (68, 71), suggesting that these conditions should be prioritised for 
intervention. 
To date, most studies examining this relationship have measured quality of life using 
short form questionnaires (70, 72) or the EQ5D (67, 68). Some authors have questioned 
the value of these measures in multimorbidity, arguing that they obscure the longer 
term benefits patients may receive from using chronic disease medications and may 
not capture all the domains of disease (68). While this may be true, others argue that 
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quality of life is of greater importance than measures of disease progression (73), and 
interventions that aim to improve these patient-reported measures in the context of 
multimorbidity should be a priority. 
Functional limitation causes additional challenges for many people with multimorbidity 
and their carers. In the Survey of Health, Ageing and Retirement in Europe (with data 
on over 40,000 patients from ten European countries), 65% of multimorbid patients 
reported established functional decline, frailty or pre-frailty (74).  
In a review of nine cohort studies, multimorbidity at baseline predicted future 
functional decline (75). People with multimorbidity are more likely to become 
dependent on long-term care, with the highest risks for functional deterioration in 
multimorbid patients with neuropsychiatric disorders (76). 
 
3.6.2. Treatment burden, experience of healthcare and self-management 
Treatment burden relates to the demands that are placed on patients in the 
management of their chronic disease. It includes adherence to medications, 
attendance for medical reviews, and lifestyle modifications. Overburdening patients 
can lead to poor adherence and poorer health outcomes and there is evidence that this 
is more often the case in patients with multimorbidity (77). In a cross-sectional survey 
of multimorbid patients in England, two thirds of patients reported “hassles” in their 
medical care, such as lacking information about their treatment options, poor 
communication and disagreements between individual doctors involved (78). 
Multimorbid patients who were younger, were in active employment and had less 
frequent contact with their GP were more likely to experience these hassles. A 
synthesis of qualitative research showed that multimorbid patients find it more difficult 
to engage in self-management if they receive conflicting information from or 
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experienced difficulties communicating with healthcare professionals (79). 
Interventions that accommodate greater consideration of treatment burden, facilitate 
the provision of consistent information to patients and improve doctor-patient 
communication are needed to address these deficits.  
 
3.6.3. Quality of health care 
A systematic review of studies examining the association between multimorbidity and 
quality of care showed mixed results (73). When quality is measured using process 
indicators, higher numbers of conditions are associated with higher quality scores. This 
relationship is only partially explained by the increased use of healthcare by patients 
with more conditions or care processes that satisfy multiple quality indicators (80, 81). 
In one study from the United States (US), quality scores for each additional condition 
increased more for patients who had seen a relevant specialist than for those who had 
not. However, for patients who received only generalist care, the relationship between 
the quality score and the number of conditions remained positive (80).  
When quality is assessed using patient-reported outcomes like continuity of care (82), 
or doctor-patient communication (83), higher numbers of conditions are associated 
with lower quality scores. This negative association was magnified in those with higher 
numbers of annual hospital outpatient attendances (82). So, care that is measurably 
better using process indicators may be perceived as worse by patients (84). The 
combinations of conditions are also relevant here: studies focusing on index conditions 
show that the quality of care is better if comorbidities are concordant, but worse if 
they are discordant (85, 86).  
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3.6.4. Healthcare utilisation and costs  
Patients with multimorbidity are major drivers of healthcare costs, as well as economic 
losses. Data from the Survey of Health, Ageing and Retirement in Europe shows that, 
everything else being equal, a multimorbid patient sees doctors 23% more often, and 
has 1.43 times greater risk of hospitalisation in a given year, than those without 
multimorbidity (74). However, the magnitude of this effect varies by health system. If 
GPs play a gate keeping role in the healthcare system, patients with higher numbers of 
conditions have large increases in primary care visits, but less significant increases in 
more expensive hospital visits, and shorter hospital admissions (3, 87). In contrast, 
when patients can self-refer to secondary care, multimorbidity is associated with larger 
increases in the demand for more intensive and more expensive secondary care (88). In 
the US, the 65% of aged Medicare beneficiaries who have multimorbidity account for 
95% of Medicare expenditure (4, 60). Unscheduled care and hospital admissions for 
ambulatory care sensitive conditions also increase with multimorbidity:  for example, 
Medicare beneficiaries with four or more chronic conditions were ninety nine times 
more likely than a beneficiary without any chronic conditions to have an admission for 
an ambulatory care sensitive condition (4). Patients with multiple chronic conditions 
also use a greater array of services: patients with five or more chronic conditions see 
on average fourteen different healthcare professionals (89). As the number of 
healthcare professionals increases, co-ordinating care becomes more difficult for 
physicians and for patients who find it increasingly challenging to understand, 
remember, and reconcile the various instructions they have been given (78, 90).  
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3.6.5. Mortality 
Estimates of the effect of multimorbidity on mortality vary by patient age and physical 
function. Marengoni et al. found only three out of five studies showed an increased risk 
of mortality in multimorbid patients. However, the other two studies involved the 
oldest old, where age rather than number of chronic conditions may have been a 
greater risk for mortality (46). In studies of index conditions, mortality rates are higher 
if comorbidities are discordant rather than concordant (91). Multimorbid patients with 
functional limitation have consistently higher levels of mortality than multimorbid 
patients without functional limitation (92, 93).  
 
3.6.6. Summary 
Increasing numbers of chronic conditions have an incremental negative impact on 
patient-reported and system level outcomes (46, 75). Negative effects are greatest in 
patients with more complex, discordant combinations of conditions or existing 
functional impairment. In light of the varying associations with mortality, re-configuring 
care to help patients live well with multimorbidity appears more appropriate than 
striving to reduce mortality alone (84). Attuning healthcare systems to the existence 
and needs of patients with multimorbidity is needed to address these disproportionate 
effects. Interventions that enhance the role of GPs as co-ordinators of care and 
empower them to provide care that is based on patients' symptoms, values and 
preferences may help reverse these trends. 
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3.7. Medications and multimorbidity 
Polypharmacy is one of the most important consequences of multimorbidity (94). 
Similar to multimorbidity, polypharmacy has also been defined in numerous ways, but 
threshold numbers of medications (e.g. four or more (95), six or more (96) etc.) are 
commonly used. The term polypharmacy has also been used to represent undesirable 
medication use. Certainly, higher numbers of medications are associated with greater 
risk of preventable drug-related morbidity (97, 98). However, using multiple 
medications for the control of chronic disease may also benefit the patient by reducing 
morbidity and improving quality of life. This has led the Kings Fund (an independent 
think-tank in England) (99), and others (95) to make a distinction between appropriate 
and inappropriate (or problematic) polypharmacy. Methods for assessing the 
appropriateness of polypharmacy are reviewed below.  
 
3.7.1. The epidemiology of polypharmacy  
In 2010, 21% of Scottish adults were prescribed five or more medications (100). This is 
very close to the 23% of Scottish patients estimated to have multimorbidity (51). The 
proportion receiving a higher threshold of ten or more drugs was 6%. As with 
multimorbidity, there are strong associations between polypharmacy and older age. In 
an Irish study of patients aged 65 years and over, 60% received five or more 
medications, while 22% received ten or more (101).  
Rates vary in low and middle income countries: 6% of Chinese but 43% of Brazilian 
primary care patients receive five or more medications (102). Explanations for the high 
prevalence of polypharmacy include increased availability of treatment, improved 
access to health care, the promotion of adherence to clinical practice guidelines, and 
patient expectation for active management (103).  
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3.7.2. When good medicines are bad for your health 
Polypharmacy can lead to preventable drug-related morbidity via medication errors 
and adverse drug reactions (ADRs) (104, 105). In the Practice Study (106), Avery et al. 
found medication errors were more common as the number of prescribed medications 
increased; errors occurred in 32% of patients on five or more medications, and in 48% 
of patients on ten or more medications. ADRs are more common in older multimorbid 
patients because of their lower physiological ability to metabolize and tolerate 
medications (98). A large proportion of ADRs are due to interactions, either between 
medications or between medications and other chronic conditions (107). In the 
aforementioned Scottish study, the number of drugs dispensed was strongly associated 
with potential interactions: 81% of people on 15 or more medications had at least one 
potentially serious drug-drug interaction (100). This is important because 6% to 17% of 
hospital admissions are due to ADRs, with the majority of these admissions deemed 
avoidable (107, 108). In the US, ADRs are amongst the top five causes of death in 
hospital (84).  
Medication regimens in multimorbidity can be demanding and restrictive, leading to 
poor adherence by some patients for reasons of impaired social and cognitive ability, 
beliefs about using multiple medications, and fear of side effects (109). As these issues 
may not stop patients from filling their prescriptions, poor adherence represents waste 
from the cost of unused medications, and the costs associated with progressive chronic 
disease (110). 
 
3.7.3. Measuring the “appropriateness” of medications 
While polypharmacy is associated with risk of hospitalisation, if the polypharmacy is 
appropriate for the individual patient’s multiple conditions, this association is less 
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pronounced (111). The difficulty lies in determining what is and what is not 
appropriate.  
A number of tools have been developed to assess medication appropriateness, and are 
broadly categorized as explicit (criterion-based) or implicit (judgment-based) (112). 
Explicit tools, such as the Beers criteria and the Screening Tool of Older Persons 
Prescriptions (STOPP) (113, 114), list medicines which should be avoided in older 
people because the potential risks are considered to outweigh the potential benefits. 
They are applied without clinical judgment, and do not take into account other factors 
that define high quality healthcare for an individual, such as patient preference or the 
presence of comorbidity. The lists themselves are criticized for a lack of transparency 
and reliability in their development and the dating of indicators as new medical 
evidence emerges (115). Despite these weaknesses, they have been widely applied to 
patient data to demonstrate substantial levels of “inappropriate prescribing” in primary 
care settings (112). In Ireland, approximately one third of medications prescribed to 
older people are reported to be potentially inappropriate using the STOPP criteria (101, 
116). These studies did not explore prescribers’ reasons for issuing potentially 
inappropriate medications but they did show an association between the offending 
medications and the presence of multimorbidity (116). 
With implicit tools, each medication is assessed across a range of prescribing domains 
and a summary score of appropriateness is generated (e.g. the Medication 
Appropriateness Index) (112). Although more patient-focused than explicit tools, 
implicit tools are time-consuming, dependent on user knowledge and generally do not 
address under-prescribing (112).  
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Tools for inappropriate omissions (e.g. the Screening Tool to Alert doctors to Right 
Treatment (START)) have also been developed. They show omissions occur in 30-50% 
of older patients (117-119), and are more likely in patients on polypharmacy (120).  
Studies linking explicit and implicit tools with outcomes such as mortality, morbidity 
and quality of life show mixed results and are weakened by inadequate consideration 
of confounders like multimorbidity (112). A leading group of researchers have 
suggested that the existing tools overlook the needs of individual patients (112). They, 
and others, have recommended that future methods of assessing medication 
appropriateness should consider patients’ comorbidities, preferences, life-expectancy 
and function (95). Medication appropriateness is also a function of time; ensuring that 
polypharmacy remains appropriate necessitates regular and comprehensive 
medication review (121).  
 
 
 
3.8. Clinical practice guidelines: the source of the problem? 
The evidence-based medicine movement has achieved safer, more consistent and 
more cost-effective care (122). However, combining evidence-based guidelines in 
patients with multiple chronic conditions can lead to burdensome and even harmful 
polypharmacy (123). For instance, the Guidelines International Network database 
currently lists more than 3,700 guidelines from 39 countries (124). Since 2002, over 
2,500 peer-reviewed guidelines have been published which relate specifically to 
cardiovascular disease alone (125). Guideline duplication is common, quality is variable, 
and there are many potential interactions between guidelines aimed at different 
conditions. 
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3.8.1. An example case 
An example of how clinical practice guidelines complicate care for patients with 
multimorbidity was described by Boyd et al. in 2005 (126). The patient was a 79 year 
old woman with chronic obstructive airways disease, diabetes, hypertension, 
osteoarthritis and osteoporosis. Implementing the clinical practice guidelines in the 
simplest way possible for each of these conditions led to prescription of twelve 
medications, nineteen doses of medication per day and fourteen non-pharmacological 
management techniques (126). Multiple drug-drug, drug-disease and drug-food 
interactions were identified. Had the patient’s blood pressure remained uncontrolled, 
the guidelines did not give the marginal benefit of adding yet another medication to 
her existing regimen. The annual cost of the medications was estimated to be over four 
thousand American dollars. The authors noted that guidelines incorporated poor 
quality or no evidence relating to older or multimorbid patients. Reviews of Canadian 
and Australian guidelines show similar findings: few guidelines account for the 
presence of multimorbidity or address treatment for older patients with multimorbidity 
(127, 128).  
 
3.8.2. Evidence underpinning guidelines 
The recommendations issued in most clinical practice guidelines often depend on lower 
levels of evidence or expert opinion (129). Even when clinical trial data do exist, they 
rarely represent multimorbid patients or their needs (130). Most trials focus on the 
benefit of one drug in one condition so exclude patients with multimorbidity (130). 
There is an over reliance on surrogate outcomes (i.e. blood pressure, lipids, 
albuminuria) rather than outcomes that matter to multimorbid patients (131). Short 
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follow-up, and under-appreciation and under-reporting of harms make valid 
assessments of time to benefit (or harm) difficult (6, 125).  
These limitations cast doubt on even high-quality clinical evidence, which in turn 
weakens prescribers’ confidence in “evidence-based guidelines”. In older complex 
patients, interpretation of the potential risks and benefits associated with guidelines is 
even more problematic (26).  
A short term solution is to re-analyse existing trial datasets to determine the outcomes 
for multimorbid participants that were recruited. In the longer term, recruiting patients 
with higher levels of multimorbidity, and following outcomes that are important to 
them, will be essential in building an evidence base that is relevant to the majority of 
people with chronic disease (6). 
 
3.8.3. The use of guidelines to measure quality of care 
Guidelines are increasingly used to define standards and focus efforts to improve 
quality and effectiveness (6, 126). The English model of general practice is acclaimed 
internationally for providing universal, free access to community-based health care. 
Over the past decade, the quality outcomes framework (QOF) has helped drive primary 
care services there in a uniformly evidence-based direction (132). QOF is a pay for 
performance programme that incentivizes adherence to guidelines to promote quality 
and effectiveness. However, the programme has had some undesirable effects (133). 
There has been a decline in non-incentivized care, and less continuity of care. 
Consultations are increasingly booked for the patient, rather than by the patient; focus 
solely on chronic disease management; and are often governed by computerised tick 
box templates (134).  
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Guidelines are not developed with quality assessment in mind; they are intended to be 
used in conjunction with professional judgement and patient preferences (135). But 
balancing these dimensions becomes complicated when adherence to guidelines is 
linked to quality and physician re-imbursement. Most pay for performance 
programmes target conditions in isolation, which can lead to inappropriate and 
inefficient care in people with multimorbidity (126). They can lessen the patient’s and 
even the physician’s role in decision-making, by highlighting the best option but rarely 
offering alternatives to this course (136).  
If pay for performance systems are to continue, they need to evolve to match the 
needs of patients with multimorbidity (134). Ideally, this evolution would facilitate a 
modified approach to guideline implementation in multimorbidity, which would allow 
balancing of the risks and benefits of medications with a patient’s health priorities (66). 
 
3.8.4. Guidelines and deprescribing 
Deprescribing is the process of tapering or stopping drugs, aimed at minimizing 
polypharmacy and improving patient outcomes (137). Deprescribing is difficult for 
physicians, and guidelines rarely advise on when or how to stop medications (138). 
However, evidence of efficacy for deprescribing is emerging. In observational studies, 
mortality is higher in octogenarians if systolic blood pressure is treated to below 
130mmHg, even after adjusting for cardiovascular history and excluding patients 
without a diagnosis of hypertension who receive anti-hypertensive agents (139). In a 
study of US Veterans aged 70 years and over, those with very low levels of HbA1c or 
blood pressure underwent de-intensification of treatment; less than 0.8% had follow-
up measurements that were elevated (140). While deprescribing reduces costs and 
potentially lowers the risk of adverse drug events, there is also evidence that it is 
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acceptable to patients. In a survey of older patients on polypharmacy, 92% stated that 
they would be willing to stop one or more of their current medications if possible (141). 
Interventions that facilitate more effective communication with patients on 
deprescribing are a first step in this process. 
 
 
 
3.9. What interventions specific to multimorbidity have been developed so far? 
Despite numerous international advisory groups emphasizing the need for 
interventions to improve the patient outcomes in multimorbidity (123, 142, 143), a 
paucity of such interventions exist, specifically in the area of medication management.  
 
3.9.1. Comprehensive care programmes 
The chronic care model addresses healthcare systems as the main barrier to effective 
care of long term conditions. Developed by Wagner in 2001, this model suggests that 
comprehensive care programmes ideally comprise of six interrelated components. Four 
components refer to the care delivered by healthcare professionals: provision of self-
management support to patients; organisational systems that are designed to deliver 
effective, efficient patient care through involvement of the multidisciplinary team; 
decision support by evidence-based guidelines; and clinical information systems that 
provide feedback and reminders to healthcare professionals. The two remaining 
components refer to the context in which chronic care is provided: a well-organised 
motivated healthcare system and community resources that support or expand care for 
chronically ill patients. 
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In 2012, de Bruin et al. reviewed the effect of comprehensive care programmes on 
management of patients with multiple chronic conditions (144). They only included 
interventions that incorporated at least two or more components of the chronic care 
model. Out of the 33 studies included, only six reported on measures of medication use 
(i.e. medication appropriateness, use of high-risk or unnecessary medications). The 
results of these six studies were inconsistent, leading the authors to conclude that 
there is insufficient evidence for a beneficial effect of comprehensive care on the 
management of medications in multimorbidity. The other results of the review showed 
insufficient or no evidence for benefits in health-related quality of life, outpatient 
healthcare utilization and costs, functional status, mortality, and caregiver burden 
(144). The authors suggested that better descriptions of interventions and their 
implementation are needed to enhance comparability between studies, and generate 
consistent evidence that will support decision-making for patients with multimorbidity. 
 
3.9.2. Other complex interventions 
Also in 2012, in a review for the Cochrane Collaboration, Smith et al. (145) reviewed 
ten interventions designed to improved physical, psychological and care utilisation 
outcomes in patients with multimorbidity in primary care. Six were organisational 
interventions and involved case management, co-ordination of care or the 
enhancement of skill mix in multidisciplinary teams. The other four interventions 
focused on patient behaviours, rather than healthcare professionals. Individual study 
results were either insignificant or mixed, with little impact on physical health, mental 
health, or care utilisation. Three studies found benefits relating to prescribing and 
medication use (secondary outcomes), which signal the potential of these interventions 
to improve other health outcomes over longer periods.  
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Based on the characteristics of the included studies, the authors made suggestions for 
future interventions. First, interventions targeting specific risk factors or “areas where 
patients have difficulties such as management of medication were more likely to be 
effective” than interventions with a broader focus (e.g. case management, changes in 
care delivery). Second, interventions that were integrated into the healthcare system 
tended to show better results. Third, the review highlighted the need for theoretical 
frameworks to guide intervention development, to allow assessment of what worked 
and why. 
Since then a number of other relevant studies have emerged. In the OPTISCRIPT study, 
Clyne et al. evaluated a multifaceted intervention which incorporated web-based 
treatment algorithms for GPs, academic detailing with a pharmacist and tailored 
patient information leaflets. Participating patients were prescribed, on average, ten 
regular long-term medications. Although the intervention led to reductions in the use 
of inappropriately high doses of proton-pump inhibitors, no significant changes in other 
classes of medications occurred and there were no positive effects in patient-reported 
outcomes (146).  
Bregnhøj et al. found that interactive educational meetings with feedback from 
pharmacists but not educational meetings alone improved medication appropriateness 
in older patients prescribed more than five regular medications. However, their 
findings were weakened by very low GP participation rates (14%) possibly because of 
the time-consuming, and thus impractical, nature of the intervention (147).  
 
3.9.3. Interventions using information technology 
Clinical decision support systems (CDSS) have been suggested as a solution to the 
problem of excess information in the management of medications in patients with 
58 
 
multimorbidity (121). These systems use inbuilt prescribing information to alert 
prescribers to indicated or interacting medications. While CDSS can improve process 
measures, the evidence for clinical, economic, workload and patient related outcomes 
remains sparse (148, 149). 
The application of CDSS to the management of patients with multimorbidity was 
recently reviewed (150). Twenty studies met the inclusion criteria, with ten focusing on 
medication management. In four studies, the recommendations of individual guidelines 
were merged, but the possible interactions between these recommendations were not 
considered. Only pairwise combinations of guidelines were used, which is too simplistic 
for most patients with multimorbidity, and none of the CDSS interventions 
incorporated patient preference in decision-making. Evaluations of the usability or 
effectiveness of the interventions were either of poor quality or absent. The authors 
highlighted the risks of uncritical integration of guidelines in CDSS and called for more 
research about how conditions interact to inform better programming of these 
interventions (150).  
 
3.10. Learning from interventions in related fields 
Although there is a lack of interventions in the specific field of medication management 
in multimorbidity, lessons can be learned from other interventions designed to improve 
or support prescribing in primary care. 
  
3.10.1. Interventions involving pharmacists 
Patterson et al. (95) included eleven pharmacist-based interventions in their Cochrane 
review of interventions to improve prescribing appropriateness. In these studies, 
pharmacists conducted medication reviews, gave advice on adherence and safe use, 
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and provided patient and physician education. Overall, the interventions led to small 
improvements in scores of medication appropriateness but they had little effect on 
hospital admissions and no effect on health-related quality of life. The authors 
recommended that consideration of practice norms and cultures is a prerequisite for 
intervention success; interventions should focus on appropriate prescribing rather than 
simple reductions in numbers of drugs or scores; and interventions must account for 
the complexity of clinical situations, the patient’s wishes, and the individuality of 
prescribers.  
Rollason et al. conducted a similar review, but restricted it to pharmacist-based 
interventions that aimed to reduce numbers of medications (151). Fourteen studies 
were included. Overall, the studies were effective in reducing numbers of medications, 
but the authors were unable to determine if they improved patient-related outcomes 
or other clinical consequences of polypharmacy. They commented that direct 
involvement between the pharmacist and physician achieved more changes in 
medicines than written recommendations. 
In 2012, the pharmacist-led information technology intervention for medication errors 
(PINCER) trial was conducted with the aim of reducing medication error in general 
practice (152). In control practices, GPs were sent computerised feedback on patients 
identified as high risk for medication error plus information on each type of error. In 
intervention practices, GPs received this feedback and also had an opportunity to 
discuss it with a pharmacist who attended the practice thrice weekly over twelve 
weeks. Although the intervention reduced medication errors, the qualitative evaluation 
showed tensions within practices that impacted on effectiveness (153). For example, 
not all errors were necessarily seen as failings by GPs, especially if patients had 
multimorbidity (e.g. the prescription of beta-blockers to a patient with asthma). As the 
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intervention did not individualize risk assessments, some GPs over-ruled pharmacists’ 
advice on the basis of clinical experience and in-depth knowledge of the patient. 
Integration of pharmacists into practices was an issue: while the face-to-face contact 
was appreciated by GPs, the pharmacists themselves reported feeling isolated from the 
clinical team. These issues arose in a similar study conducted in an Irish setting (154). 
In summary, while pharmacists have valuable expertise to contribute to medication 
management in multimorbidity, existing interventions do not seem to have utilised this 
expertise in a way that leads to improvements in clinically meaningful outcomes. 
Further research on the context and dynamics of pharmacists and physicians working in 
close liaison, with shared access to patients’ medical records, may lead to greater and 
sustained success in this field. 
  
3.10.2. Interventions in primary care involving geriatricians 
Interventions involving geriatricians offer potential advantages for tailoring 
management plans to the needs of elderly, frailer patients. However, in a review of 
interventions to improve inappropriate prescribing in the elderly, only two out of three 
interventions that involved geriatricians in a primary-care based team led to 
improvements in prescribing appropriateness and none of the interventions improved 
other patient-reported or clinical outcomes (112, 155).  
In the Dutch Geriatrics Intervention Programme (156), nurses visited vulnerable older 
patients at home under the collaborative supervision of GPs and geriatricians. The GP 
retained primary responsibility for care of the patient and made the final decisions on 
referrals, medication changes etc. The published results did not report on changes in 
medications, but the intervention did lead to improvements in functional performance 
and mental well-being at 3-month and 6-month follow-up. The qualitative evaluation 
61 
 
showed that GPs valued the input of geriatricians for issues such as cognition, mood 
and mobility but difficulties occurred in communication between providers and 
achieving agreement on the goals of care (157).  
While harnessing the expertise of geriatricians is a promising approach for select 
groups of older community-dwelling patients, these interventions will not be accessible 
for the majority of multimorbid patients that are aged less than 65 years. Furthermore, 
there are logistical challenges to implementing multidisciplinary reviews in the 
community, namely resourcing, staffing and communication issues.  
 
3.10.3. Interventions involving other healthcare professionals  
In 2009, Boult et al. published a review of models of comprehensive healthcare for 
older persons with chronic conditions (158). Out of the 123 high-quality studies 
included, only six specifically addressed medication management or pharmaceutical 
care. Five of these six focused on prescribers at secondary care level, and only one 
improved patient-reported outcomes (a study that used a pharmacist in a hospital 
heart failure clinic).  
In 2001, a Canadian study examined the effect of team-based medication reviews on 
reducing the number of potentially inappropriate prescriptions given to elderly patients 
(159). The team included two hospital physicians, a pharmacist and a nurse, who made 
written recommendations to the patient’s primary care physician. Although the 
intervention led to significantly fewer inappropriate medications, this difference was 
not statistically significant in the intention-to-treat analysis. Extrapolating the 
conclusion of the Cochrane review by Patterson et al. (95), perhaps if greater attention 
was given to the role of the primary care prescriber, more significant effects would 
have been seen. 
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In a review of interventions to reduce preventable drug-related morbidity, Royal et al. 
assessed protocol-based, nurse-led interventions that aimed to improve prescribing for 
single chronic conditions such as diabetes, heart failure and asthma. Even with this 
narrow focus, no significant improvements in medication management occurred (160). 
Although not focusing directly on prescribing, the recent Collaborative Interventions for 
Circulation and Depression (COINCIDE) trial provides a useful example of the benefits of 
integrated collaborative care in multimorbidity (43). The trial showed that depression 
scores improved in patients with long-term conditions (diabetes or chronic heart 
disease) after integrating low-intensity psychological interventions with the routine 
primary care management of the chronic conditions (161). Patients in intervention 
practices received up to eight sessions with psychological wellbeing practitioners, two 
of which were delivered jointly with the practice nurse. This study highlights the role 
for interventions that facilitate collaboration between the healthcare professionals 
involved in an individual patient’s care, with potential benefits in the co-ordination of 
care, self-management and patient-centredness.  
 
3.10.4. Educational interventions 
As multimorbidity is infrequently incorporated into medical training curricula, 
educational interventions have the potential to address an important learning need for 
GPs. Educational interventions have been used to improve prescribing in other areas of 
general practice with varying degrees of success. In a review of initiatives to optimize 
the use of antibiotics, passive educational initiatives directed at GPs were unsuccessful 
(162). This failure was attributed to a didactic approach that did not acknowledge the 
context and complexities involved in prescribing. In contrast, interactive educational 
meetings on antibiotic use led to significant changes in prescribing behaviour, perhaps 
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through better engagement of the prescribing physician (162). Similarly, in an 
educational intervention study on inappropriate prescribing in Norwegian general 
practice, Rognstad et al. found that engaging GPs in critical review of their prescribing 
by using audit and feedback at continuing medical education meetings significantly 
reduced potentially inappropriate medications for patients aged 70 years are over 
(163). 
 
3.11. New opportunities 
Ideally, interventions in multimorbidity would help physicians achieve a balance 
between patient-centred care and guideline adherence; however, none of 
interventions described above have tackled this issue. Some interventions achieved 
success in medication-related outcomes such as prescribing appropriateness and 
medication errors. Although these outcomes may not be a priority for patients with 
multimorbidity, lessons can still be learned from their success. Future interventions 
should integrate well into existing practice, focus on specific areas of difficulty, 
facilitate tailoring to patient complexity, and involve face-to-face interaction between 
clinical decision-makers. This information presents a huge opportunity to develop 
interventions that not only improve medication use in patients with multimorbidity, 
but also improve patient-related outcomes such as treatment burden, patient 
satisfaction and health-related quality of life. 
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CHAPTER 4. METHODOLOGICAL FRAMEWORK AND OVERVIEW OF STUDY METHODS 
This chapter provides a description of the MRC framework and its application in this 
thesis. An overview of methods used to address each phase of the framework is 
provided here; greater detail on each method is provided in the relevant chapter. 
 
4.1. The Medical Research Council guidance on complex interventions  
Complex interventions use behavioural rather than pharmacological approaches to 
improve health outcomes. They can involve several interacting components, target one 
or multiple behaviours, involve individuals or organisations, and may aim to achieve a 
range of different outcomes. In the past, the evaluation of complex interventions has 
proved difficult because of problems defining, identifying, documenting, and 
reproducing the intervention. Therefore, the MRC proposed a phased approach to the 
development and evaluation of complex interventions, which is akin to that used for 
the development of pharmacological interventions. Broadly, this approach involves 
using the best available evidence (supplemented if necessary by new primary research) 
and appropriate theory in intervention development, testing it using pilot and 
feasibility studies to resolve key uncertainties in the design, before moving on to an 
exploratory and then a definitive evaluation (see Figure 3). These phases do not 
necessarily occur in a linear order, but the framework can help researchers define 
where they are in the research process. Detailed description of the intervention 
facilitates better replication, evidence synthesis and wider implementation. 
This thesis focuses mainly on the first two phases of the MRC framework: intervention 
development and assessing feasibility. 
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Figure 3. The Medical Research Council (UK) framework for developing and 
evaluating complex interventions 
 
 
4.2. MRC phase 1: Intervention development 
Because of the paucity of research on medication management in multimorbidity 
(described in Chapter 3), there is a need for pre-intervention research to inform the 
development of an intervention that will meet the needs and expectations of patients 
and the capabilities of healthcare professionals (164, 165). 
 
4.2.1. Identifying the evidence base 
4.2.1.1. Existing evidence 
I. The existing evidence on GPs’ perceptions of the management of 
multimorbidity was systematically reviewed and synthesized using a meta-
ethnographic approach, as described by Noblit and Hare. Meta-ethnography is 
the most commonly used method of reviewing and synthesizing qualitative 
health literature, and is described in detail in Chapter 5. 
 
66 
 
4.2.1.2. New evidence 
The existing evidence on multimorbidity was supplemented with new information 
generated by three studies:  
II. The first was a qualitative interview study to explore the challenges 
experienced by GPs when prescribing for multimorbid patients. The methods of 
data collection and analysis in the qualitative interview study were informed by 
grounded theory as described by Charmaz (166) and are discussed in detail in 
Chapter 6. 
III. I used the technique of chart-stimulated recall during qualitative interviews 
with GPs, and afterwards conducted a review of prior use of this technique in 
other clinical research. The five step approach for scoping reviews described by 
Arksey and O’Malley (167) was used to guide this study, and is described in 
detail in Chapter 7.  
IV. Stewart et al. have stated that quantitative research can enhance our 
understanding of patient complexity and context, and can inform the delivery 
of patient-centred care (7). To examine the association between psychosocial 
complexity and multimorbidity reported by GPs in the qualitative study further, 
I conducted secondary analysis of quantitative data from the Mitchelstown 
Cohort Study in Chapter 8. The Center for Disease Control Adverse Childhood 
Experience (ACE) pyramid was used to inform the multivariable ordinal logistic 
regression analysis (168). The ACE pyramid links adverse childhood experiences 
to other social and behavioural risk factors in adulthood, which in turn can lead 
to health consequences such as chronic disease higher up the pyramid (169). 
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4.2.2. Identifying theory, and modelling process and outcomes 
Developing an intervention using robust knowledge and theory can increase its success 
in improving clinical outcomes (170).  
V. The Behaviour Change Wheel (BCW) and related models were used to explicitly 
integrate behavioural theory with data from Chapters 5, 6 and 8 to develop a 
complex intervention (171). The model of behaviour at the core of the BCW 
supposes that the interaction between one’s capability (C), opportunity (O) and 
motivation (M) provides explanations for why a particular behaviour (B) is or is 
not performed (COM-B). The COM-B behavioural analysis guides the choice of 
intervention strategies most likely to achieve behaviour change, and highlights 
the behaviour change techniques particularly suitable for each intervention 
strategy. Following this structured approach lends transparency to the process 
of intervention development, and facilitates its subsequent implementation 
and evaluation [12]. The application of these models to our data is described in 
detail in Chapter 9. An expert panel informed modelling of intervention 
characteristics (e.g. which multimorbid patients should be targeted, choice of 
prescribing tool etc.). This process is also described in Chapter 9 with additional 
details provided in Appendix V. 
 
4.3. MRC phase 2: Assessing feasibility 
A key question in evaluating complex interventions is whether they are effective in 
everyday practice. Interventions to improve the quality of healthcare often fail or have 
only modest impact if there is inadequate attention paid to the target population or 
subject matter (172), and interventions may work better if a specified degree of 
adaption to local settings is allowed. Regardless of this flexibility, the implementation 
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of and fidelity to the various components of the intervention should be monitored, to 
see what works, where it works and why (8). 
VI. The acceptability of the intervention, key uncertainties identified during 
development, and the impact of context on implementation is evaluated in the 
feasibility study described in Chapter 10. The approach was informed by the 
work of a group of researchers who are developing CONSORT guidelines for 
pilot and feasibility studies (173-176), and the National Institute for Health 
Research guidance on feasibility studies (177). Within the study, I explored 
feasibility by focusing the analysis on a core set of implementation outcomes: 
acceptability, adoption, appropriateness, cost, feasibility, fidelity, penetration, 
and sustainability (178, 179).  
 
 
 
4.4. Philosophical orientation 
Clinical research traditionally fits with the biomedical model of positivism. However, as 
I intended to examine physicians’ thought processes and decision-making behaviours, a 
constructivist approach was required for the first phase of intervention development. 
Following the suggestions of Hammersley on subtle realism, I have assumed that an 
independent reality exists, but one which cannot be directly accessed; knowledge of 
this reality is a human construction, based on assumptions and purpose (180). Beyond 
this, I also agree with the suggestions of Patton: that practical research questions can 
be addressed without definite allegiance to a specific philosophical stance and that 
‘methods of qualitative inquiry now stand on their own as reasonable ways to find out 
what is happening in programmes and other human settings’ (181). 
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In qualitative research, the aim determines the most appropriate methodology and 
type of analysis (182). However, in my experience, different methodologies offered 
diverse but potentially useful perspectives on how GPs face the issue of multimorbidity. 
Qualitative methods are generally not ‘pure’ but textured with features and ‘hues’ of 
many possible approaches (183). So during this thesis, I have come to appreciate the 
need for a ‘situated methodology’: adopting a research-centred view of the place of 
methodological rules and adapting methodology to the research situation (184). I have 
taken a ‘bricoleur’ approach by first synthesizing existing qualitative studies but then 
conducting a qualitative interview study that incorporated many features of grounded 
theory (which traditionally eschews prior systematic reviews). The coding of data using 
theoretical frameworks in the intervention development and feasibility studies is more 
akin to framework analysis (185). Thus, rather than adopting one qualitative method 
across the thesis, I have used different approaches depending on the study or phase of 
research (186).  
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5.1. Abstract 
Objective  
To synthesize the existing published literature on the perceptions of GPs or their 
equivalent on the clinical management of multimorbidity and determine targets for 
future research that aims to improve clinical care in multimorbidity.  
 
Design  
Systematic review and meta-ethnographic synthesis of primary studies that used 
qualitative methods to explore GPs’ experiences of clinical management of 
multimorbidity or multiple chronic diseases. 
 
Data sources  
EMBASE, Medline, CINAHL, PsycInfo, Academic Search Complete, SocIndex, Social 
Science Full Text, and digital theses/online libraries (database inception to September 
2012) to identify literature using qualitative methods (focus groups or interviews). 
 
Review methods  
The seven step meta-ethnographic approach described by Noblit and Hare, which 
involves cross-interpretation between studies while preserving the context of the 
primary data. 
 
Results  
Of 1805 articles identified, 37 were reviewed in detail and ten were included, including 
a total of 275 GPs in seven different countries. Four areas of difficulty specific to the 
management of multimorbidity emerged from these papers: disorganization and 
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fragmentation of health care; the inadequacy of guidelines and evidence based 
medicine; challenges in delivering patient-centred care; and barriers to shared 
decision-making. A ‘line of argument’ was drawn which described GPs’ sense of 
isolation in decision-making for multimorbid patients. 
 
Conclusions 
This systematic review shows that the problem areas for GPs in the management of 
multimorbidity may be classified into four domains. There will be no ‘one size fits all’ 
intervention for multimorbidity but these domains may be useful targets to guide the 
development of interventions to assist healthcare professionals and improve the 
provision of care to patients with multimorbidity. 
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5.2. Introduction  
Multimorbidity, the co-existence of two or more long-term conditions in an individual 
patient, is increasingly the norm in chronic disease management in primary care (2, 33). 
The management of patients with multiple morbidities presents unique challenges for 
healthcare professionals, and there is evidence that patients with multimorbidity 
receive a lower quality of care than those with single diseases (85, 187). Healthcare 
utilisation, hospitalization rates and total healthcare costs are higher among 
multimorbid patients, even in systems where access to secondary care is restricted to 
referral by a primary care physician (3, 4, 188). 
The epidemiology of multimorbidity is thus well described and there is now a need for 
interventions to improve healthcare in this patient group (145, 189). A necessary step 
in the development of interventions is to understand why problems arise and what 
processes in the delivery of care are amenable to change. Interviews with stakeholders 
such as healthcare professionals can be important sources of this information (8). To 
date, qualitative studies from a range of countries have elicited GPs’ views on 
challenges in the clinical management of multimorbidity, with diverse and sometimes 
conflicting findings. A synthesis of these studies has the potential to achieve a greater 
conceptual understanding of the challenges associated with multimorbidity than a 
single empirical study.  
Meta-ethnography, one of the most commonly used methods for synthesizing 
qualitative research studies, employs a process of comparison and cross-interpretation 
between studies while preserving the context of primary data (190). Similar to 
traditional systematic reviews, this process can generate new insights, highlight gaps in 
our knowledge and show areas of data saturation where no further primary research is 
required (191).  
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An awareness of the overall picture of challenges faced by GPs in multimorbidity is 
needed to direct research efforts and intervention development in this field. To achieve 
this, we synthesised and analysed the existing literature on the views of GPs on the 
management of multimorbid patients and determined targets for future research to 
improve multimorbidity care.  
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5.3. Methods  
The seven step model of meta-ethnography described by Noblit and Hare was used to 
guide the search and synthesis (192). (The study protocol is provided in Supplementary 
material 1.)  
The first step involved a clear statement of the specific research question and the 
contribution it will make to the field.  
In step two, a search strategy was devised to retrieve papers related to this aim. We 
focused our search to locate primary studies that used qualitative methods to explore 
the clinical management of multimorbidity or multiple chronic conditions by GPs or 
their equivalent. We searched seven databases using database specific search terms 
and validated methods for retrieving qualitative studies: EMBASE (Elsevier), Medline 
(Ovid), CINAHL, PsycInfo, Academic Search Complete, SocIndex, Social Science Full 
Text(all Ebsco) (search terms provided in Supplementary material 2)(193-196). We 
supplemented this by searching databases of grey literature and reference lists. The 
search was not limited by language or dates of publication. The titles and abstracts of 
retrieved citations were read by one reviewer (CS). Full papers were ordered for all 
potentially relevant abstracts (197). These papers were reviewed by two researchers 
(CS, CB) and included if they met our inclusion criteria. Studies that examined the 
management of multimorbidity as part of a wider research question were included. We 
assessed the quality of included studies using the Critical Appraisal Skills Programme 
(CASP) for qualitative research (198). Assessment of study quality was not used to 
exclude studies that otherwise met the inclusion criteria, but gave useful insights into 
the methods used for data collection and analysis. 
Step three of the meta-ethnographic synthesis involved reading the studies. Initially 
two reviewers (CS and CB) read and re-read the included studies, and independently 
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listed the main findings from each one. Study findings were defined as all data in the 
results and discussion sections of the included papers – including both the first order 
interpretations (views of the participants) and second order interpretations (views of 
authors). In studies where GPs were interviewed with another healthcare professional, 
the analysis was restricted to the views of the GP where possible. We abstracted data 
on standard fields such as study aims, design, methods, setting and participants (data 
abstraction form provided in Supplementary material 3) (199). Data was entered in to 
QSR International’s NVivo 9 software to assist our qualitative analysis and synthesis 
(200).  
In step four, we determined how the studies were related to each other by comparing 
individual study findings. Four key concepts were chosen which reflected the main 
findings of all included studies. 
In step five, studies were translated into each other by examining the contribution of 
each study to a key concept. Within the key concepts, similarities and differences in 
study findings and contexts were noted, and deviant cases were sought. To address the 
potential for clinical bias a third reviewer with a non-medical background (SMH) 
independently read all included papers and cross-checked the derivation and 
development of the key concepts. 
In step six, we synthesized the translations in each key concept to develop third order 
interpretations, or higher levels of abstraction of the data for each key concept. We 
linked the third order interpretations using a ‘line of argument’, which represented the 
overarching perspective of GPs towards multimorbidity.  
The final step involved expressing the results of the synthesis, for which we used 
tables, figures and text. The ‘Enhancing transparency in reporting the synthesis of 
qualitative research’ (ENTREQ) statement was used to inform the reporting of our 
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results (provided in Supplementary material 4) (201). Additionally, a summary of our 
findings were supplied to the first authors of all included papers, in order to validate 
our findings as representative of the original sources. 
 
5.4. Results  
The electronic database search returned 2,005 citations, leaving 1805 citations after 
removal of duplicates (Figure 4). A further 1768 citations were excluded by reading the 
title or abstract: 48 did not concern primary care, 891 were not qualitative studies, 769 
did not concern multimorbidity, and 60 did not concern the GP’s perspective. Full text 
articles were retrieved for 37 citations. Eleven of these were excluded because they did 
not use qualitative methods. A further 16 articles were excluded because, although 
they concerned patients with multiple chronic conditions, their exploration was 
focused on the management of an index condition. One possible relevant citation was 
in abstract form only (the study authors were contacted and the full account of this 
data has not been published yet) (details on excluded full texts are available in 
Supplementary material 5). One additional study was retrieved from reference 
searching of the nine remaining studies. Ten studies were included in the final 
synthesis. 
The included studies were conducted in seven countries: Belgium, England, Germany, 
Ireland, Scotland, the Netherlands and the United States (Table 1). A total of 275 GPs 
were involved; five studies used focus groups and five used interviews with individual 
GPs. One of the included articles was published in German. The authors were contacted 
for an English translation and as none was available, the article was translated by a 
native German speaker in collaboration with CS. 
 
78 
 
 
Figure 4. Flow chart of studies in the systematic review 
 
The overall quality of the ten included studies was high, with all papers meeting the 
majority of CASP criteria (details available in Supplementary material 6). The most 
common weaknesses related to data saturation (not reported in six studies) (202-207) 
and reflexivity (not discussed in five studies) (204-206, 208, 209). GPs with 
academic/research affiliations were over-represented as research subjects in five 
studies, representing a potential source of bias (202, 205, 208-210).  
Six studies primarily focused on multimorbidity. In these studies, multimorbidity was 
defined for study participants as two or more chronic conditions (203, 205, 208, 211) or 
introduced to participants using a multimorbid case vignette (209) or an editorial on 
multimorbidity (202). Four studies retrieved by our search did not focus primarily on 
multimorbidity but were included as multimorbidity emerged as an important issue for 
study participants; two studies addressed polypharmacy (207, 210) and two explored 
the role of guidelines in primary care (204, 206). 
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Table 1. Characteristics of studies included in the systematic review (n=10) 
First 
Author 
Objective Data Collection Participants (n) Qualitative 
methodology 
/analysis 
Country Year 
of 
pub 
Smith 
(202) 
To explore the views and attitudes 
of GPs and pharmacists managing 
patients with multimorbidity in 
primary care. 
Focus group with topic guide; 
participants were given a 
published editorial on 
multimorbidity before hand 
GPs (13) & pharmacists.  
GPs were tutors to undergraduate 
medical students, worked in a mix of 
rural/urban, deprived/affluent 
practice and varied by gender and 
years of experience 
Framework Ireland 2010 
O'Brien 
(203) 
To understand GPs and practice 
nurses' experiences of managing 
multimorbidity in deprived areas 
and elicit views on what might help. 
Individual semi-structured 
interview facilitated by 
researched topic guide 
GPs (15) & nurses, working in areas of 
high deprivation in Scotland 
Constant 
comparison 
Scotland 2011 
Steinman 
(204) 
To investigate clinician attitudes 
about the usefulness of heart failure 
guidelines in patients of various 
ages/morbidity 
Telephone based interview using 
Likert scales followed by open 
ended questions 
Primary Care Practitioners (48/58) 
and Internists (10/58) responsible for 
sub-optimally managed patients with 
heart failure. 
Content analysis US 2012 
Fried 
(205) 
To explore clinicians' perspectives of 
and experiences with therapeutic 
decision-making for older persons 
with multiple medical conditions 
Focus groups with broad 
discussion initially, then focused 
questions on polypharmacy, side 
effects, and evidence based 
medicine in multimorbidity 
GPs (36) purposively sampled to vary 
on academic, community and Veteran 
Affair settings 
Content analysis US 2011 
Solomen  
(206) 
To explore the relationship between 
prescribing guidelines and patient-
partnership by exploring the 
attitudes of patients, GPs and 
prescribing advisors 
Semi-structured interviews GPs (8) sampled using maximum 
variation by location, gender, single 
vs. group practice 
Framework  England 2012 
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Anthierens 
(207) 
To describe GPs' views and beliefs 
on polypharmacy  
Semi-structured interviews 
 
65 GPs working in mixed rich/poor 
urban environment 
Content Analysis Belgium 2010 
Bower 
(208) 
To explore GP and nurse perceptions 
of multimorbidity and the influence 
on service organization and clinical 
decision-making 
Individual semi-structured 
interview using topic guide with 
questions and case vignettes.  
GPs (15) & nurses, working in a pay 
for performance system. Purposively 
sampled from research network, to 
vary on list size and deprivation. 
Framework England 2011 
Schuling 
(209) 
To explore how experienced GPs 
feel about deprescribing medication 
in older patients with multimorbidity 
and to what extent they involve 
patients in these decisions. 
Focus groups GPs (29) split into 3 groups. All were 
GP trainers of at least 5yrs experience 
'used to reflecting on their practice' 
Thematic  Netherlands 2012 
Marx 
(210) 
To explore the ‘dilemma of 
polypharmacy’ in primary care 
Focus groups GPs (21) in three focus groups. 
Fulltime GPs, junior and senior 
academic GPs, conducted at an 
academic GP conference. 
Mind maps and 
grounded 
theory 
Germany 2009 
Luijks 
(211) 
To explore GPs’ considerations and 
main aims in the management of 
multimorbidity, and factors 
influencing this management in daily 
practice. 
 
Focus groups using an interview 
guide 
Purposively sampled GPs (25), 
with/out involvement in 
training/academia, in five focus 
groups. 
Constant 
comparison 
Netherlands 2012 
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Translation of included studies 
GPs in all studies reported challenges in multimorbidity, which they faced with 
“moderate optimism to something close to despair” (209). Even in the context of 
deprivation, some participants reported feeling like a “wrung out rag” after complex 
multimorbidity consultations while others felt “energised” by the “privilege and 
rewards” that could be obtained from working in such a complex environment (203). 
Four key concepts that reflected the principal findings of all included studies were 
determined (Figure 5). The key concepts are described below and with quotations in 
Table 2. The subthemes in each key concept are highlighted in bold in the text and are 
shown in tabular form in Supplementary material 7. 
 
 
 
Figure 5. Four domains in which GPs experience difficulties in the management of 
patients with multimorbidity. 
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Disorganisation and fragmentation of health care 
The included studies covered a range of different health systems, all of which lacked 
specific systems for treating patients with multimorbidity. In most studies this lack of 
organisation hampered care by causing logistical difficulties and excessive consultation 
demands on the patient and their GP. Only one study mentioned that these problems 
were not serious enough to warrant a change in service organisation (208).  
The prevailing structure of primary healthcare reduced GPs' ability to respond to the 
needs of patients with multimorbidity. Insufficient consultation time led to amended or 
suboptimal approaches in many cases (202, 203, 208). It was suggested that weighting 
consultation lengths according to the complexity of multimorbidity would facilitate 
more effective management (202, 208). 
Fragmented care resulted from “the involvement of several medical specialists, who 
each emphasize the importance of ‘their’ guideline” (209) and “poor communication 
from specialists and hospitals to the family physician” (210) which meant that “co-
ordination and overview on medication were hard to maintain” (211). In some studies, 
GPs had a broad sense of responsibility towards overseeing and screening patients’ 
medications (207, 210, 211); others were unsure about their role in screening 
prescriptions and felt that a clear line of responsibility was required (202). It was 
suggested that specialists did not “consider the wider harms and benefits of organ-
specific intervention”, thereby adding to the problems of multimorbidity, in contrast to 
GPs who had a “holistic” view of the patient; “The cardiologists, you know, don’t mind 
if they bleed to death” (205). 
Despite these reservations, the input of specialists was desired. A “balance of equals” 
was called for, that would allow GPs and specialists to discuss complex patients, and 
improve the awareness of complexity in multimorbidity amongst specialists (202, 210). 
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This would help all doctors involved “to speak with one voice. Different stories provoke 
distrust”(209). 
 
The inadequacy of guidelines and evidence based medicine 
There was concern amongst GPs about clinical guidelines, which are “generally written 
for sole conditions” and do not account for “the unique circumstances of each patient” 
(204, 206). Most GPs felt guidelines were less useful in multimorbidity and that they 
actually added to the complexity in some cases: “no one can tell you the added benefit 
of an additional agent for blood pressure if you are already on ten” (205, 209). 
However, others felt that using guidelines in multimorbidity ensured patients received 
the best quality care: “why should their asthma be treated any differently just because 
they've got asthma and heart disease and you know osteoporosis or whatever” (208). 
GPs doubted if the evidence underpinning guidelines could be extrapolated to patients 
with multimorbidity: “The guidelines are going to be set for optimum situations, and 
someone with multiple comorbidities [is] not going to be optimum”(204-206, 210). 
They also questioned the relevance of disease specific outcomes and guideline 
recommendations for the use of primary prevention (i.e. antihypertensive or lipid 
lowering agents) in multimorbidity, preferring to orient management to symptoms or 
quality of life (202, 204). 
GPs adopted modified approaches to guidelines, such as estimating the risk associated 
with particular diseases/treatments (205, 209). However, some felt this modification 
was in conflict with “best practice” and felt guilt for not implementing guidelines fully 
(203, 209). Initiatives that linked physician reimbursement with adherence to 
guidelines were seen as a threat to GPs’ ability to deliver patient-centred care (203, 
205). 
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Challenges in delivering patient-centred care  
In response to the many demands of multimorbidity, GPs recognized the importance of 
delivering patient-centred care, which incorporated two principal concepts: 
individualised management and a generalist approach (202-205, 207-211). Delivering 
patient-centred care was seen as a useful approach by some but a challenge for others. 
For instance, some GPs felt that taking a broader view of the patient, incorporating 
nonmedical or psychosocial issues, increased the level of complexity in their 
management (203). However, for others adopting a patient-centred approach was seen 
as a way of resolving the conflicts and uncertainty that can occur, particularly with co-
implementation of multiple sets of guidelines (203, 211).  
In most studies, the longitudinal nature of the patient-GP relationship was seen as a 
“major facilitator” and “elementary component” of patient-centred care in 
multimorbidity (202, 203, 207-211). Within the specific context of deprivation, 
longitudinal care was “potentially transformative” by giving “time to build relationships 
with patients” but it was also was a source of problems, by creating dependence and 
increased demands by patients for consultations (203).  
The impact of treatment burden was an important consideration given the greater 
costs and risk of adverse drug events associated with the use of multiple medications 
(202, 208, 211). This burden was compounded by certain patient characteristics such 
as cognitive or memory problems, poor social supports and finances, and low levels of 
motivation (202-205, 207, 208) which were likely to affect a patient’s ability to 
understand and adhere to treatment (204, 205, 209-211).  
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Challenges in shared decision-making 
Shared decision-making was considered to be more complicated in the context of 
multimorbidity due to many of the issues discussed above. The importance of eliciting a 
patient’s preferences was widely acknowledged, but GPs had difficulties doing this in 
practice (209, 211). GPs reported that many patients actively participate in decision-
making, can prioritize and are “good with trial and error” (208, 209). However, for 
certain patients making choices could be a “source of distress” and contributed to them 
becoming “over the top anxious about their conditions” (208). Discussing the risks and 
outcomes associated with treatment options in a way that facilitated patient 
involvement was particularly challenging, as was discussing the balance between 
quantity and quality of life (203-205, 209, 211). In response to difficulties in shared 
decision-making, GPs employed a range of techniques including prioritization of the 
doctor’s or the patient’s agenda (207, 208, 210), avoidance of decision-making (202, 
209), drawing on one’s own personal experience (210) or using additional 
investigations to support a decision (205). 
Enhanced communication skills were needed in multimorbidity to facilitate clear and 
concise discussion with patients on the interplay between their chronic conditions and 
to help with deprescribing medications, which if done badly could be interpreted as 
withdrawing care (205, 209, 210). GPs felt they had a pivotal role to play in patients 
who were in the advanced stages of a chronic disease but due to multimorbidity may 
no longer be receiving specialist input. In this setting, adopting a palliative approach 
was useful when making decisions on medications (209, 211). 
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Third order interpretations and the ‘line of argument’ 
By synthesizing the individual contributions of each study to the key concepts, third 
order interpretations were generated and linked using a ‘line of argument’ (Table 2).  
1) Disorganisation and fragmentation of health care: The involvement of multiple 
specialists and the emphasis on single disease care is antagonistic to the ‘holistic’ goals 
of GPs. This problem is compounded by poor co-ordination and communication within 
the health service, leaving GPs feeling excluded from their patients’ care and with a 
sense of uncertainty regarding their role.   
2) The inadequacy of guidelines and evidence based medicine: Guidelines offer GPs less 
support in the management of multimorbid patients and may in fact cause additional 
problems when they try to adhere to them.  
3) Challenges in delivering patient-centred care: Patient-centredness is an overriding 
principal for GPs in multimorbidity but trying to achieve this increases the complexity of 
care in some cases, and can lead the GP into additional conflict with specialist services 
or evidence based medicine. 
4) Challenges in shared decision-making: The patient’s role in decision-making in 
multimorbidity is limited by difficulties in communicating risk-benefit and outcomes in 
a field where there is much more uncertainty on these issues. 
These key concepts represent four problematic domains in the provision of healthcare 
in multimorbidity, as seen by GPs. The line of argument linking these domains suggests 
that GPs feel isolated in the management of patients with multimorbidity, a group that 
they are specifically tasked with caring for. 
  
87 
 
Table 2. Translations between studies with third order interpretations. 
First 
Author 
Disorganisation & Fragmentation of 
health care 
The inadequacy of guidelines & 
evidence based medicine 
Challenges in patient-centred care Challenges in shared decision-
making 
Smith 
(202) 
‘lines of communication need time and 
nobody appears to have time’ 
 
‘collusion of anonymity, which is, you 
know, this is not my patient, not my 
patient’ 
 
‘the paradox faced by 
conscientious GPs in attempting to 
balance the potentially competing 
demands of health promotion, 
evidence-based medicine, and the 
use of multiple medications’ 
‘a focus on function and quality of 
life was preferable to considering 
specific disease outcome measures’ 
 
‘..decision-making very difficult to 
achieve.’ 
 
‘decisions were linked to the theme 
of avoidance of complex issues 
which...can appear to become 
increasingly problematic and 
unsolvable’ 
O'Brien 
(203) 
 
‘ adaptation of existing practice 
systems, particularly appointment 
length, relationship continuity, and 
referral systems for resources outside 
primary care, may improve services 
from the perspectives of professionals’ 
‘need .. to demonstrate that we 
are interested in (patients) as a 
person, not someone who has 
heart failure’ 
‘wanted to develop relationships 
with patients because she thought 
that greater understanding of their 
circumstances would help her get 
to the root of (medical) problems’ 
‘there was a need to address ‘a bit of 
the patient’s agenda and our agenda’ 
within consultations’ 
Steinman 
(204) 
- ‘...those with multiple comorbid 
conditions were more likely to 
experience harm from aggressive 
guideline based treatments’ 
‘guidelines represent a criterion 
standard of evidence-based 
care....regardless of patient age or 
comorbid burden’ 
‘Each patient is a unique situation 
and is not going to be the same as 
another patient…. We have to go by 
the individual patient, by the 
patient’s comfort, how is he feeling, 
and how is he doing.’ 
 
 
 
‘a suggested approach to decision-
making for older adults that provides 
guidance on prioritizing care, 
accounting for comorbid conditions, 
and factoring in the role of estimated 
life expectancy’ 
Fried 
(205) 
‘fragmentation of care for patients who 
receive care for their multiple 
conditions from many physicians.’ 
 
‘the limitations imposed by current 
reimbursement systems, which fail to 
‘If they cannot manage... I am not 
going to complicate it further by 
adding something to get to the 
goal range.’ 
 
‘other clinicians believed that 
‘Tailoring their approach …from a 
consideration of such factors as 
patients' cognition and availability 
of social support’ 
 
‘...conflicts between what they 
wanted to do for the patient and 
what the patient wanted’ 
 
‘...patients' and families' inaccurate 
understanding of harms and benefits, 
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acknowledge the complexities of caring 
for older persons with multiple 
conditions’ 
guideline-directed care would 
produce the best outcomes’ 
and they described performing 
testing to help patients understand 
their risk.’ 
Solomen 
(206) 
- ‘there was a perception that real 
patients differ from those 
recruited to the trials that inform 
guidelines’ 
‘Many GPs felt they needed  
to be able to interpret guidelines in 
the context of individual patients’ 
‘ to reach a compromise by following 
guidelines and accommodating 
patient factors, such as patient 
preferences or the patient’s ability to 
tolerate medicines’ 
Anthierens 
(207) 
‘ The co-ordination of the medication 
regime of different disciplines is a tough 
job...”  
‘preventive aims are often minimal 
considering their age and 
polypathology, which is in contrast 
with guidelines talking about one 
specific disease. ’ 
‘As a GP you have a broader view of 
your patient. You look at him/her 
from his own life.’ 
‘They have a holistic view of the 
patient because of the long standing 
doctor-patient relationship.…. a very 
tough job for GPs with major 
implications for their workload’ 
Bower 
(208) 
‘clash between services and the needs 
of patients was most salient in terms of 
logistics and inconvenience’ 
 
‘Difficulties in information sharing 
between professionals meant that 
patients often had to co-ordinate care’ 
 
 
‘...ambivalence about the need to 
consistently change clinical 
practice to reflect multimorbidity’ 
 
‘...why should their asthma be 
treated any differently just 
because they’ve got asthma and 
heart disease and you know, 
osteoporosis or whatever’ 
‘Weighing up what that patient can 
manage on the conditions they 
have, as to what it actually says to 
do.’ 
 
‘benefits of continuity of care in 
patients with multimorbidity’ 
 
 
‘Dealing with multiple competing 
agendas in multimorbidity was 
important.’ 
 
‘limited impact of multimorbidity on 
clinical decision-making’  
 
 
Schuling 
(209) 
‘...medication lists of the doctors 
involved are not exchanged and are 
consequently inconsistent.’ 
‘...several healthcare providers are  
involved in a patient’s treatment and 
communication is sometimes poor’  
‘guidelines are kind of a hindrance. 
At the moment they do not cater 
for older patients.’ 
 
‘ I have difficulty not following the 
guidelines if I don’t have good 
reasons to do so. ‘ 
‘GPs report to support the concept 
of a patient-centred management 
as best practice’ 
 
‘take her quality of life into account 
and ask myself will she live long 
enough to benefit from this 
(preventive) drug? ‘ 
‘the importance of exploring patient 
preferences about treatment goals, in 
practice GPs appear hesitant.’ 
 
‘… GPs tend to avoid discussing 
withdrawal of preventive medication 
with their elderly patients’ 
Marx 
(210) 
‘poor communication from specialists 
and hospitals to the family physician’ 
‘highlights the need for professional 
‘The desire of family doctors to 
deliver the best possible patient 
care quickly leads to 
‘conflict arose in the actions of GPs 
trying to deliver personalized care 
to individuals and trying to 
‘uncertainty could be counteracted 
by good communication between the 
doctor and patient.’ 
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discussion on the one hand and 
avoiding unnecessary medication by 
multiple prescribers on the other hand.’ 
polypharmacy, if guidelines are 
used’ 
 
delivering guideline orientated 
care’ 
 
‘the patient and the doctor are in an 
interactive process, which 
necessitates careful negotiation’ 
Luijks 
(211) 
 
‘in multimorbidity, fragmentation of 
care is a pitfall.... stimulated by disease-
centred reimbursement systems’  
 
‘ impeding multimorbidity 
management... insufficient time and 
compensation’ 
‘adhering to standard regimens or 
strict guidelines was unwanted, as 
it contradicts their integrated 
perception of a unique person 
with a specific combination of 
diseases’ 
 
‘A personal patient–doctor 
relationship was considered a 
major facilitator in the 
management of multimorbidity’ 
‘patient-centredness can be 
regarded as ‘tool’ to counteract 
multimorbidity’s potential pitfalls’ 
‘GPs agreed that they want to involve 
their patients’ perspectives and 
preferences into the decision-making 
process’ 
 
TOIs The involvement of multiple specialists 
each operating on a single disease 
paradigm without an overview of the 
‘whole patient’ leads to fragmented 
care in multimorbidity. Single disease 
care is antagonistic to the goals of GPs 
in primary care. This problem is 
compounded by poor co-ordination and 
communication within the health 
service, leaving GPs feeling excluded 
from their patients care and with a 
sense of uncertainty regarding their 
role.  
GPs have reservations about the 
outcomes and risk-benefit of 
guidelines in multimorbid patients. 
Although useful as a template, GPs 
feel that guidelines offer them less 
guidance or support for 
multimorbid patients and may in 
fact cause additional problems 
when they try to adhere to them. 
Patient-centred care is an 
overriding principal for GPs in 
multimorbidity and incorporates 
the principles of individualization 
and generalism. Trying to achieve 
this aim increases the complexity of 
care in some cases, and can lead 
the GP into additional conflict with 
specialist services or evidence 
based medicine. 
While GPs recognize the importance 
of involving patients in decision-
making process, they have difficulties 
in doing so. Communicating risk and 
outcomes in way that will engage 
patients in the decision-making 
process is an area that GPs feel 
unskilled in, thereby limiting the 
patients influence as factor that 
would help the decision-making 
process  
Italicized extracts represent first order interpretations (views of participants in included studies). Non-italicized extracts represent second order 
interpretations (views of authors of included studies). TOIs= third order interpretations.  
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5.5. Discussion  
The studies presented here used a bottom-up approach to explore the management of 
patients with multimorbidity. This paper is the first to our knowledge to systemically 
review and synthesize their findings, and demonstrates the diversity in how GPs see 
this issue. The difficulties that GPs encounter span a number of clinical domains 
including system factors, the evidence base for chronic disease management and their 
own communication skills in the context of multiple physician and patient agendas. 
These findings are important because they highlight the separate but interacting areas 
of clinical practice that require intervention to improve care in multimorbidity. Thus, 
this study is additive to the findings of the individual studies reviewed; synthesizing the 
contributions of existing qualitative investigations in this area has led to a broader 
description and fuller understanding of the range of challenges that exist. Given the 
considerable overlap and repetition of data that emerged from the primary studies, it is 
unlikely that further scoping work on the challenges of multimorbidity will be useful. 
However, despite the commonalities, the significance of each domain varied between 
settings. Further research should focus on the reasons why some domains matter more 
in particular settings and how local factors modify and influence these domains, with a 
view to exploring what solutions exist and what those solutions may be (212). There 
will not be a ‘one size fits all’ intervention to support and improve the quality of care in 
multimorbidity. However, the domains that have emerged from this review give a 
useful framework for future work in this field. 
 
Comparison with other research 
Disorganisation and fragmentation of care 
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Integrating patient care across services is important in all aspects of medicine, but 
there is a pressing need to address this in multimorbidity. Patients attending four or 
more doctors experience problems such as conflicting medical advice, unavailable test 
results and duplication of tests more commonly (213). Our study indicates that, across 
settings, GPs receive poor communication from other care providers in multimorbidity, 
leaving them guessing about the course of management. Enhanced use of information 
technology may support more seamless multimorbidity care, by allowing bi-directional 
communication and local integration between care providers.  
Satisfaction with prevailing health systems also varied between studies. Generalisations 
relating to a health system cannot be made from one single study, but this divergence 
is worthy of further exploration. For instance, a comparative analysis, using a 
multimorbidity perspective, of the strengths and weaknesses of the UK system (which 
uses explicit quality frameworks for chronic disease management) and a health system 
without such an approach may help inform policy and the development of 
interventions at health system level.  
 
 The inadequacy of guidelines and evidence based medicine 
GPs in the studies reviewed here desired evidence on which to base their management 
but had mixed feelings on the clinical utility of guidelines as they currently stand. This 
finding is supported by prior studies showing that, internationally, few guidelines offer 
modified advice for patients with multimorbidity (126, 127). To increase the relevance 
of clinical guidelines for multimorbid patients, our findings support the call for greater 
representation of multimorbid patients in trials and greater involvement of GPs in the 
writing of guidelines (130).  
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Chronic conditions can occur in combinations that are concordant (have synergies in 
treatment) or discordant (conflicting treatments or interactions) (85). Although the 
synergies between certain conditions were discussed in the papers reviewed here, 
examples of specific discordant conditions were rare. It would be useful to explore 
what discordant combinations commonly occur in practice. This information could be 
used to inform the development of caveats in guidelines, educational initiatives or 
prioritization tools that would support safe approaches to competing diseases (121). 
 
Delivering patient-centred care 
This domain emerged as an intuitive and over-riding goal of GPs in all studies, thus 
interventions in multimorbidity must help GPs deliver patient-centred care. Continuity 
of care emerged as an important tenet of patient-centredness and should be promoted 
in any such interventions. Three subtypes of continuity of care have been previously 
described (214). Informational and management continuity were seen here as 
necessary for patient safety and cohesive management. However, it was relational 
continuity that appeared to most facilitate care in multimorbidity, by allowing GPs to 
foster trust, anticipate preferences, and empower their patients over time. GPs felt 
that multimorbid patients with cognitive impairment, mental health issues or low social 
support require greater attention, and may benefit from more nuanced interventions 
to support their care. 
 
Challenges in shared decision-making 
Shared decision-making is facilitated by many aspects of primary care (215-217). 
Nevertheless, GPs reported a need for additional skills in shared decision-making in 
multimorbid patients, especially for complex decisions that involve not prescribing or 
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discontinuing medications. It is known that interventions to improve shared decision-
making may fail due to barriers such as lack of time and perceived lack of suitability of 
the patient (218, 219). Given the overlap between these barriers and those that GPs 
encounter in multimorbidity, it is likely that special attention is warranted for the 
development of models of decision-making for multimorbid patients. Evaluating 
existing models of shared decision-making, such as the choice talk/option talk/decision 
talk model described by Elwyn and colleagues, in clinical encounters with multimorbid 
patients may be a useful place to start this process (220). 
 
Usefulness of meta-ethnography 
The systematic approach of meta-ethnography as applied in this study has a number of 
strengths. It gives a fuller description of multimorbidity care while preserving the 
important contextual features that are inherent in general practice research. Our 
themes, developed from the experiences of 275 participants, indicated considerable 
overlap from each of the primary studies. Nevertheless, different opinions within 
particular themes gave useful insights into how system factors and context can 
influence practice. The step by step approach used in our analysis generated themes in 
a transparent and reproducible way. The robustness of our findings is supported by 
several features. First, the quality of the studies reviewed was assessed using a 
published framework and quality levels were uniformly high. Secondly, there was 
concordance in the themes derived by non-clinical and the clinical reviewers on the 
research team. Thirdly, the findings from our analysis were disseminated to the authors 
of the primary studies. In the resulting feedback, the authors felt their results were 
represented within the findings of the synthesis. 
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Limitations and challenges 
Retrieving qualitative studies from biomedical databases is challenging despite recent 
advances in the indexing of qualitative literature. We used validated combinations of 
qualitative search terms to optimize the list of citations returned (193-196). 
Furthermore, we also used non-biomedical databases to ensure that articles of 
relevance in the sociology or psychology literature were not missed (197).  
Multimorbidity is not a MeSH (Medical Subject Heading) term and there is a lack of 
consensus on what the term means or encompasses with regard to diseases and 
disease severity (36). We used a broad but less specific search strategy to account for 
this (detailed in Supplementary material 2) which resulted in the retrieval of papers 
with important information on multimorbidity, despite their original focus not being on 
this issue. Achieving consensus on the definition of multimorbidity will be important for 
the generalisability of findings and evaluation of future interventions in this field. 
The term ‘multimorbidity’ was first discussed in the literature in 1976. However, the 
first article that we found investigating this issue with GPs using qualitative methods 
was published in 2009. There has been a surge in quantitative research on 
multimorbidity, which may be explained by the increasing prevalence and economic 
impact of multimorbid patients (51). 
There was no language restriction used for inclusion of studies, and translations of 
potentially relevant titles and papers were conducted. However, we could have missed 
papers not listed on English language databases.  
Although the quality of included studies was generally good, the over-representation of 
academic GPs as participants was a potential source of bias and may limit the 
generalisability of our findings to the overall GP population. Future studies should 
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endeavour to include GPs outside of the academic field to ensure the full range of 
clinical challenges is explored. 
The primary data in our review originated from focus groups or clinical vignettes, 
reflecting what clinicians say rather than what they do. It would be valuable to use 
case-based data in future studies, to see for example what specific conflicts arise 
between guidelines and how shared decision-making is currently broached in practice. 
Such data would also help inform educational programmes in multimorbidity for GPs 
and GP trainees.  
Our findings are limited to the challenges experienced by healthcare professionals in 
management of multimorbidity; the patient perspective also requires consideration. 
Elderly patients report functional decline, poor quality of life, and high healthcare costs 
as major consequences of multimorbidity, therefore these issues should be addressed 
in the development of interventions in this field (46). 
 
5.6. Conclusions  
This systematic review shows that the problem areas for GPs in the management of 
multimorbidity may be classified into four domains: disorganization and fragmentation 
of health care; the inadequacy of guidelines and evidence based medicine; challenges 
in delivering patient-centred care; and barriers to shared decision-making. There will be 
no ‘one fits all’ intervention for multimorbidity but these domains may be useful 
targets to guide the development of interventions that will assist and improve the 
provision of care to multimorbid patients.  
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6.1. Abstract 
Background 
Using clinical guidelines in the management of patients with multimorbidity can lead to 
the prescription of multiple and sometimes conflicting medications.  
 
Aim 
To explore how GPs make decisions when prescribing for multimorbid patients, with a 
view to informing intervention development in this field. 
 
Design and Setting 
In-depth qualitative interviews incorporating chart stimulated recall (CSR) with 
purposively sampled GPs in the Republic of Ireland. 
 
Methods  
Grounded theory analysis with iterative theory development.  
 
Results  
Twenty GPs were interviewed about 51 multimorbid cases. In these cases, GPs 
integrated information from multiple sources including the patient, specialists and 
evidence based medicine. Difficulties arose when recommendations or preferences 
conflicted. GPs responded to these conflicts by ‘satisficing’: accepting care that they 
deemed satisfactory and sufficient for a particular patient. Satisficing was manifest as 
relaxing targets for disease control, negotiating compromise with the patient, or 
making ‘best guesses’ about the most appropriate course of action to take. In 
multimorbid patients perceived as stable, GPs preferred to ‘maintain the status quo’ 
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rather than rationalize medications, even in cases with significant polypharmacy. GPs 
took this approach due to the potential negative repercussions associated with 
changing medications. Proactive changes in medications were facilitated by continuity 
of care, sufficient consultation time and open lines of communication with the patient, 
other healthcare professionals and other GPs.  
 
Conclusion 
GPs respond to conflicts in the management of multimorbidity by satisficing, which 
involves making compromises between patient-centred and evidence-based care. 
These findings will help inform the development of interventions that aim to improve 
medication management and patient-centred care in multimorbidity. 
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6.2. Introduction 
Multimorbidity, the co-occurrence of two or more chronic conditions, affects over 50% 
of patients with chronic disease in primary care and leads to increased mortality, higher 
rates of disability, and lower quality of life (51, 87). For healthcare systems, 
multimorbidity leads to higher rates of healthcare utilization, especially high cost 
services such as hospitalisations and emergency department visits (3, 46, 221). Due to 
the aging demographic, this burden continues to rise and optimizing the management 
of multimorbidity is a major concern for health research, policy and education (59). 
Multimorbid patients are also more likely to experience polypharmacy and potentially 
inappropriate prescribing than patients with single conditions (222, 223). However, 
prescribing ‘appropriately’ in multimorbidity is not always straight forward (111, 116). 
Guidelines exist for most common chronic conditions and offer benefits associated with 
the best available evidence, but adhering to guidelines in the management of a patient 
with multimorbidity almost invariably leads to multiple medications, resulting in 
increased risk of drug interactions, adverse effects and poor adherence (103, 224). 
Furthermore, most guidelines do not address patient preferences, quality of life or the 
expected time to benefit (66). Thus prescribing in multimorbidity poses a dilemma: to 
prescribe a recommended medication that may, via polypharmacy, lead to adverse 
effects or not to prescribe a medication that may have potential benefits (225).  
Despite the prevalence of multimorbidity, there have been few professional-orientated 
interventions developed to improve patient outcomes in this field (145). Prescribing 
behaviour appears to be a worthy candidate for such an intervention. We know that 
GPs question the usefulness of single disease guidelines in multi-disease patients 
(Chapter 5) (226). However, we know little about how GPs choose what to do when 
faced with guidelines that indicate that multiple and sometimes conflicting medicines 
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should be prescribed. An important first step in intervention design is to gain a 
thorough understanding of existing behaviour (8, 227). Thus, our aim in this study was 
to explore how and why GPs make the decisions they do when prescribing for 
multimorbid patients, with a view to informing the development of interventions to 
assist prescribing in multimorbidity care. 
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6.2. Methods 
Design 
We conducted a qualitative study using a grounded theory approach. We performed in-
depth interviews with GPs using chart stimulated recall (CSR), a clinical assessment tool 
that uses a medical chart to stimulate a physician’s recall of a case and its management 
(228, 229).  
 
Setting 
We conducted this study in the Republic of Ireland, where GPs play a gate keeping role 
in the healthcare system. Most GPs in Ireland are private practitioners, but the majority 
also provide public health services to people with the means tested medical card which 
allows free GP care at the point of access (15).  
 
Sampling 
A purposive sample of GPs was selected from attendees at two regional continuing 
professional development meetings and supplemented by snowball sampling where 
necessary to gain representation of GPs by: length of time qualified (over/under ten 
years); practice location (rural/urban); and practice size (single/group practice).  
 
Data collection 
Interviews took place in participants’ clinics between February and November 2013. 
Prior to the interview, we requested GPs to choose patients from their practice that 
had three or more chronic diseases, and were prescribed five or more long-term 
medications for the purpose of CSR. We asked GPs to choose, where feasible, patients 
seen on the day of or the day preceding the interview, to maximise their recollection of 
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the case details. During the interview, the GP was asked to give a summary of each 
patient case including demographics, diagnoses and prescribed medications, and then 
describe the patient’s recent consultations using the medical notes as an aide 
memoire. The interview followed the participant’s description of a chosen patient’s 
sequential consultations as far as possible. A topic guide, which was derived from the 
key findings of a systematic review of the literature (i.e. Chapter 5) (226), was referred 
to during interviews. The topic guide included prompts on the use of clinical guidelines, 
goals of care and shared decision-making, and was modified after each interview to 
pursue emergent themes (the evolution of the topic guides is shown in Supplementary 
material 8). All interviews were conducted by CS, audio-recorded and transcribed in 
full. 
 
Analysis 
Coding was data driven according to the grounded theory approach described by 
Charmaz (166). The first stage involved open coding of GPs’ actions in multimorbidity, 
and the causes, conditions and consequences of these actions. The second stage of 
coding involved categorization of the coded data based on conceptual similarity. 
Divergent cases were actively sought. This approach to coding was agreed a priori by 
team consensus. The first three transcripts were read, coded and compared by CS and 
MB, focusing on interviewing technique and the development of preliminary codes. 
The next three interviews were coded and compared by CS and CB. CS coded all 
remaining interviews as they took place, adhering to the principles of constant 
comparison. Once data collection was complete, the other members of the team (CB, 
SMH, MB) independently coded an additional three randomly assigned interviews. 
Field notes, memos, coding and theoretical development were discussed at regular 
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team meetings. NVivo 10 was used for data management (230). Demographic and 
chronic disease information of the cases discussed were analysed descriptively using 
Microsoft Excel. The consolidated criteria for reporting qualitative research (COREQ) 
statement was used to inform the reporting of our findings (provided in Supplementary 
material 9). Ethical approval was granted by the Clinical Research Ethics Committee of 
the Cork University Teaching Hospitals (reference ECM 4(t) 12/6/12) and from the 
Research Ethics Committee of the Irish College of General Practitioners. 
  
104 
 
6.3. Results 
Twenty GPs were interviewed. Characteristics of participating GPs are shown in Table 
3. A total of fifty one patients with multimorbidity were discussed during the twenty 
interviews. The median patient age was 75 years (range 39-92) and 55% were female. 
Patients had an average of 8.3 chronic conditions and were prescribed an average of 
10.6 regular medications (detail on the each patient’s list of conditions is provided in 
Supplementary material 10). Interviews lasted on average 42 minutes (range 32 to 65 
minutes). Conceptual data saturation occurred at interview 18, as subsequent 
interviews did not contribute to the development of new themes.  
We have selected participant quotations representative of typical responses to 
illustrate our qualitative findings, supplemented with relevant case details where 
applicable.  
 
Table 3. Characteristics of GP participants in qualitative interview study (total 
number of participants=20) 
 % of participants (n) 
Practice Location 
-Rural 
-Urban 
-Mixed 
 
45% (9) 
35% (7) 
20% (4) 
Type of practice 
-Single handed 
-Group practice 
 
30% (6) 
70% (14) 
Length qualified 
<10years in practice 
>10years in practice 
 
30% (6) 
70% (14) 
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Factors influencing decisions in multimorbidity 
Figure 6 shows the diverse range of medical and psychosocial influences on GPs’ 
decisions in multimorbidity. GPs considered and integrated the factors deemed 
relevant to a particular case in order to make an appropriate decision for that patient. 
Multiple chronic conditions did not always lead to difficult decisions, even when 
multiple medications and complex combinations were present.  
“I have a lot of patients with hypertension, lipid disorder and thyroid disease but 
I wouldn’t classify those as multimorbid. They are most of the time fairly 
straight forward. It is only when you add something else into the mix that it gets 
complicated” (gp15) 
 
 
 
Figure 6. Influences on GPs’ decision-making in multimorbidity. 
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Satisficing: An approach to decision-making in multimorbidity 
Conflicts arose in cases due to potential interactions between diseases and 
medications; discrepancies between the patient’s preferences and best practice 
recommendations; or lack of an evidence base relevant to multimorbidity. In response 
to these conflicts, GPs tried to find a balance between optimal disease management 
and patient-centred care using a process of satisficing: settling for chronic disease 
management that was satisfactory and sufficient, given the particular circumstances of 
that patient. Figure 7 shows the different manifestations of satisficing that were 
observed; the approach taken by GPs depended on the patient’s disease trajectory or 
level of stability. 
 
 
 
Figure 7. GPs’ approaches to decision-making in patients with complicated 
multimorbidity 
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Relaxing targets 
Satisficing meant that GPs accepted less stringent levels of disease control than was 
advised by guidelines. This was seen in cases where the management of one disease 
was prioritized over others because of severity or symptoms. 
“I’m not aiming for very tight control - I’m happy if his sugars are running a little 
higher than normal. I mean he has got cardiac failure as well, his life expectancy 
isn’t brilliant - so long term I think, I don’t think it’s his type 2 diabetes that’s 
going to kill him” (gp7 discussing a 77 year old man with nine chronic diseases 
prescribed sixteen regular medications) 
Suboptimal targets were also accepted in patients with poor adherence in whom GPs 
felt that, due to the impact of multiple medications, disease “control is as good as he 
(patient) will allow it to be, he’s not madly compliant” (gp17).  
When patients developed side effects from guideline recommended medications, GPs 
considered other factors before deciding whether to relax disease targets or continue 
the drug:  
“if we increase her drugs for her cardiac failure and she is getting more dizzy, 
then we will always go back to the last stage before she had symptoms.” (gp20 
discussing her decision to prioritize patient comfort in a 71 year old woman 
with cardiac failure, orthostatic hypotension, seven other chronic diseases and 
nine regular medications) 
“I think, I suppose, at the end of it his cardiac and renal function are what are 
going to kill him, not getting up at night to pee”(gp17 discussing his decision to 
prioritize disease control in a 64 year old man with ten chronic diseases and 
thirteen regular medications, whose urinary symptoms are exacerbated by 
diuretics) 
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Negotiating compromise  
Conflicts sometimes arose between what the GP thought best for a patient and the 
patient’s requests or a specialist’s recommendations. Here, GPs negotiated to find a 
satisfactory compromise, using techniques such as concessions over drug dose or 
duration, gradual weaning of medications, or substitution with lower risk alternatives.  
“Well it wouldn’t be ‘my way or the highway’; you need to negotiate it, because 
as you know people have all sorts of kind of fixed ideas about things really and it 
can be difficult to dislodge them.” (gp14 on an 81 year old man with a recent 
myocardial infarction and hypertension who requested anti-inflammatories for 
increasing joint pain.) 
 
Hunches and best guesses 
When presented with a range of options, none of which were clearly right or wrong, 
many GPs used a “hunch” or made a “best guess” as to which option to take. This 
occurred in situations where the reason for a patient’s symptoms was unclear, 
potentially attributable to many of the patient’s existing diagnoses. 
 “he has lots of reasons to be short of breath -so his pulmonary emboli can do it; 
his anaemia can do it, his lobectomy can do it, his CCF could do it and his COPD 
could do it; so ah, it’s basically a case of trying to figure out and sort them out. I 
know him quite well, and what his baseline is, so it’s a case of trying to figure 
out what is the major cause each time he comes in... we generally try and make 
a best guess at it” (gp7 discussing 77 year old man with nine chronic diseases 
on sixteen regular medications) 
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Best guesses were also required because “you don’t have guidelines for every situation- 
there are times when you just have to make a decision as best you can” (gp6). GPs 
relied heavily on their prior knowledge and experience of the patient in this process.  
 
Maintaining the status quo  
Once a multimorbid patient appeared to be stable, GPs’ default approach was to 
“maintain the status quo” (gp1) rather than interfere with drug regimens, unless they 
saw clear evidence of adverse drug effects.  
 “really didn’t entertain changing them because why stir things up?”(gp19) 
 “look she’s on it, she’s fine, it doesn’t bother her, its suiting her fine” (gp12) 
 “like he is very stable on them all but it does seem like an awful lot.” (gp2)  
“she’s doing better than she has in a long time-I’m not going to rock the boat at 
all” (gp11) 
Although concerned about polypharmacy, GPs had a greater fear of medico-legal 
repercussions or negative responses from the patient or their next of kin if rationalizing 
medications led to adverse clinical events:  
 “I think litigation is a huge issue: as I say the wife is on the ball; okay I say ‘look 
let’s get rid of his aspirin and his statin - he has no ischemic heart disease’. And 
then say, he gets a myocardial infarction in four months’ time and you say 
‘should I have left him on the statin?’”(gp6 discussing an 84 year old man with 
hypertension, hyperlipidaemia, osteoarthritis, recent deep venous thrombosis, 
prostate cancer, osteoporosis and constipation on thirteen medications) 
GPs were reassured that the on-going use of some medications was “justified” (gp7) 
because they were commenced by a specialist or due to best practice guidelines, in 
many cases years before:  
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“There is very little we can get away with in terms of manoeuvring with her. She 
has a lot of pathology and she probably needs virtually everything she is on 
there.”(gp9 discussing an 86 year old lady with anxiety, osteoporosis, stage 3 
kidney disease, hypothyroidism, coronary artery disease, atrial fibrillation, 
cardiac failure, osteoarthritis, stress urinary incontinence, COPD, diverticular 
disease, aortic stenosis and constipation on fourteen medications) 
 
Resources to assist decision-making in multimorbidity 
Figure 8 shows the key facilitators to resolving conflicts in prescribing decisions: 
“broadening the loop” of communication to involve others in the decision-making 
process and the availability of time. Deficiencies in these processes were common 
which left GPs less comfortable with their decisions. 
 
Figure 8. Facilitators of decision-making in multimorbidity 
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Broadening the loop to patients 
GPs believed that many multimorbid patients preferred not to be involved in decisions, 
where “the more complex their needs, the more they rely on you to be the final 
arbitrator or the over-seer” (gp19). Some GPs felt that patients would be unable to 
understand the various conflicts and uncertainties faced, and so would “just worry 
about it myself … rather than imparting a huge amount of knowledge” (gp16). This 
contrasted with cases where the GP shared the uncertainty and responsibility for a 
decision with the patient, evident in situations involving younger GPs or those with a 
shorter professional relationship with the patient.  
“you have to go 'this is your life, your decision’ and then give them my advice 
but they have to make the decision for themselves”(gp3 discussing primary 
prevention in a 54 year old man with six chronic diseases on six regular 
medications) 
GPs had specific difficulties talking to multimorbid patients about stopping 
medications; they feared this could be interpreted by the patient as a withdrawal of 
care and potentially damage the doctor-patient relationship. 
“what you are saying by stopping it [a statin] is ‘I’m stopping this now because 
really now you are so old so if you get a heart attack at this stage… 
whatever.”(gp5 discussing the message he feared he would give by stopping a 
statin in an 84 year old lady with seven chronic diseases on eighteen 
medications) 
 
Broadening the loop to other healthcare professionals  
GPs liked to “share the onus of responsibility” (gp16) with specialists and pharmacists in 
complicated multimorbid patients “rather than flying solo on it” (gp14). However, the 
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usefulness of specialist input was limited by a lack of timely access to and 
communication from specialists, or by their single disease rather than generalist 
approach to the patient:  
 “in fairness to them, all their letters were bang on ... for COPD: do the sputum, 
give him the azithromycin, he has the home oxygen- tell him to use that. 
Everything was according to guidelines. Renal the same, trial this - if this doesn’t 
work this is what we're doing - push this as far as we can, nephro-protection 
and all this, and it’s all bang on target. The same for cardiology. But when you 
put it in the clinical setting it isn’t working…” (gp2 discussing a 51 year old man 
with eight chronic diseases on thirteen medications) 
 
Broadening the loop to fellow GPs 
When faced with difficult decisions, many GPs elected to “have a practice discussion 
about it I think, it won’t take very long” (gp18). They found that “to bounce [ideas] off 
your colleagues just helps, even if it is just something like ‘what in the name of God am I 
going to do about this’, it’s really important” (gp8). Single handed GPs struggled in this 
regard, although some used continuing medical education, especially small group 
meetings, as a forum for discussing complicated cases with other GPs. 
 
Time over multiple consultations 
Return consultations were an opportunity to re-evaluate the patient, thereby 
reassuring the GP and patient, giving clarity on the best approach to take, and 
facilitating the management of multiple competing demands:  
“We checked her blood pressure; upped her medications; had a chat about her 
knees; I encouraged her to go back to the weight watchers. I’m going to follow 
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her up in a month’s time; she hasn’t had her bloods done for a bit, so she’ll have 
that done before she gets back. I chatted to her about the antidepressant - she 
was keen on cutting it down but I’ve known her for years and winter is her bad 
time… so, I said ‘Look Mary how about waiting until the spring again we can 
have a chat about it then and just see?’ and maybe if she loses a bit of weight, 
she might find that she is feeling a little bit better in herself and it might be a 
more appropriate time to do it” (gp11 discussing a 52 year old woman with 
depression, anxiety, hypertension, ANA positive arthritis, prior cauda equine 
syndrome, osteoarthritis, obesity and acne on six medications) 
A lack of relational continuity of care adversely affected management, especially in 
some of the larger practices where “you have different people making a clinical 
judgement on him based on how he is from week to week which is difficult” (gp2). 
 
Time within the consultation 
GPs reported that rationalising medications “is time consuming, you definitely want to 
have your wits about you, and without it (extra time) the potential for making mistakes 
is very much increased” (gp14). Thus, lack of time pushed GPs towards “maintaining the 
status quo” rather than active attempts to change management, especially if 
considering changing “something that you have been giving them for the last fifteen 
years -and now you’re suddenly saying the evidence is saying that we shouldn’t be 
giving you aspirin anymore - it takes time, time to explain that to them” (gp6).  
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6.4. Discussion 
This qualitative study demonstrates the range of influences on GPs’ prescribing 
decisions in multimorbid patients. When conflicts arise between these factors, GPs take 
an approach of satisficing – providing care they feel is satisfactory and sufficient for a 
particular patient. With changing chronic disease trajectories, satisficing means 
accepting trade-offs between drugs, diseases and best practice recommendations. In 
stable multimorbidity and in the absence of nuanced communication techniques, GPs 
act to preserve the doctor-patient relationship ahead of medication rationalization.  
 
Strengths and limitations 
The credibility of our findings was enhanced by using chart stimulated recall (CSR), 
which has been shown to be a valid way of assessing clinical decision-making through 
improving recall of actual rather than perceived behaviour. CSR also facilitated probing 
of why certain decisions were made which was necessary for our purpose of identifying 
targets for a professional intervention (228, 229, 231). By combining CSR and grounded 
theory, substantive issues for GPs emerged from our data which are additive to existing 
qualitative research with GPs on multimorbidity, much of which is based on case 
vignettes or focus groups (202, 208, 209, 211). Although we recruited a sample that 
was representative of the national GP profile, those who participated may have had a 
greater interest in, or a particular agenda relating to the study question (232). The 
sample size was likely sufficient given data saturation was achieved (233). Clinician 
researchers have been shown to get richer data from GP participants than non-clinical 
researchers, but can introduce clinical biases into data collection and interpretation 
(234). In this study, the risk of professional bias was addressed by including researchers 
with diverse professional backgrounds on the research team (235).  
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Main findings and comparisons with other studies 
Satisficing, a portmanteau of the words satisfy and suffice, was initially described by 
Simon in 1956 as human decision-making that is limited by “uncertainty about the 
consequences that would follow from each alternative, incomplete information about 
the set of alternatives and complexity that prevents necessary computations from 
being carried out” (236). Satisficing involves evaluation of the options available only 
until an acceptable one is found. It was evident in this study in situations where GPs 
were unable to evaluate the risk-benefit of all potential options for a multimorbid 
patient, because of deficiencies in the evidence base and a lack of time available for 
making decisions.  
In a focus group study, Smith et al. described GPs’ and pharmacists’ views that 
polypharmacy in multimorbid patients resulted from the appropriate prescribing of 
risk-reducing medications indicated by single-disease guidelines (202). The current 
study moves beyond this concept to describe the strategies used by GPs to manage 
multiple medications where conflicting guidance exists.  
Some of the approaches to satisficing, such as relaxing targets for disease control, may 
have arisen due to the relative clinical independence of GPs in the Irish healthcare 
system. This contrasts with the findings of Bower et al. who found greater tensions 
between disease-focused and patient-centred care in English general practice, where 
GPs strive to meet the demands of the Quality Outcomes Framework (208).  
Processes similar to satisficing are also evident in large quantitative studies in 
multimorbidity. For example, studies from the US show that patients with discordant 
multimorbidity are less likely to have guideline-consistent hyperlipidaemia 
management (85, 237). In Switzerland, trends for preventative care are lower in 
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multimorbid patients with dementia (238). However, there is increasing recognition 
that improving adherence to guidelines may not be the best management strategy for 
patients with multiple medical problems (225, 239). 
 
Implications for research and practice 
Although prescribing in multimorbidity is challenging, the potential negative outcomes 
associated with both polypharmacy and suboptimal disease management must be 
remembered (116). Approaches to support GPs’ prescribing in multimorbidity are 
required to mitigate these negative effects. In hospital specialities, there is an 
increasing trend towards multidisciplinary team (MDT) meetings, which operationalize 
collaborative decision-making to deliver evidence-based yet patient-centred care. The 
potential for multidisciplinary review in primary care has also been evaluated in trials 
such as PINCER, a pharmacist-led information technology intervention that reduced 
medication errors in general practice (152). However, the qualitative findings from 
PINCER showed that some ‘prescribing errors’ were over-ruled by GPs on the basis of 
their superior knowledge of the patient and there were concerns about the long-term 
feasibility of pharmacists working in a general practice (153). Participants in our study 
undertook informal case reviews of complicated multimorbid patients with their fellow 
GPs. Even without the rigorous processes of the MDT, participants benefitted from the 
close proximity, ready availability and generalist perspective of their colleagues. 
Collaborative decision-making between GPs deserves further exploration as a potential 
intervention strategy in this field (240).  
Regarding shared decision-making, previous research has shown that although patients 
like to hear about the management options available to them, many still seek and 
accept their GP’s advice on the best option to take (241). This implies that GPs must 
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have the knowledge and confidence to offer patients specific recommendations (242, 
243). Although attempts are underway to improve the attentiveness of guidelines to 
multimorbidity, they will not be able to cover all eventualities in multimorbidity and 
some professional judgement will always be required (121, 142). Relational continuity 
of care was an essential feature of how such judgements were made in this study, and 
should be prioritized in interventions that aim to promote shared decision-making with 
multimorbid patients. 
Lastly, in consultations with patients with multimorbidity, there are often multiple 
competing demands on a GP’s time, which can distract the GP from proactive 
management of medications. A number of trials are already addressing the issue of 
time as part of a multifaceted intervention in multimorbidity and the results of these 
studies are keenly awaited (244, 245). 
 
6.5. Conclusions  
The Cochrane review group suggested that future multimorbidity interventions should 
be embedded with inter-professional collaboration and integrated into existing 
healthcare systems (145). Our results suggest that interventions to support prescribing 
in multimorbidity should also prioritize relational continuity of care, facilitate 
communication with patients on available and preferred options, and provide GPs with 
a means of collaborative decision-making and treatment planning. These findings will 
help inform the development of interventions that aim to improve medication 
management and patient-centred care in multimorbidity.  
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8.1. Abstract 
Background 
To effectively meet the healthcare needs of multimorbid patients, the most important 
psychosocial factors associated with multimorbidity must be discerned. Our aim was to 
examine the association between self-reported adverse childhood experiences (ACE) 
and multimorbidity, and the contribution of other social, behavioural and psychological 
factors to this relationship. 
 
Methods 
We analysed cross-sectional data from the Mitchelstown study, a population based 
cohort recruited from a large primary care centre. ACE was measured by self-report 
using the Centre for Disease Control ACE questionnaire. Multimorbidity status was 
categorized as no, one or two or more chronic conditions, which were ascertained by 
self-report of doctor diagnosis. Ordinal logistic regression was used to calculate odds 
ratios (OR) and 95% confidence intervals (95% CI) for multimorbidity, using ACE as the 
independent variable with adjustment for social (education, public health cover 
through the GMS scheme), behavioural (smoking, exercise, diet, body mass index), and 
psychological factors (anxiety/depression scores). 
 
Results 
Of 2047 participants, 45.3% (n=927, 95% CI 43.1-47.4%) reported multimorbidity. ACE 
was reported by 28.4% (n=248, 95% CI 25.3-31.3%) of multimorbid participants, 21% 
(n=113, 95% CI 18.0-25.1%) of participants with a single chronic condition, and 16% 
(n=83, 95% CI 13.2-19.7%) of those with no chronic conditions. The OR for 
multimorbidity with any history of ACE was 1.6 (95% CI 1.4-2.0, p<0.001). Adjusting for 
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social, behavioural and psychological factors only marginally ameliorated this 
association, OR 1.4 (95% CI 1.1-1.7, p=0.002). 
 
Conclusions 
Multimorbidity is independently associated with a history of adverse childhood 
experiences. These findings demonstrate the psychosocial complexity associated with 
multimorbidity, and should be used to inform healthcare provision in this patient 
cohort.  
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8.2. Introduction 
Multimorbidity, the co-occurrence of two or more chronic conditions, affects over 50% 
of patients with chronic disease in primary care (33, 51). However, the management of 
chronic disease tends to be aligned to individual rather than co-occurring conditions 
(66). This mismatch in patients’ manifestations of disease and healthcare provision 
leads to problems in the co-ordination of care, excessive treatment burdens and high 
levels of healthcare utilisation (3, 226 ). As the prevalence of multimorbidity continues 
to rise, there are calls for re-configuration of how we deliver chronic disease care, to 
better meet the needs of our aging multimorbid populations (51, 276, 277). 
To date, efforts have focused on increasing the applicability of guidelines to 
multimorbidity and integrating guidelines to limit duplication and waste (121, 276). 
However, it is increasingly evident that multimorbidity represents more than just the 
sum of single diseases. Recently, a large population based study revealed a strong 
social gradient in multimorbidity, with an average age of onset ten years earlier in 
areas of deprivation compared to more affluent areas (51). Health behaviours such as 
smoking (278, 279), physical inactivity (278, 280), and obesity (278, 281), as well as 
poor educational attainment (279), are also all more common among multimorbid 
patient cohorts. This new information will help guide the development of patient-
centred interventions to improve health outcomes in multimorbidity. Yet, the 
relationship between multimorbidity and other psychosocial factors, especially those 
relating to early life and childhood, remains to be discerned (66, 277). For instance, 
there is strong evidence that adverse childhood experiences (ACE) are associated with 
the development of individual chronic conditions (e.g. ischaemic heart disease, chronic 
lung disease etc.), mediated by the adoption of unhealthy behaviours in later life 
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(Figure 10) (168, 169, 282). However, the association between ACE and multimorbidity 
has not been examined.  
A history of adverse childhood experiences would represent a potentially important 
psychological burden in multimorbid patients, in addition to being a potential 
aetiological factor in the development of multiple rather than single chronic conditions. 
Our aim in this study was to examine the association between ACE and multimorbidity, 
and to determine the contributing role of other social, behavioural and psychological 
risk factors in this relationship. 
 
 
Figure 10. The Center for Disease Control and Prevention Framework for adverse 
childhood experiences, chronic disease and premature mortality (168) 
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8.3. Methods 
Study design and subjects  
We used cross-sectional baseline data from the Mitchelstown Cohort, a study of 50 to 
69 year old adults randomly selected from a single large primary care centre in 
Mitchelstown, Ireland in 2010-11. Participants were invited to complete a detailed 
health and lifestyle questionnaire, and attend for a physical examination by research 
nurses using standardised measurements and validated instruments. The study 
methods have been reported in detail previously (283), but an overview is provided 
here. Ethical approval for the original study was granted by the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals.  
 
Predictor: Adverse childhood experiences 
Adverse childhood experiences were measured using the ACE questionnaire, a 
validated instrument used to assess associations between ACE and health and well-
being in later life (282, 284). This ten-item questionnaire categorizes ACE into three 
groups which relate to: abuse (emotional, physical or sexual), neglect (emotional or 
physical), and household dysfunction (domestic abuse, parents divorced, parents in 
prison, parental addiction or parental mental illness). Responses were dichotomized 
into any history of ACE (yes/no), and were also categorized by type of ACE (abuse, 
neglect, household dysfunction). During data collection, participants were offered 
separate sealed envelopes in which to submit their responses to the ACE questionnaire. 
 
Outcome: Multimorbidity status 
The presence of a chronic condition was determined by the question “Has a doctor 
ever told you that you have xx?” referring to twenty common chronic conditions (which 
147 
 
are listed in Figure 11). Multimorbidity status was determined by categorizing 
responses into three ordered groups: no chronic condition, one chronic condition or 
multimorbidity (two or more chronic conditions) (28). Participants who answered no, 
don’t know or did not answer a chronic condition question were categorized as not 
having the condition in question.  
 
Covariates 
Education: Educational attainment was ascertained by the question “What is the 
highest level of education you have completed?” and responses were dichotomized 
into primary level or secondary level and above. 
 
Social class: Social class was defined using the European socio-economic occupation-
based classification scheme, validated for use in the Irish population (285). Participants 
were asked “What job have you done for the longest period of time?” The ten class 
model was collapsed to four classes: salariat, intermediate, working class and never 
worked/long-term unemployed.  
 
General Medical Services (GMS) cover: Participants were asked whether they had 
public health cover through the GMS scheme, which entitles those covered to free 
medical care at the point of access. Responses were categorized as GMS patient 
(yes/no). Eligibility for the GMS scheme is based on low income thresholds.  
 
Dietary habits: A standardised food frequency questionnaire, validated for use in the 
Irish population (286), was used to assess dietary habits. For this analysis, fruit and 
vegetable intake was collapsed to a binary variable, with participants consuming five or 
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more servings daily categorized as having a healthy diet, and those consuming less than 
five servings daily as having an unhealthy diet.  
 
Physical Activity: Physical activity was measured as metabolic equivalents (METs) 
minutes per week using the short form International Physical Activity Questionnaire 
(287), and was dichotomized into two groups (low or moderate-high) based on MET 
minutes per week in all activity types.  
 
Smoking: Smoking status was dichotomized as never smoked or current/former smoker 
in response to the questions “have you smoked at least 100 cigarettes in your entire 
life?” and “are you a current smoker?” 
 
Alcohol: Alcohol consumption was derived from the question “During the past seven 
days how many standard drinks of any alcoholic beverage did you have each day?” and 
was categorized as within or above the gender specific recommended weekly 
allowance (≤21units for men and ≤14units for women) (288). 
 
Body mass index: Height and weight were measured using standardised methods by 
study personnel and used to calculate body mass index (BMI, kg/m2).  
 
Psychological health: Psychological health was measured by the Centre for 
Epidemiologic Studies Depression Scale (CES-D) (289) and Hospital Anxiety and 
Depression Scale (HADS) (290) anxiety questions. These instruments measure point-in-
time psychological health, in contrast to the prior doctor–diagnosis of depression and 
anxiety used in the outcome variable. In the CES-D, answers are scored from one to 
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four over twenty questions. Depression is considered likely in scores of sixteen and 
above. In the HADS-A, answers are scored zero to three over seven questions. Anxiety 
is considered likely in scores of eight or above. 
 
Statistical Analysis 
Stata statistical software IC 12.0 was used for all analyses. Descriptive analysis was 
stratified by multimorbidity status. Categorical variables were expressed as frequencies 
(percentage) and continuous variables as means with standard deviations (SD) or 
medians with interquartile range (IQR). Differences between groups were tested using 
chi square, ANOVA or Kruskal Wallis tests as appropriate. We used the Center for 
Disease Control and Prevention framework of ACE and subsequent chronic disease, 
shown in Figure 10 (168), to inform multivariable modelling. We included covariates to 
the regression model by forward stepwise selection, including only variables that had a 
p<0.05 level of significance with multimorbidity on univariate analysis. Ordinal logistic 
regression was used to calculate the odds of a higher ordinal category (multimorbidity) 
versus the middle and lower categories (one or no chronic conditions). The 
proportional odds assumption for multimorbidity status as an ordinal variable was 
satisfied using the Stata omodel and Brant tests. We calculated the adjusted odds 
ratios (OR) and 95% confidence intervals (95% CI) for multimorbidity by inclusion of 
ACE, age, gender, GMS status, educational attainment, dietary habits, smoking status, 
physical activity, BMI, depression score and anxiety score in the models. Statistical 
interactions were sought between ACE and age, gender, and GMS cover.  
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Subgroup analysis 
Subtypes of ACE 
Multivariable ordinal logistic regression was used to examine the relationship between 
each of the subtypes of ACE (abuse, neglect, household dysfunction) and 
multimorbidity.  
 
Subtypes of multimorbidity 
Within the group with multimorbidity, we categorized participants according to 
whether they had a psychiatric condition as a component of their multimorbidity or 
not. The mean number of physical conditions for those with and without a psychiatric 
condition as a component of their multimorbidity was calculated. Multivariable logistic 
regression was used to determine odds ratios for the associations between ACE/ACE 
subtypes and a multimorbid patient having a psychiatric condition. 
 
Sensitivity analysis 
We first repeated the analysis after excluding doctor-diagnosed anxiety or depression 
from the outcome variable, to assess whether the observed association was 
attributable to psychiatric sequelae of ACE. Secondly, we used logistic regression to 
examine the association between ACE and multimorbidity defined with increasing 
numbers of conditions (three or more, four or more etc.).  
 
Missing data 
In multivariable analysis, missing data in predictor and included co-variates were 
replaced using Stata chained multiple imputation functions. Complete case sensitivity 
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analysis was performed. The STROBE statement was used to inform the study report 
(provided in Supplementary material 15).  
 
 
8.4. Results 
Baseline characteristics 
Of 3051 people invited to participate in the Mitchelstown Cohort study, 2047 
completed the baseline assessment (response rate 67%) and were included in the 
current analysis. The mean age at baseline was 55.8 years and 51% (n= 1,039) were 
female. Overall, 45.3% (n= 927, 95% CI 43.1-47.4) of participants reported 
multimorbidity and 23.4 % (n= 444, 95% CI 21.5-25.3) reported any ACE.  
ACE was reported by significantly more multimorbid participants at 28.4% (n= 248, 95% 
CI 25.3- 31.3%) than participants with a single chronic condition, 21% (n=113, 95% CI 
18.0-25.1%) or participants without any chronic condition, 16% (n=83, 95% CI 13.2-
19.7%) (p<0.001), as shown in Table 7.  
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Table 7. Baseline characteristics of participants in the Mitchelstown Cohort Study 
stratified by multimorbidity status 
 
 
 
No chronic 
condition 
N=564 N (%) 
One chronic 
condition 
N=556  
N (%) 
Multimorbidity 
N=927  
 
N (%) 
P 
value 
Missing 
data 
 
N (%) 
Age -mean (SD) 55.6 (14.7) 55.4 (15.7) 56.2 (16.5) 0.55 0 
Gender  
 Female  
 Male 
 
242 (42.9) 
322 (57.1) 
 
273 (49.1) 
283 (50.9) 
 
524 (56.5) 
403 (43.5) 
 
<0.001 
 
0 
 
Early life factors  
     
Any history of ACE 83 (16.5) 113 (21.6) 248 (28.4) <0.001 146 (7.1) 
Education 
Attainment  
Primary  
Secondary or above  
 
 
128 (24.8) 
389 (75.2) 
 
 
118 (22.7) 
403 (77.3) 
 
 
291 (33.5) 
579 (66.5) 
 
 
<0.001 
 
 
 
139 (6.8) 
Later life social 
factors 
     
Occupational class 
Salariat 
Intermediate 
Working class  
Long-term 
unemployed 
 
71 (15.9) 
127 (28.4) 
193(43.2) 
56 (12.5) 
 
80 (17.1) 
125 (26.7) 
199 (42.5) 
64 (13.7) 
 
110 (13.6) 
187 (23.1) 
387 (47.9) 
124 (15.4) 
 
0.11 
 
324 (15.8) 
GMS status 
GMS cover 
 
134 (29.6) 
 
156 (31.5) 
 
445 (53.2) 
 
<0.001 
 
262 (12.8) 
Later life 
behavioural factors 
     
Alcohol 
Within RWA 
 
317 (90.6) 
 
340 (91.2) 
 
546 (90.7) 
 
0.95 
 
722 (35.3) 
Dietary habits 
Unhealthy diet 
 
226 (42.0) 
 
212 (39.0) 
 
316 (34.8) 
 
0.02 
 
58 (2.8) 
Physical Activity  
Low  
Moderate/high 
 
218 (42.9) 
290 (57.1) 
 
253 (48.1) 
273 (51.9) 
 
461 (52.2) 
423 (47.8) 
 
0.004 
 
129 (6.3) 
Smoking 
Never  
Current /former 
 
271 (51.9) 
251 (48.1) 
 
299 (55.7) 
238 (44.3) 
 
432 (47.7) 
474 (52.3) 
 
<0.012 
 
 
82 (4.0) 
BMI  
BMI- median (IQR)
  
 
27.4 (25.0, 
29.9) 
 
28.0 (25.0, 
30.7) 
 
28.7 (25.8, 
31.9) 
 
<0.001 
 
7 (0.3) 
Later life mental 
health 
CES-D, median (IQR) 
HADS-A, median 
(IQR) 
 
 
6 (3, 11) 
 
3 (1, 5) 
 
 
7 (3, 12) 
 
3 (2, 5) 
 
 
10 (5, 15) 
 
4 (2, 7) 
 
 
<0.001 
 
<0.001 
 
 
173 (8.5) 
 
210 (10.3) 
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Participants with multimorbidity were more likely to be female, to have GMS cover, 
and to have only attained primary level education. Multimorbid patients also had 
higher BMIs, lower levels of physical activity, and were more likely to be 
current/former smokers. Depression and anxiety scores were significantly higher in 
multimorbid patients. Figure 11 shows the prevalence of each individual chronic 
condition in participants with or without ACE (numerical data for this figure is provided 
in Supplementary material 16).  
 
 
 
Figure 11. Prevalence of chronic conditions and multimorbidity in participants in the 
Mitchelstown cohort study, stratified by history of adverse childhood experiences 
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Ordinal logistic regression analysis 
In the unadjusted model, participants who reported a history of ACE had an odds ratio 
for multimorbidity of 1.6 (95% CI 1.4-2.0), shown in Table 8. After including age, 
gender, and the social and behavioural co-variates that were significantly associated 
with multimorbidity in univariate analysis, the relationship between ACE and 
multimorbidity remained of similar magnitude, OR 1.6 (95% CI 1.3-1.9). However, 
including current psychological status in the model partially attenuated the 
relationship, OR 1.4 (95% CI 1.1 – 1.7). Other covariates significantly related to 
multimorbidity in the fully adjusted model included female gender, OR 1.4 (95% CI 1.2-
1.7) and GMS cover, OR 1.7 (95% CI 1.3-2.1). Educational attainment was inversely 
associated with multimorbidity, OR 0.8 (95% CI 0.6-0.9). BMI, depression and anxiety 
scores were marginally but significantly associated with multimorbidity. No significant 
statistical interactions between ACE and age, gender or GMS cover were observed.  
 
Subgroup analysis 
Subtypes of ACE  
The subtypes of ACE (abuse, neglect, household dysfunction) were examined for their 
independent association with multimorbidity: ACE relating to abuse and household 
dysfunction were significantly associated with multimorbidity in the fully adjusted 
model but ACE relating to neglect was not (shown in table 25 in Supplementary 
material 17). 
 
Subtypes of multimorbidity  
In the subgroup of patients with multimorbidity (n=927), 66% (n=615, 95% CI 63.2 – 
69.4%) reported only physical multimorbidity while 34% (n=312, 95% CI 30.6 – 36.7%) 
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had a psychiatric condition as a component of their multimorbidity. Those with a 
psychiatric condition had a mean of 2.1 (SD 1.5) physical conditions, compared to 2.7 
(SD 1.0) in those with only physical conditions (p<0.001). ACE was associated with 
higher odds of a multimorbid patient having a psychiatric condition, adjusted OR 1.5 
(95% CI 1.1-2.1). Each subtype of ACE was independently associated with a multimorbid 
patient having a psychiatric condition (shown in figure 15 in Supplementary material 
18). 
 
Sensitivity analysis  
Sensitivity analyses showed similar results. When we excluded doctor-diagnosed 
anxiety or depression from the outcome variable, the adjusted odds ratio between ACE 
and multimorbidity was 1.3 (95% CI 1.0-1.5, p=0.019). ACE was more strongly 
associated with multimorbidity defined by higher numbers of conditions (Figure 12).  
 
Missing data 
In complete case sensitivity analysis (n= 1335), the association between ACE and 
multimorbidity remained of similar magnitude, OR 1.6 (95% CI 1.2-2.0). 
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Figure 12. Unadjusted and adjusted* odds ratios and 95% confidence intervals for the 
association between adverse childhood experiences and multimorbidity, using 
increasing numbers of conditions to define multimorbidity in baseline data from the 
Mitchelstown cohort study. 
*The adjusted models include age, gender, education, GMS status, behavioural factors 
(BMI, diet, physical activity, smoking), depression and anxiety scores.  
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Table 8. Odds ratios and 95% CIs for multimorbidity in multivariable ordinal logistic regression models in participants at baseline in the 
Mitchelstown cohort study 
 
 
The reference categories for the multivariable model are: ACE, no ACE as reference; gender, male as reference; GMS cover, no GMS cover as reference; 
educational attainment, primary level as reference; smoking, never smoked as reference; physical activity, low activity as reference; diet, unhealthy diet as 
reference. The bold values indicate co-variates that are significantly associated with multimorbidity. 
*P < 0.05; **P < 0.001
 Unadjusted OR 
(95% CI) 
Age & Gender 
OR (95% CI) 
+ Early life factors 
OR (95% CI) 
+ Social factors 
OR (95% CI) 
+ Behavioural  
OR (95% CI) 
+ Mental health 
OR (95% CI) 
ACE 
 
1.6 (1.4 – 
2.0)** 
1.7 (1.4-2.1)** 1.7(1.4 – 2.1)** 1.6 (1.3 – 2.0)** 1.6 (1.3 – 1.9)** 1.4 (1.1 – 1.7)* 
Age 
Female gender  
 1.0 (0.9-1.0) 
1.6 (1.3 – 1.8)** 
1.0 (1.0-1.0) 
1.6 (1.4 – 1.9)** 
1.0 (1.0– 1.0) 
1.5 (1.3-1.8)** 
1.0 (1.0– 1.0) 
1.6 (1.3-1.9)** 
1.0 (1.0– 1.0) 
1.4 (1.2 – 1.7)** 
Early Life:  
Higher educational 
attainment 
   
.6 (0.5 - 0.7)** 
 
0.8 (0.7– 0.9)* 
 
0.8 (0.6 – 1.0)* 
 
0.8 (0.6- 0.9)* 
Later life social factors: 
GMS cover  
    
1.9 (1.6 – 2.4)** 
 
1.8 (1.5 – 2.2)** 
 
1.7 (1.3 – 2.1)** 
Behavioural factors: 
BMI (kg/m2) 
Healthy diet 
Mod-high physical 
activity  
Current/former smoker  
     
1.1 (1.0-1.1)** 
1.3 (1.1-1.6)* 
.9 (0.7-1.0) 
1.2 (0.9 -1.4)  
 
1.1 (1.0 – 1.1)** 
1.3 (1.1 – 1.6)* 
0.9 (0.8 – 1.1) 
1.1 (0.9 – 1.3) 
Mental health: 
CES-Depression score  
HADS-Anxiety score 
     
 
 
1.0 (1.0 - 1.1)** 
1.1 (1.0 - 1.1)* 
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8.5. Discussion 
In this population based study, adverse childhood experiences were reported by 
approximately one third of multimorbid participants, a significantly higher proportion 
than in those without multimorbidity. This association persisted even after adjusting 
for related social, behavioural and psychological factors. While other studies have 
reported an association between ACE and individual chronic conditions, ours is the first 
study to show that adverse childhood experiences are a specific concern in 
multimorbid patients. These findings have implications for both disease prevention 
activities for survivors of childhood adversity and for the development of patient-
centred interventions that aim to improve health outcomes in multimorbidity.  
 
Comparison with existing literature 
Almost half of our participants reported multimorbidity. This is slightly lower than 
previous national estimates which were of the order of 66% (3). The difference may 
relate to the method of determining multimorbidity status: Glynn et al. (3) extracted 
data on 147 chronic conditions from patient records, rather than using self-report on 
twenty conditions. In addition, the age profile of patients in the Mitchelstown cohort 
was younger than that in the study by Glynn et al. We found similar relationships 
between female gender, public health (GMS) cover and educational attainment with 
multimorbidity as other international studies (33, 291). 
Overall, the prevalence of ACE in the Mitchelstown study was 23%. In the Irish 
Longitudinal Study on Ageing (TILDA), the prevalence of self-reported childhood 
adversity was marginally higher at 34% (292). In contrast to the specific ten-item 
questionnaire used in the Mitchelstown study, TILDA used a compound measure of 
adversity in childhood which included five questions relating to physical abuse, sexual 
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abuse and parental addiction, and a self-rating of being “poor” in childhood. However, 
the authors found similar associations between childhood adversity and health 
outcomes, with increases in the risk of individual chronic diseases of the order of 19% 
to 69% (292).  
Notwithstanding the cross-sectional nature of our data, the temporality between ACE 
and multimorbidity in later life suggests that ACE may play an aetiological role in the 
development of multimorbidity in some patients. A number of theories exist to explain 
this relationship. Adverse childhood experiences have been linked with individual 
chronic conditions via the adoption of hazardous lifestyle behaviours, such as smoking, 
unhealthy diet or problem alcohol consumption (169). While we found multimorbidity 
was associated with lower levels of physical activity, higher rates of smoking and higher 
BMI, the relationship between ACE and multimorbidity was independent of these risk 
factors. Biological theories purport that early manifestations of childhood adversity, 
such as failure to thrive or neurodevelopmental stress, may initiate pathophysiological 
processes that manifest as chronic disease in later life (282). An alternative theory 
holds that traumatic issues relating to one’s childhood may go unaddressed within 
conventional medical care. Patients who attend primary care physicians with vague 
symptoms or somatic manifestations of distress are at risk of higher numbers of 
screening and diagnostic tests. The consequent diagnostic labelling may compound the 
patient’s list of morbidities, without getting to the source of their problems (282). The 
latter explanation is supported by our subgroup analysis which showed that ACE was 
associated with an incremental risk of having a psychiatric condition as a component of 
one’s multimorbidity.  
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Implications for research and practice  
The true nature of the relationship between ACE and multimorbidity is likely to be 
complex and multifactorial, so may be best tackled at multiple levels. From a public 
health perspective, efforts to reduce childhood abuse and neglect are on-going (282). 
Interventions that target the coping strategies of survivors of child abuse may yield 
future benefits in chronic disease prevention (169). For general practice, it is important 
that the challenge of multimorbidity is not reduced to the simple aggregation of 
multiple sets of guidelines. Our findings reinforce the need for comprehensive, patient-
centred care in multimorbidity, which goes ‘beyond protocols’ and gives consideration 
to the psychosocial causes and consequences of multiple chronic diseases (51, 276, 
277). Prospective cohort studies of multimorbidity are underway which will also help to 
inform healthcare delivery to this complex group (293). 
 
Strengths and limitations 
The Mitchelstown cohort study is underpinned by validated standardised instruments 
and objective measures of health and well-being (283). Although the sample is a 
relatively homogenous 50 to 69 year old Caucasian population taken from a single 
primary care centre, it is representative of the profile of the source population 
reported in national census data (283). Nevertheless, care is required when 
interpreting the results. ACE was measured by retrospective self-report of events that 
happened approximately thirty years previously. While most questions concerned 
specific events such as abuse, or parental incarceration, questions on neglect 
concerned less objective events, such as whether the participant felt unloved. These 
questions may be subject to greater recall bias, which may explain the weaker 
association between multimorbidity overall and neglect in this study. Despite the risk of 
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recall bias, the questionnaire has been previously shown to have good test-retest 
reliability (294). The sensitive nature of the ACE questions was acknowledged during 
data collection by offering patients a separate sealed envelope in which to submit their 
responses.  
Multimorbidity status was also ascertained by self-report. Although also subject to 
response bias, this method has high sensitivity and specificity for identifying chronic 
disease compared with available administrative data collection. Moreover, as patients 
are more likely to report conditions that have a material impact on their health related 
quality of life, self-report may be more patient focused than alternative methods (295). 
As we were limited to the twenty conditions included in the original Mitchelstown 
study questionnaire, the true burden of multimorbidity in this cohort may have been 
underestimated. Other influential papers in this field have included from five to over 
300 conditions in their indices (33, 51). Debate on the most appropriate definition of 
multimorbidity continues; we chose the most commonly used definition, two or more 
conditions, for reasons of comparability (28).  
 
8.6. Conclusion 
This population based observational study of middle-aged adults found a significant 
association between multimorbidity and self-report of adverse childhood experiences, 
even after accounting for other social, behavioural and psychological factors. These 
findings have implications for disease prevention activities for victims of childhood 
maltreatment, and highlight the importance of psychosocial dimensions to 
interventions that aim to meet the healthcare needs of, and improve health outcomes 
in, people with multimorbidity.  
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9.1. Abstract 
Background 
Multimorbidity, the presence of two or more chronic conditions, affects over 50% of 
patients in primary care. Due to its association with polypharmacy, the development of 
interventions to optimize medication management in patients with multimorbidity is a 
priority. The Behaviour Change Wheel is a new approach for applying behavioural 
theory to intervention development. Here, we describe how we have used results from 
a review of previous research, original research of our own and the Behaviour Change 
Wheel to develop an intervention to improve medication management in 
multimorbidity by GPs, within the overarching UK Medical Research Council guidance 
on complex interventions. 
 
Methods  
Following the steps of the Behaviour Change Wheel, we identified behaviours 
associated with medication management in multimorbidity by conducting a systematic 
review and qualitative study with GPs. From the modifiable GP behaviours identified, 
we selected one and conducted a focused behavioural analysis to explain why GPs 
were or were not engaging in this behaviour. We used the behavioural analysis to 
determine the intervention functions, behaviour change techniques and 
implementation plan most likely to effect behaviour change. 
 
Results  
We identified numerous modifiable GP behaviours in the systematic review and 
qualitative study, from which active medication review (rather than passively 
maintaining the status quo) was chosen as the target behaviour. Behavioural analysis 
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revealed GPs’ capabilities, opportunities and motivations relating to active medication 
review. We combined the three intervention functions deemed most likely to effect 
behaviour change (enablement, environmental restructuring and incentivisation) to 
form the Multimorbidity Collaborative Medication Review And Decision-making (MY 
COMRADE) intervention. MY COMRADE primarily involves the behaviour change 
technique of social support: two GPs review the medications prescribed to a complex 
multimorbid patient together. Four other behaviour change techniques are 
incorporated: restructuring the social environment, prompts/cues, action planning, and 
self-incentives. 
 
Conclusions 
This study is the first to use the Behaviour Change Wheel to develop an intervention 
targeting multimorbidity, and confirms the usability and usefulness of the approach in 
a complex area of clinical care. The systematic development of the MY COMRADE 
intervention will facilitate a thorough evaluation of its effectiveness in the next phase 
of this work.  
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9.2. Introduction 
Multimorbidity, the co-occurrence of two or more chronic conditions, affects over 50% 
of patients with chronic disease in primary care (33, 51). In a healthcare system that 
has evolved around the management of single chronic diseases, this presents major 
challenges to healthcare provision, research and medical education (51). In 2014, the 
US Department of Health and Human Services recognised these challenges by stating 
the need to better equip clinicians in the management of multimorbidity, making 
specific reference to medication management (66). Multimorbidity frequently leads to 
the prescription of multiple long-term medications (222). The resulting polypharmacy is 
an independent risk factor for negative health outcomes such as adverse effects and 
drug interactions (6). For prescribers, this creates a tension between keeping the 
number of medicines to a minimum while still prescribing what evidence-based 
guidelines advocate as being in the patient’s best interest (126). This is especially the 
case for GPs, who must co-ordinate and oversee the medications prescribed by 
numerous doctors involved in the care of a multimorbid patient (202).  
Despite the prevalence of multimorbidity, few interventions have been developed to 
improve medication management in this field to date. A recent systematic review, 
which focussed on interventions to optimize outcomes in patients with multimorbidity 
in primary care, found only two studies that specifically addressed medication 
management. However, both interventions related to enhanced involvement of 
pharmacists, rather than the prescribing actions of GPs (145). Thus the development of 
interventions to GPs’ contribution to medication management in patients with 
multimorbidity is a priority.  
In the past, interventions that aimed to change healthcare professionals’ behaviour 
have resulted in suboptimal effects, due to a lack of theoretical consideration at the 
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development stage (296). The UK Medical Research Council (MRC) guidance for the 
development of complex interventions in healthcare emphasizes the importance of 
using theory in intervention design (8). However, the MRC document does not put 
forth any specific suggestions on how to do this which leaves intervention designers, 
many of whom are interested in theory only to the extent that it can help them achieve 
improvements in clinical care, with an array of dilemmas (297). The large pool of 
available theoretical models means that critical theories may be missed, and there is 
little clarity on how to choose the most appropriate theory for the behaviour in 
question (227). In addition, intervention developers have traditionally had little to 
guide them on the specification of intervention content (298).  
Over the last few years, this gap has been addressed by an approach known as the 
Behaviour Change Wheel (BCW), which explicitly integrates behavioural theory with 
the development and description of behaviour change interventions (171). A core 
feature of the BCW is a theoretical model, known as the COM-B, which is used to 
conduct an analysis of the behaviour in question. The COM-B model is based on the 
hypothesis that the interaction between one’s capability (C), opportunity (O) and 
motivation (M) can provide explanations for why a particular behaviour (B) is or is not 
performed. Each of these components can be further subdivided (Figure 13). Capability 
may be physical (the physical skill, strength and stamina) or psychological (the 
knowledge or psychological skills, strength or stamina to engage in the necessary 
mental processes). Opportunity may be physical (afforded by the environment, 
including resources, locations, time etc.) or social (afforded by interpersonal influences, 
social cues, and cultural norms that influence the way we think about things). 
Motivation may be reflective (plans, self-conscious intentions or evaluations) or 
automatic (reflex responses, impulses, drive states). The COM-B behavioural analysis 
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guides the choice of intervention functions (or strategies) most likely to achieve 
behaviour change. Additionally, the intervention functions have been linked to a 
taxonomy of 93 replicable behaviour change techniques (299), and the techniques 
particularly suitable for each intervention function have been highlighted (171). 
Following this structured approach lends transparency to the process of intervention 
development, and facilitates its subsequent implementation and evaluation [12].  
  
 
 
Figure 13. The Behaviour Change Wheel 
 
 
Since its original publication in 2011, the BCW has received a lot of academic interest, 
and a number of groups have already used it to develop or study the implementation 
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of interventions by healthcare professionals (300-303). To our knowledge, there are no 
published examples using the BCW to develop a de-novo intervention targeted at 
healthcare professionals in the complex field of multimorbidity. As the application of 
the BCW may vary according to the setting and target behaviour, examples of the 
generalisability of the approach are required. Furthermore, published examples of its 
use will contribute to the on-going development and refinement of the approach.  
In this paper, we describe the development of an intervention to improve medication 
management in multimorbidity by GPs, in which we applied the steps of the BCW to 
enable a more transparent implementation of the MRC framework for design and 
evaluation of complex interventions.  
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9.3. Methods  
In the MRC framework, intervention development comprises three stages: identifying 
the evidence base, identifying and applying appropriate theory to the available (and if 
necessary, new) evidence, and modelling processes and outcomes (8). Like the MRC 
framework, the BCW (171) also has three broad stages but they involve different tasks 
(i.e. understanding the behaviour; identifying intervention options; and identifying 
content and implementation options) and are subdivided into a further eight steps (i.e. 
defining the problem in behavioural terms; selecting the target behaviour; specifying 
the target behaviour; identifying what needs to change; identifying appropriate 
intervention functions; identifying policy categories; identifying behaviour change 
techniques; and determining the mode of delivery) (171). As we were using the BCW 
within the overarching framework of the MRC, we mapped the eight BCW steps 
directly on to the three development stages of the MRC to enhance the clarity and 
generalisability of our approach (see Table 9).  
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Table 9. Mapping steps of Behaviour Change Wheel to the three stages of 
intervention development in the UK Medical Research Council guide 
MRC Development 
Stage(8) 
BCW Steps(171) BCW Stages 
1. Identify the evidence 
base 
1. Define the problem in 
behavioural terms 
1. Understand the behaviour 
2. Select the target behaviour 
3. Specify the target 
behaviour 
2. Identify/develop 
theory 
4. Identify what needs to 
change 
5. Identify appropriate 
intervention functions 
2. Identify intervention options 
6. Identifying policy 
categories 
3. Model process and 
outcomes 
7. Identifying behaviour 
change techniques 
3. Identify content and 
implementation options 
8. Determine the mode of 
delivery 
 
 
 
MRC Stage 1: Identifying the evidence base 
To begin, we reviewed the existing evidence on medication management in 
multimorbidity and supplemented this with new evidence in order to clearly define our 
problem of interest and then select and specify the behavioural target for intervention.  
 
BCW Step 1. Define the problem in behavioural terms.  
We searched for relevant published literature, in particular existing systematic reviews, 
to help us understand the problems associated with medication management in 
multimorbidity in primary care. While we identified two relevant quantitative reviews 
(103, 145), we also found a number of pertinent qualitative studies. Therefore, we 
conducted a systematic review and synthesis of the relevant qualitative evidence 
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(Chapter 5) (226). We addressed the gaps identified from the qualitative synthesis by 
conducting a qualitative interview study, specifically to generate further information on 
their approaches to prescribing in multimorbidity. The methods for the interview study 
are described elsewhere (Chapter 6) (257). A cross-sectional study was conducted to 
examine the psychosocial factors that add additional complexity to the management of 
patients with multimorbidity (Chapter 8) (304). 
 
BCW Step 2: Select the target behaviour.  
From the aggregated qualitative synthesis and interview data, we (CS & CB) identified 
the modifiable GP behaviours relating to medication management in multimorbidity, 
and selected one key behaviour to target in our intervention. This judgement was 
informed by criteria set out in the BCW guide which are: the likelihood that behaviour 
change would be implemented, the likely impact of changing the behaviour, the spill-
over or knock on effect of change on other behaviours, and the ease with which each 
behaviour could be measured (171). 
 
BCW Step 3: Specify the target behaviour.  
Once the target behaviour was decided, we specified in greater detail what and who 
needed to change, and where and when this change should happen.  
 
MRC Stage 2: Identifying/developing theory  
In the next stage, we used the COM-B (capability, opportunity, motivation - behaviour) 
model to develop a theoretical understanding of the target behaviour and guide our 
choice of intervention functions. 
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BCW Step 4: Identify what needs to change to achieve the desired behaviour.  
We used the COM-B model to frame our qualitative behavioural analysis of the 
qualitative synthesis and interview data. We (CS & CB) coded empirical data relevant to 
GPs’ psychological and physical capabilities (C), social and physical opportunities (O) 
and reflective and automatic motivations (M) to highlight why GPs were or were not 
engaging in the target behaviour, and what needed to change for the target behaviour 
to be achieved. Where multiple COM-B components were potentially relevant to one 
section of the data, the component whose definition (as set out in the BCW guide 
(171)) best fit the context of our data was chosen. The results of this analysis was 
presented to the other authors at a consensus meeting and refined accordingly. 
 
BCW Step 5: Identify intervention functions to achieve the desired behaviour 
The BCW incorporates a comprehensive panel of nine intervention functions, shown in 
red in Figure 13, which were drawn from a synthesis of 19 frameworks of behavioural-
intervention strategies (171). We determined which intervention functions would be 
most likely to effect behaviour change in our intervention by mapping the individual 
components of the COM-B behavioural analysis onto the published BCW linkage 
matrices (171). Each intervention function that was potentially relevant to our data was 
considered in detail. We used the APEASE criteria (affordability, practicability, 
effectiveness and cost effectiveness, acceptability, side effects/safety and equity), 
another component of the BCW approach, to grade the potentially relevant 
intervention functions into first and second line options (171).  
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BCW Step 6: Policy categories 
The BCW also includes matrices which sign post seven broad policy-level interventions 
for achieving behaviour change, shown in grey in Figure 13. As we were not primarily 
concerned with changing policy in this study, we did not undertake this step in detail, 
other than listing the options that may be relevant to levering our intervention in the 
future.  
 
MRC Stage 3: Modelling process and outcomes 
In this third stage, we specified our intervention content in more detail and identified 
an appropriate way of implementing the intervention within our context.  
 
BCW Step 7: Identify behaviour change techniques   
The selected intervention functions represented our broad approach to achieving 
behaviour change, but we required fine-grained techniques to operationalize these 
functions. We used the links previously drawn between the BCW and the taxonomy of 
93 behaviour change techniques (171, 305) to list those techniques most frequently 
used with our selected intervention functions. We held an expert panel consensus 
meeting to review the suitability of each of these techniques, in light of our previously 
collected qualitative data, the context of the intervention, and by referring to the 
APEASE criteria. Each member of the panel had expertise in one or more areas of 
relevance (clinical pharmacology and prescribing (CB, MD, RP), general practice (CB, CS, 
MD, RP, SM), behavioural science and intervention design (MB), and multimorbidity 
(CS, RP, SM)).  
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BCW Step 8: Identify mode of delivery 
 As we were developing an intervention to be implemented by individual GPs, this step 
(mode of delivery) required explicit consideration of implementation in the 
heterogeneous setting of general practice. We used the expert panel consensus to 
specifically address modelling questions posed in the MRC framework which were: 
would it be possible to use this; what subgroup of patients should it be used for; what 
outcomes should be sought; and what are the facilitators/obstacles at practice level (8). 
If multiple implementation options existed, agreement was reached by discussing each 
option, with reference to the APEASE criteria (171).  
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9.4. Results   
MRC Stage 1: identifying the evidence base 
BCW Step 1. Define the problem in behavioural terms. 
We identified two existing systematic reviews which were relevant. Patterson et al. 
reviewed existing interventions to improve prescribing and polypharmacy in older 
patients (103). Only one of the included studies involved GPs and showed that 
computer decision-support reduced inappropriate drug initiation in primary care (306). 
The authors suggested that future polypharmacy interventions must address the 
complexity of clinical situations and the individuality of prescribers. Smith et al. 
reviewed interventions to improve patient outcomes in multimorbidity in primary care. 
Two included studies addressed medication management but these involved 
pharmacists rather than GPs. Here, the authors suggested that future interventions 
should target specific problems relating to multimorbidity, be integrated into existing 
healthcare systems, and be embedded with inter-professional collaboration (145). 
Our qualitative synthesis included ten studies from seven countries involving a total of 
275 GPs (see Chapter 5)(226). A key theme was GPs’ sense of professional isolation in 
the management of multimorbid patients. This emanated from the interplay between 
four aspects of the management of patients with multimorbidity: i) the disorganization 
and fragmentation of healthcare between primary and secondary care; (ii) the 
inadequacy of guidelines and evidence-based medicine for multimorbidity; (iii) 
challenges in delivering patient-centred, rather than disease-focused, care; and (iv) 
barriers to shared decision-making. 
In the qualitative interview study, we found that GPs responded to clinical dilemmas in 
multimorbidity by ‘satisficing’, i.e. accepting care that they deemed satisfactory and 
sufficient for a particular patient, yet acknowledging that aspects of that care may not 
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be optimal (see Chapter 6)(257). In patients with changing disease trajectories, 
satisficing was manifest as relaxing targets for disease control, negotiating compromise 
with the patient, or making ‘best guesses’ about the most appropriate course of action 
to take. In multimorbid patients perceived as stable, GPs’ default approach was to 
‘maintain the status quo’ rather than actively rationalize medications. The cross-
sectional study demonstrated the negative psychosocial factors that can introduce 
additional complexity into the management of patients with multimorbidity; these 
findings emphasized the need for patient-centred interventions that prioritize a view of 
the whole patient in context (304). 
 
BCW Step 2: Select the target behaviour.  
The modifiable GP behaviours relating to medication management in multimorbidity 
are shown in Figure 14. “Maintaining the status quo” was observed in all of the 
qualitative interviews despite best practice guidelines which state that patients 
receiving long-term medicines need medication reviews at regular intervals. Targeting 
this behaviour would likely result in behaviour change as the qualitative study showed 
GPs’ extant discomfort with it (discussed in Chapter 6). Furthermore, it would be 
desirable to see GPs adopt a less passive approach to medication management even if 
it did not always lead to downstream changes to medications. There was a high 
possibility of “spill over” from the actions of medication review for multimorbidity to 
other prescribing activities. Lastly, changing this behaviour would be relatively easy to 
measure. We judged that the other modifiable behaviours were not as attractive. 
Adopting practice protocols would have a big impact and high spill over, but given 
current financial and staffing pressure on practices, would be a difficult organisational 
change to achieve. Relaxing targets for disease control is likely appropriate in some 
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patients in multimorbidity, and enforcing strict adherence to guideline targets is not 
patient-centred and may be resisted by GPs. Addressing shared decision-making has 
merit but requires interventions targeting GPs’ communication skills (rather than 
prescribing) which was not our specific focus.  
 
 
 
 
Figure 14. Modifiable GP behaviours in medication management in multimorbidity 
identified in qualitative synthesis (Chapter 5) and interview study (Chapter 6) 
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BCW Step 3: Specify the target behaviour.  
The target behaviour was specified as active, purposeful medication review instead of 
passive “maintaining the status quo” for patients with multimorbidity, to be conducted 
by GPs, in routine general practice, on a regular basis.  
 
MRC Stage 2: Identifying/developing theory  
BCW Step 4: Identify what needs to change to achieve the desired behaviour 
We used COM-B to identify GPs’ capabilities (C), opportunities (O) and motivations (M) 
for engaging, or not engaging, in active medication review. The themes that emerged 
from this analysis are shown in Table 10, with illustrative quotes from the qualitative 
synthesis and the interview study. For example, GPs adopted a passive approach to 
medication management due to their uncertainty (lack of psychological capability) 
about which medications were most valuable in patients with multimorbidity, 
especially given the absence of satisfactory guidelines in this field. Insufficient 
consultation time led to a lack of physical opportunity to review medications. GPs also 
found medication review difficult because of a cultural milieu which holds that 
treatment for chronic disease is lifelong (lack of social opportunity). This was 
particularly the case if the patient had been compliant with their medications for many 
years. Many GPs had developed a habitual response to “not rock the boat” in patients 
with multimorbidity, an approach which involved not making changes to medications 
unless there was a pressing reason to do so. This response was reinforced by their 
experiences of the negative consequences of stopping or changing medications for 
patients with multimorbidity in the past (automatic motivation). GPs’ reflective 
motivations against medication review included the opportunity cost of using their 
professional time for this purpose, and a fear of negative consequences from 
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rationalising medications. GPs also had motivations to review medications which 
included improving patient outcomes, reassuring themselves that they were delivering 
best care, and guarding against medico-legal repercussions. 
 
BCW Step 5: Identify intervention functions  
We found that all nine intervention functions listed in the BCW were relevant to our 
behavioural analysis. Supplementary material 19 shows our assessment and grading of 
each intervention function into first and second line options using the APEASE criteria. 
The three intervention functions most relevant for our intervention were enablement, 
environmental re-structuring, and incentivisation. The relationships between the 
components of the COM-B behavioural analysis and these three intervention functions 
are shown in Table 10. 
 
BCW Step 6: Policy categories 
The broad policy options, signposted by the BCW matrices as being potentially useful 
for achieving behaviour change, were communication/marketing, service-provision 
policy, legislation, guidelines and regulation. 
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Table 10. Behavioural analysis, selected intervention functions and behaviour change techniques, referencing empirical data from the qualitative 
synthesis (QS) and the interview study (IS) 
Behavioural Analysis using COM-B: Why does medication review not happen in 
multimorbidity?  
(Step 4) 
Intervention 
functions  
(Step 5) 
Selected behaviour change techniques (labelled in bold) and empirical 
data to support their selection 
(Step 7) 
Uncertainty about what medications were most valuable 
IS gp2 “she is not fitting in to either box for us so we are not using 
any guidelines, we're not using anything you know - we're just 
using our clinical acumen on a daily basis with her” 
IS gp14 “Well, in some instances there is no evidence at all, 
because most clinical trials don’t include, you know, 80 
something year olds..” 
IS gp5 “Well the difficulty is, with evidence-based medicine, there 
is no place in one sense for the opinions of the family physician or 
any doctor, because they don’t fit, there’s no place for them 
(patients with multimorbidity) in guidelines… so if people are 
going on about evidence-based medicine- it is all about you 
know, what’s the cholesterol, what’s this, what’s the FEV1s, so if 
it’s down below that you put them on this, you put them on that, 
you know. There is nowhere in guidelines where they say, you 
know, you don’t put them on warfarin if they are living on their 
own and they are seventy odd years of age, so that’s the 
difficulty” 
Capability: 
Psychological  
Enablement 
  
  
Social support (practical) 
Advise on, or provide 
practical help (e.g. 
colleagues) for performance 
of behaviour  
 
Two GPs support each other to review 
medications, tapping into professional 
convention to discuss cases anecdotally. 
QS: “GPs feel isolated in the 
management of patients with 
multimorbidity, a group that they are 
specifically tasked with caring for.” 
IS: “it helps sometimes to talk it over 
with the lads and say ‘how will we handle 
this’.” 
Perceptions that social norms make patients unwilling to stop 
long-term medications 
IS gp13“some of the stuff she is on, like the domperidone and the 
betahistine and stuff, I’m not really convinced that she needs it. I 
have talked to her a little bit about it - about whether or not it 
might be useful to take things off but she’s reluctant to take them 
out and as far as she is concerned they’ve been started at some 
point over the years for her for the dizziness - as she sees it, and 
so she wants to try and keep them”  
Opportunity: 
Social 
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Lack of time to properly review medications 
IS gp1“if you just had a 30-minute consultation with a patient 
while you don’t have the waiting room building up… you could 
actually get to the bottom of some of the stuff they’re on”  
Opportunity: 
Physical 
Environmental 
restructuring  
Restructuring social 
environment 
Change, or advise to change 
the social environment in 
order to facilitate 
performance of the wanted 
behaviour 
Action planning  
Prompt detailed planning of 
performance of behaviour 
(must include at least one of 
frequency, context, duration, 
intensity. 
Planning and agreeing on protected time 
for the two GPs to come together to 
conduct the review is necessary.  
QS: “Insufficient consultation time seen 
as reason for suboptimal approach to 
multimorbidity care.” 
IS: “I’ll have to do some of this another 
day... in a different structure or format”  
An instinct not to ‘rock the boat’  
IS gp11“she’s been doing better than she has in a long time- I’m 
not going to rock the boat at all”  
IS gp14 “there is that aspect of not rocking the boat, you know 
and being straight up about it as well, sometimes as well you can 
get into the routine ‘oh are you just in for the prescription?’, you 
just print it off automatically without giving due consideration to 
can we shorten this, can we do this that and the other.” 
IS gp18 “Take the line of least resistance! Here’s another 3 
months prescription for it!!” 
IS gp19 “anything that complex I really didn’t entertain changing 
because why stir things up?” 
QS “avoidance of decision-making” 
Motivation: 
Automatic 
Environmental 
restructuring 
  
Enablement 
Prompts/cues 
Introduce environmental or 
social stimulus for the 
purpose of prompting or 
cueing behaviour 
 
GPs will use a list of generic prompts 
prompt the medication reviews.  
QS: “Most GPs felt that guidelines were 
less useful in multimorbidity and that 
they actually added to the complexity in 
some case.” 
Opportunity cost of using time to conduct medication reviews  
IS gp11“she has had multiple other things going on as well, so the 
consultation time is all taken up” 
 
Fear of negative consequences  
QS “would be loath to stop it, it’s probably medico-legal”  
Motivation: 
Reflective 
Incentives  Self-incentives 
Plan to reward self in future 
if and only if there has been 
effort and/or progress in 
performing the behaviours. 
 
GPs can award themselves professional 
development points for conducting the 
reviews. Some GP’s were already 
meeting to discuss troublesome cases for 
this purpose although without a focus on 
medications. 
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MRC Stage 3: Modelling process and outcomes 
BCW Step 7: Identify behaviour change techniques   
From the taxonomy of 93 behaviour change techniques, we listed the techniques most 
frequently used to deliver the three intervention functions we had selected (171, 305). 
The resulting 32 potentially relevant techniques are listed in Supplementary material 
20. We reviewed, with the expert panel, how each of these techniques could be 
applied to the context of medication management in multimorbidity. The panel’s 
choice of techniques was influenced principally by the key findings of the qualitative 
studies: GPs’ sense of isolation in the management of multimorbid patients revealed in 
the qualitative synthesis (Chapter 5), and GPs’ lack of certainty and efforts to “share 
the onus of responsibility” seen in the interview study (Chapter 6). Thus, we focused on 
options that would enhance GPs’ means of professional support. Although enhanced 
communication between GPs and pharmacists is being investigated in other healthcare 
systems, it was felt not to be an option for our intervention due to the lack of 
community pharmacists available in Ireland. Similarly, communication between GPs 
and specialists involved in the care of patients with multimorbidity was seen in both 
qualitative studies to be fraught by poor access and a single-disease approach. 
However, GPs considered their GP colleagues to be a useful source of support (Chapter 
6). These interactions occurred on an informal basis within practices, and were notable 
for their ready accessibility and generalist nature. We were unaware of any work 
exploring collaborative decision-making between GPs in multimorbidity, so focused on 
this as a new approach. From the list of 32 techniques, we considered which 
techniques would pragmatically facilitate collaborative decision-making between GPs. 
Many techniques were quickly eliminated as they were irrelevant to the context or 
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purpose of the intervention (described in Supplementary material 20). The five 
techniques eventually selected as “active ingredients” were: social support (practical), 
restructuring the social environment, use of prompts/cues, action planning, and self-
incentives. The definition of each technique, and qualitative data to support their 
selection, are shown in Table 10. The combination and integration of each technique 
into the overall intervention, named Multimorbidity Collaborative Medication Review 
And Decision-making (MY COMRADE), is shown in Table 11.  
 
 
Table 11. Description of final intervention 
 
The Multimorbidity Collaborative Medication Review And Decision-making (MY 
COMRADE) intervention 
 
GPs will be asked to schedule protected time for themselves and one of their GP 
colleagues to conduct the collaborative medication review, and enter this time into the 
practice appointment book. They will be asked to choose a day/time/office that suits 
them best, and decide how many patient cases to review in one sitting (action 
planning)*. The GPs will choose multimorbid patients from their caseload, and in the 
scheduled review time will review medications, supported by their GP colleague (social 
support and restructuring social environment). The medication review will be 
prompted by the seven prompts described in the NO TEARS (307) medication checklist 
(prompts and cues). GPs will be asked to record recommendations for medication 
change that arise from the review in the patient’s notes, to allow them to discuss these 
with the patient during their next consultation. After completing the review, GPs will 
award themselves continuing professional development points: one point for each 
cumulative hour of the activity completed (self-incentives). 
 
*behaviour change techniques indicated in brackets 
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BCW Step 8: Identify mode of delivery 
In the expert panel meeting, we then formulated an intervention implementation plan. 
Four specific aspects of implementation were reviewed, and the various options 
considered for each aspect are fully described in Supplementary material 21. In 
summary, the following implementation plan was formulated:  
 
What prompts should be used to guide medication review in MY COMRADE? 
After reviewing eight different prescribing tools and checklists (listed in Supplementary 
material 21), it was agreed that a modified version of the seven prompts in the 
NOTEARS (307) checklist for medication review would be used to prompt the review. 
 
How should GPs choose which patients to review using MY COMRADE? 
After reviewing multiple options (listed in Supplementary material 21), it was agreed 
that GPs should choose patients prescribed ten or more regular medicines or five or 
more medicines with at least one other complicating factor (i.e. meets criteria for 
potentially inappropriate prescribing, at risk of a well-recognised drug-drug interaction, 
has poor adherence or receiving end-of-life or palliative care), in line with 
recommendations from the Kings Fund report on Polypharmacy and Medication 
Optimisation (99). 
 
How should the behaviour change technique “action planning” be operationalized?  
One of the behaviour change techniques, action planning, specifically relates to 
implementation and was selected to account for the wide variety of structures and 
systems that occur in general practice. Each GP will be given clear guidance on how to 
tailor MY COMRADE to suit their practice. This will involve asking them to choose a 
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particular day, time of the day, and office in which to do the review. They will decide on 
the number of cases to review in one sitting, and the GP pairs that will conduct reviews 
within a practice. In advance of trialling MY COMRADE, GPs will be asked to consider 
what they envision as problematic for its implementation, and how these problems 
could be tackled, knowing their own practice. 
 
How should the intervention be evaluated?  
The initial evaluation will focus on intervention implementation (i.e. did medication 
review take place?). The behaviour change techniques and other causal or contextual 
mechanisms associated with behaviour change will be determined using qualitative 
methods. If MY COMRADE is shown to be acceptable and implementable, future 
evaluations will assess effectiveness using health outcomes such as the number of/type 
of medication changes made and changes in rates of healthcare utilisation. 
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9.5. Discussion 
This paper describes the systematic, structured development of an intervention to 
improve medication management for multimorbid patients by GPs. The intervention is 
called Multimorbidity Collaborative Medication Review And Decision-making (MY 
COMRADE). It is, to our knowledge, the first intervention directed at the management 
of multimorbidity in primary care, developed by using the Behaviour Change Wheel to 
clearly implement the framework of the MRC guide on complex interventions. 
MY COMRADE involves collaborative decision-making by two GPs who support each 
other in the review of medications prescribed to a complex multimorbid patient, 
guided by prompts which relate to safe prescribing. The broad functions of the 
intervention (enablement, environmental restructuring and incentivisation) are 
theoretically based. These functions will be achieved using five specific behaviour 
change techniques: social support (practical), restructuring the social environment, use 
of prompts/cues, action planning, and self-incentives. The technique of peer support is 
a crucial feature of our intervention, which we expect will greatly enable GPs’ 
capabilities in conducting active medication reviews. Peer support may be particularly 
important in deprescribing medications or prioritising patient-centred rather than 
disease-focused care in multimorbidity; these aspects of medication management are 
challenging for GPs due to fear of litigation which the MY COMRADE intervention may 
now help ameliorate.  
 
Comparison with other work 
Since its publication in 2011, the BCW has been used in the development of 
interventions targeting healthcare professionals in a variety of ways. For example, 
Alexander et al. used COM-B to understand barriers and enablers to preventative 
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health examinations for young children in Australian general practice, with a view to 
designing an implementation intervention to increase the conduct of these 
examinations (300). They did not describe later steps of the BCW, such as choice of 
intervention functions, and did not provide any detail on the format of their 
implementation intervention. In contrast, we used the BCW to highlight areas for 
improvement in professional practice and then develop an intervention targeted to 
these areas, rather than simply increasing the implementation of a pre-existing 
intervention.  
Murphy et al. used COM-B to develop a capacity-building programme to enhance 
pharmacists’ roles in mental healthcare (303). This group felt that implementation 
processes must be prioritised during the early stages of intervention development, and 
they wove theories of behaviour change and implementation together in an iterative 
way. While we agree that implementation should be considered at all stages of 
development work, we did not find it necessary to use a specific implementation 
framework. The initial steps of the BCW revealed multiple behaviours that could be 
targeted to improve GPs’ professional practice. Once one behaviour had been chosen, 
the remaining steps of the BCW involved developing an implementation intervention to 
enhance the performance of this desired behaviour. Additionally, by incorporating the 
behaviour change technique of action planning, implementation was explicitly 
integrated into our intervention. Action planning requires an individual GP to plan the 
frequency, duration and intensity of the planned intervention activity (171). Thus, 
rather than a prescriptive implementation strategy, action planning will allow each GP 
to adapt the intervention for use within their own practice. The variation in 
implementation, as well as fidelity to other behaviour change techniques, will be 
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evaluated in the next phase of this work and will help to inform the debate on optimal 
approaches to implementation planning in intervention development. 
Strengths and weaknesses 
We began this work with the broad aim of developing an intervention to improve 
medication management in multimorbidity, but we did not have a predefined idea of 
what the intervention would be at the outset. Adhering to the guidance of the MRC by 
using a theoretical approach, which was chosen a priori, gave direction, structure and 
transparency to this process in multiple ways. 
First, the MRC states the need to identify the evidence base, and supplement this with 
new evidence if necessary. In doing this, we generated much needed data on the 
management of medications in multimorbidity, increased our understanding of the 
problematic areas experienced by GPs, and revealed how they currently respond to 
these difficulties. Second, we then used this empirical data to directly influence the 
development of the intervention. Following the steps of the BCW allowed us to develop 
a list of options for behaviour change and to clarify what we were, and what we were 
not, trying to achieve. Third, we benefitted from using the links between the BCW 
model and the taxonomy of behaviour change techniques. The taxonomy highlighted 
novel strategies for behaviour change, many of which we would heretofore not have 
considered. Although only five techniques are ultimately included in the final 
intervention, many of the other techniques influenced our thinking during the 
development of the intervention and the implementation strategy.  
Despite the highly systematic and structured approach of the BCW, there are 
challenges associated with its use and it is not a magic bullet for intervention 
development. For example, the researcher must make a series of subjective and 
pragmatic decisions throughout the process. These ‘real life’ decisions can seem at 
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odds with the scientific approach. To counter this and to improve the transparency and 
generalisability of our methods, we recorded in detail the multiple options available to 
us at each step of the BCW and expanded on why options were or were not taken 
Furthermore, the multiple steps of intervention development involved a lengthy 
process: from the beginning of our systematic review to final refinements of the 
intervention spanned almost three years. Such a prolonged course must be factored in 
by those pursuing and funding evidence-based intervention development.  
Other intervention developers have used a ‘top-down’ approach of applying classical 
behavioural theories such as social cognitive (308) or control theory (309) to inform 
their choice of intervention functions and behaviour change techniques. In contrast, we 
employed a ‘bottom-up’ approach to theory development in which the framework of 
the BCW guided our use of existing evidence and our own qualitative explorations. This 
led to an intervention which was logical and practical yet still theoretically based.  
In addition to the COM-B, the BCW also includes an optional, more detailed framework 
for behavioural analysis known as the Theoretical Domains Framework (171). After 
completing our intervention development as described above, an additional exercise 
was conducted in which the qualitative data were assessed using the Theoretical 
Domains Framework. This process is described in detail in Supplementary material 22, 
and reassuringly demonstrated the same associations between the qualitative data, 
and the intervention functions and behaviour change techniques that were 
incorporated into the MY COMRADE intervention. 
  
Implications for future research 
We used the BCW as a lens for viewing GP behaviour, understanding what needed to 
shift, and determining how this shift could be achieved. Our experience confirms the 
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usefulness and generalisability of this approach. Multimorbidity presents many 
challenges to GPs, particularly relating to the conflicts between patient-centred and 
disease-focused care but the BCW approach was not hampered by these complexities. 
Based on our experience, the method is potentially useful for intervention developers 
across disciplines as long as sufficient contextual and empirical data exists or can be 
generated.  
Throughout this study, we adhered to the “less is more” maxim of intervention design 
(171). We could have taken a more complex multi-faceted approach, such as 
incorporating other stakeholders i.e. pharmacists or specialists. Instead, we adopted 
the recommendations from the systematic review by Smith et al. that changes 
targeting specific problems are more likely to be effective (145). Smaller changes can 
be achieved, sustained and built upon in future interventions, and substantial 
behaviour change is more likely to result from the aggregation of these smaller changes 
(171). We applied the same tenets to our assessment of outcomes – rather than 
initially looking at downstream effects such as changes in prescribing, we will 
concentrate first on proximal changes such as implementation of the intervention. 
Once we are assured that it is acceptable, feasible, and leads to behaviour change, then 
we can assess the impact on patient-related outcomes, prescribing safety and 
polypharmacy. 
To date there is limited evidence available on which behaviour change techniques are 
most effective in specific settings. We expect that characterizing the active components 
in the MY COMRADE intervention using the taxonomy of behaviour change techniques 
(299) will aid implementation and replication of the intervention. The clear 
specification of the intervention will also facilitate a thorough evaluation of the impact 
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of the selected behaviour change techniques and will help to inform evidence-based 
strategies for intervention development in the future.  
In this study, we did not undertake the sixth step of the BCW relating to policy options 
in detail. However, if the intervention is shown to be effective in our on-going 
feasibility and pilot work, scaling-up of the intervention will require greater 
consideration of the external context of healthcare policy and widespread 
implementation. 
 
9.6. Conclusions 
This paper describes the development of an intervention to improve medication 
management in multimorbidity by GPs. The intervention, which is called Multimorbidity 
Collaborative Medication Review And Decision-making (MY COMRADE), is based on 
purposively collected data on behaviour in context and a novel approach to 
intervention design, the Behaviour Change Wheel. While the Behaviour Change Wheel 
is not a magic bullet for intervention design, this paper confirms the usability and 
usefulness of this approach in a complex area of clinical care. The systematic, 
transparent approach used in the development of the MY COMRADE intervention will 
facilitate its thorough evaluation in the next phase of this work.  
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CHAPTER 11. DISCUSSION 
11.1. Main findings 
The overarching aim of this thesis was to develop an intervention to support patient-
centred prescribing for patients with multimorbidity. Previous interventions have had 
limited impact because they were not integrated into clinical practice, did not focus on 
specific issues that physicians and patients have difficulty with, or did not involve 
sufficient interaction between clinical decision-makers (95, 145). By following the 
guidance for intervention development set out by the MRC, the consecutive pieces of 
work in this thesis have transparently and systematically addressed these limitations. 
The product is a promising intervention which uses a new approach to support patient-
centred prescribing for patients with multimorbidity: collaborative medication review 
by two GPs.  
Although the guidance from the MRC states that intervention development is not 
necessarily a linear process, it was useful to conduct the phases of work in sequence, 
with each study iteratively informing the next. First, the existing qualitative literature 
on GPs’ perceptions of the management of multimorbidity was synthesized using a 
meta-ethnographic approach (Chapter 5). The review showed that GPs experience 
challenges in four domains of clinical practice (disorganization and fragmentation of 
health care; the inadequacy of guidelines and evidence based medicine; challenges in 
delivering patient-centred care; and barriers to shared decision-making), which can in 
turn lead them to feel unsupported and professionally isolated in the management of 
patients with multimorbidity. The study was published in the BMJ Open in 2013, and 
has already been cited by over twenty peer-reviewed papers. 
As none of the papers included in the review provided detailed information on how GPs 
deal with difficulties in medication management in multimorbidity, a qualitative study 
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was conducted with GPs to explore this issue in depth (Chapter 6). The key finding was 
that GPs’ default approach was to “maintain the status quo” rather than actively 
review medication for their multimorbid patients. This study was published, and 
editorialised, in the British Journal of General Practice in March 2015. 
In the qualitative interview study, chart-stimulated recall was found to be a useful and 
efficient technique for gaining insights into clinical decision-making. Therefore, a 
scoping review of the application of chart-stimulated recall to clinical research was 
performed, to serve as a guide for other researchers interested in using the technique 
(Chapter 7). A manuscript of this paper is currently under peer-review. 
One of the challenges which emerged from the qualitative study was the influence of 
psychosocial complexity on the clinical management of multimorbid patients. To 
explore this issue further, a cross-sectional study using baseline data from a regional 
cohort study was conducted (Chapter 8). A significant association between 
multimorbidity and adverse childhood experiences, as well as other negative 
psychosocial factors such as lower socioeconomic class, poor diet and high body mass 
index was found. This study highlighted the complex health needs and psychosocial 
problems that often co-occur in patients with multimorbidity. The findings emphasize 
the need for interventions that promote consideration of the whole-person in context, 
and allow prioritization of non-physical issues or deviation from clinical practice 
guidelines if necessary. The study was published in Family Practice in April 2015 and 
received attention in the national press (e.g. Irish Examiner, Irish Herald), medical press 
(e.g. Irish Medical News, Medical Independent) and in social media (Twitter). 
To inform the development of a prescribing intervention, the new qualitative data were 
applied to the Capability-Opportunity-Motivation-Behaviour (COM-B) model, the 
Behaviour Change Wheel framework of intervention strategies and the Behaviour 
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Change Technique Taxonomy (Chapter 9). A panel of experts was convened to guide 
intervention development and enhance the transparency and rigour of our approach. 
The result was the Multimorbidity Collaborative Medication Review And Decision-
making (MY COMRADE) intervention, which incorporates five components, principal of 
which is collaborative medication review between two GPs. One of other features of 
the intervention was a simple prescribing checklist. This checklist was chosen ahead of 
more complicated prescribing tools, and was prefaced with an instruction to the GP to 
share details of the patient including their social situation (Supplementary material 25). 
In line with the conclusion of Chapter 8, this put the “whole person” view of the patient 
up-front of the medication review, and aimed to avoid reducing the patient to a series 
of biomedical issues.  
The feasibility study of the intervention was described in Chapter 10. The focus here 
was on implementation rather than effect, and the implementation outcome 
framework published by Proctor et al. (178) was a key resource. The intervention was 
well received by GPs, who deemed it acceptable and appropriate to the context of 
multimorbidity in general practice, and reported that recommendations for medication 
optimisation emerged from all reviews.  
At the end of this series of studies, the main product is a carefully developed 
intervention that is ready to undergo larger scale evaluation. The systematic review, 
qualitative study and cross-sectional study were conducted to inform the development 
of a specific intervention. However, the publication of these studies in international 
journals means they may also inform and benefit the work of other research groups 
aiming to improve healthcare for patients with multimorbidity. 
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11.2. Medical decision-making 
A better understanding of GPs’ decision-making processes in multimorbidity was 
needed to underpin intervention development, and gaining this understanding was a 
key focus in this work. Broadly, there are two approaches to decision-making. Optimal 
decision-making involves collecting and evaluating every single option before choosing 
the best one. Satisficing, the human response to decision-making when optimization is 
out of reach, involves using a limited range of options until an option that is ‘good 
enough’ is found (236). In multimorbidity, optimization is certainly out of reach due to 
the difficulties revealed in the systematic review in Chapter 5. Satisficing is a pragmatic 
and iterative approach to decision-making and it should not be perceived as wrong. 
However, interventions that incorporate peer support (like MY COMRADE) may help 
GPs to satisfice “better”.  
At its origins, evidence-based medicine involved integrating patient preference, clinical 
expertise and the best available external evidence (135). Since then, external evidence 
has gained primacy, and as illustrated in Chapter 3, this can lead to harmful 
consequences for patients with multimorbidity. Physicians may feel insecure if not 
practicing in adherence with “the evidence”, therefore they need support and 
reassurance in order to tip the balance back in favour of patient preference and clinical 
expertise (84). Peer support, as it is used in the MY COMRADE intervention, allows 
sharing of tacit and explicit medical knowledge and informed reflection on alternative 
options (240). It can help to maintain professional standards while simultaneously 
giving consideration to the broader context of the patient. Other decision-making 
support such as information technology, computer decision support systems, or explicit 
prescribing tools do not allow the same level of individualisation or generalist 
approach. 
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11.2.1. Inter-professional peer supported decision-making 
Evidence on the usefulness of professional collaboration is emerging, although it tends 
to focus on collaboration between different professions. In the review of models of 
comprehensive healthcare for older persons with chronic conditions conducted by 
Boult et al. (158), nine out of the fifteen successful models involved interdisciplinary 
primary care, or models that supplemented primary care. In 2015, Bleich et al. updated 
this review with new studies that focused specifically on multimorbidity (321). Of the 
twenty seven studies included, sixteen were based in primary care and incorporated 
some element of multidisciplinary care (i.e. appointing a nurse or social worker to help 
patients navigate the healthcare system, provide them with information about their 
chronic conditions or engage them in actively managing their chronic conditions). 
These interventions led to improvements in healthcare use and clinical outcomes, but 
not in patient-reported outcomes.  
The Collaborative Interventions for Circulation and Depression (COINCIDE) trial, 
described in Chapter 3, integrated the healthcare provided by psychological well-being 
practitioners and nurses, and led to reductions in patients’ depression scores. However, 
the qualitative evaluation of the study generated interesting insights (161). Healthcare 
professionals found that collaborating with each other allowed them to offer an 
expanded range of services to the patients. However, some of the professionals 
highlighted the boundaries of their responsibility which may have hampered true 
sharing of information and therapeutic integration. Patients were positive about 
enhanced communication between professionals, but they did not feel that this 
needed to happen when they were present. Some patients volunteered that they 
preferred treatment spaces that separated out management for different conditions.  
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Therefore, multidisciplinary care holds promise but future work in this field must be 
sensitive to patients’ preferences, and optimize interactions between professionals to 
effect sustained improvements in patient-reported outcomes.  
 
11.2.2. Intra-professional peer supported decision-making 
Grass-root approaches to collaborative decision-making between GPs, such as quality 
circles or practice-based small group learning programmes, have emerged in recent 
years and mirror the intra-disciplinary nature of our intervention (322). Quality circles 
and related groups provide an opportunity for reflective practice and discussion of 
troubling or challenging patient cases between GPs. They have been shown to improve 
medication costs (323), the prescribing of generic medications (324), and healthcare 
utilisation (325). Additionally, participants report that practice-based learning groups 
are places of social support and provide protection against burnout (326). In an 
exploration of cases brought by GPs to such a programme, many of the cases related to 
complexities in the management of patients with multimorbidity (310). 
 
11.2.3. Sharing decision-making with patients 
The MY COMRADE intervention upholds the importance of shared decision-making 
with patients although it does not directly incorporate shared decision-making. Charles 
et al. suggested that shared decision-making had three stages: bidirectional exchange 
of information, relaying of options, and choice of one option. For patients, feeling 
involved in decision-making can be more important than actually making the decision 
(327, 328). Patients are often guided by physician recommendations (243), and 
physician uncertainty can inhibit shared decision-making (242). By removing 
medication review from the competing demands of the consultation (on average, three 
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issues are addressed in every consultation in general practice (253)), physicians can 
focus on medications and clarify what changes should be made. This clarity should 
facilitate more meaningful communication with patients, which in turn, should lead to 
higher patient satisfaction and improved outcomes (329, 330).  
 
11.4. Strengths and limitations 
This section provides a synopsis of the overall strengths and limitations of this thesis. 
The strengths and limitations of the individual papers have been addressed in the 
previous chapters.  
 
By starting this work with a synthesis of the existing qualitative literature, the 
subsequent qualitative research was tailored to answer new questions, address 
knowledge gaps and prevent research waste.  
Obtaining rich, case-based data during the qualitative interviews helped to reveal the 
day-to-day challenges experienced by GPs, and their responses to those challenges; this 
information was crucial for developing an intervention that would be useful to and 
used by GPs. The dependability of the study findings was further enhanced by gaining 
thematic data saturation. 
GPs reported the psychosocial influences on decision-making in the qualitative study; 
these findings were explored further in the cross-sectional study. Triangulating the 
findings from the qualitative interviews and the quantitative analysis gives weight to 
the clinical and statistical importance of the association. 
There is debate on the value of theory in intervention development (164, 170, 312). We 
found the theoretically informed approach was useful. It lent transparency and 
structure to the process of intervention development, and led to the development of a 
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novel intervention that we had not conceived of before the thesis began. By using the 
taxonomy of behaviour change techniques, the final intervention was highly specified 
thus easier to implement, replicate and evaluate. 
 
As with all clinical research, there are also limitations in this work. The qualitative 
interviews and the feasibility study of the new intervention involved GPs working in the 
South West of Ireland. Although potential benefits were seen in this limited 
geographical area, the intervention remains untested elsewhere. Participants were 
purposively sampled to represent the spectrum of Irish general practice, which 
improves the transferability of the findings within Ireland. Furthermore, the likelihood 
of the intervention’s wider applicability is enhanced because it addresses many of the 
challenges found in the systematic review (Chapter 5) which represented GPs from 
seven different countries. 
The search for the published systematic review was conducted in September 2012. An 
update of the search in November 2015 shows that there are nine new qualitative 
studies relevant to the review (Supplementary data 28). The qualitative findings of 
these nine studies map onto the domains outlined in the original systematic review 
with one exception: the newer studies show a greater emphasis on the need for 
education and training for GPs in the management of patients with multimorbidity. This 
interesting development shows the evolution of the qualitative literature on 
multimorbidity from focusing on problems to moving towards solutions.  
Many different health professionals are involved in the management of medications in 
patients with multimorbidity. As explained in Chapter 3, interventions incorporating 
different professionals (i.e. pharmacists, geriatricians) have not demonstrated 
consistent success in improving patient outcomes, suggesting a need for alternative 
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new approaches. Although the focus in this thesis came to lie on a new approach 
involving collaboration between two GPs, strategies to enhance better inter-
disciplinary collaboration in the management of patients with multimorbidity are also 
needed. 
Patients were not directly involved in the intervention, although it was emphasized 
that any changes to medications must first be discussed with the patient. Developing 
communication techniques to enhance patient involvement in decision-making, 
especially when it comes to deprescribing, are also required.  
The MY COMRADE intervention will assist GPs working in group practices. However, a 
significant proportion of Irish GPs continue to work single-handedly (232). For these 
GPs, local continuing medical education groups or e-communication may allow 
collaborative case reviews with GP colleagues. 
There is a risk that my medical background influenced my interpretation of findings 
throughout all of this work. To counter this and improve the neutrality of study 
findings, I engaged researchers who were not GPs to double code interview data, check 
interpretation of statistical findings, assess implementation outcomes etc. 
This thesis did not deal directly with the contribution of overdiagnosis and excessive 
disease labelling to multimorbidity. Recently, groups of researchers and clinicians have 
formed to raise and address these issues and help avoid unwanted and unhelpful 
medicine (331, 332). 
 
11.5. Policy implications 
Since 2001, Irish healthcare policy has recognised the potential for primary care to 
improve patient outcomes and reduce healthcare costs in chronic disease (10). More 
recent policy documents, such as Future Health and the National Service Plan for 2016, 
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prioritize the reform of current services to promote integrated person-centred 
approaches to chronic disease management, especially in older more complex patients 
(333, 334). One of the pillars of the proposed reforms is to move away from the current 
hospital-centric model of care towards a new model of integrated care which treats 
patients at the lowest level of complexity that is safe, timely, efficient, and as close to 
home as possible.  Such efforts are expected to reduce costs, improve access and move 
from the existing emphasis on episodic reactive care towards preventative, planned 
and co-ordinated care.  The novel approach to medication review developed in this 
thesis will be a useful tool to support the delivery of co-ordinated, community based 
comprehensive care.   
However, the budgetary allocations for healthcare present significant challenges for 
the development and even the maintenance of existing services. The MY COMRADE 
intervention has the potential to meet many of the current health policy objectives and 
is not resource intensive. Furthermore, unbiased syntheses of existing information and 
research on behaviour change are two of the most important contributions researchers 
can offer to policy makers (335), both of which were incorporated into the 
development of the intervention. 
In Chapter 9, a range of policy options were signposted as being potentially useful for 
achieving behaviour change associated with the MY COMRADE intervention. These 
policy options merit consideration for the up-scaling of the intervention if its 
effectiveness is demonstrated in a larger scale study. 
In 2015, the first pay for performance initiative for chronic disease care was introduced 
in Ireland. It involves a new cycle of care for diabetes, and because it provides 
additional resources to primary care, was broadly welcomed by GPs. However, caution 
is required with single-disease pay for performance schemes if patient-centred care in 
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patients with multimorbidity is to be protected. The MY COMRADE intervention is an 
example of a performance initiative that could be used to channel resources to 
complex patients. Furthermore, the aforementioned Future Health document proposes 
the introduction of a new Money Follows the Patient (MFTP) funding model, which will 
create incentives that encourage safe, timely, and efficient care at the lowest level of 
complexity. This funding model will facilitate GPs’ engagement in activities such as 
collaborative medication review. Morbidity-adjusted capitation payments or morbidity-
based bonuses are an alternative option for directing limited financial resources to care 
for the patients who need it most.  
Lastly, the complexity of management of multimorbidity revealed in Chapters 5, 6 and 
8 highlights the need for greater representation of primary care physicians at a national 
policy level. Their presence is needed so that multimorbidity is accounted for in the 
planning and implementation of all future chronic disease initiatives and guidelines 
(130). 
 
11.6. Future research 
The most important next step in this project is to move on to a larger scale evaluation 
of the MY COMRADE intervention. This step is justified by our results to date and is 
consistent with the overall approach advocated by the MRC. Up-scaling the 
intervention to the level of a cluster-randomised control trial will allow definitive 
assessment of effectiveness and an economic evaluation. Outcomes will include those 
of interest to policy makers (i.e. healthcare utilisation rates, hospital referral rates, 
medication costs and overall healthcare costs) and patients (i.e. measures of 
satisfaction with care or patient-centredness (329)). To optimize the relevance of 
future research on the MY COMRADE intervention for patient-centred care, public and 
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patient involvement will be sought in the governance, priority setting, and conduct of 
the research. Patient representatives will be invited to sit on the project advisory group 
for the trial, asked to help identify outcome priorities, and contribute to the 
development of patient information leaflets. 
The range of methodological and theoretical approaches used here warrant greater 
consideration by other researchers interested in quality improvement and intervention 
development. We have shown that the Behaviour Change Wheel is useful for 
operationalising the guidance of the MRC for intervention development. However, the 
time required to adhere to each step of the MRC process is considerable and works 
against the urgency with which many healthcare interventions are required (335). As 
experience with these models grows, more pragmatic approaches to intervention 
development may emerge.  
The applicability of clinical evidence to the management of patients with 
multimorbidity must be improved. As discussed in Chapter 3, reanalysis of trial data 
and preferential enrolment of patients with common combinations of chronic diseases 
into trials will help (336). Focusing future trials on the impact and outcomes associated 
with multimorbidity (i.e. health utilisation, treatment burden, patient illness 
perceptions etc.) may lead to more clinically and economically meaningful research 
outputs (143). 
Undergraduate and post-graduate medical curricula lack content and skills training on 
the clinical management of multimorbidity (27). The checklist and collaborative 
approach to decision-making incorporated in the MY COMRADE intervention could be 
easily adapted for educational use, either with data from vignettes or patients seen in 
practice.  Educational research is warranted to determine if such an adaption provides 
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an effective learning experience for students and GP trainees in the management of 
medications for patients with multimorbidity. 
 
11.7. Conclusion 
This thesis responds to the call for interventions to improve patient-centred medication 
management in multimorbidity. The choice of intervention option was not clear at the 
outset. However, taking the time to explore the difficulties encountered by GPs in 
clinical practice helped to reveal pragmatic solutions. Careful application of existing and 
new evidence to models of behaviour and behaviour change have led to the 
development of a novel intervention which fits well into clinical practice. Thus, this 
work has made a meaningful contribution to our understanding of chronic disease care 
in general practice; the process of intervention development in areas of clinical 
complexity; and hopefully, the improvement of healthcare delivered to and 
experienced by patients with multimorbidity.  
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Appendix I. Supplementary material for Chapter 5. Systematic review 
The materials in this appendix are online supplements to the published version of the 
systematic review. 
 
Supplementary material 1. Review protocol 
Study protocol for a systematic search, appraisal and synthesis of qualitative research 
on GPs experience of patients with multimorbidity. 
 
Objectives (defining the focus) 
1. To search the medical and grey literature in a systematic way to retrieve qualitative 
research studies addressing difficult decisions encountered by GPs in the medical 
management/prescribing for patients with multimorbidity. 
2. To appraise the quality of studies retrieved using the CASP criteria (198) for 
appraising qualitative research. 
3. To conduct a synthesis of retrieved studies using the meta-ethnographic method 
(192). 
4. To interpret the synthesized literature in a way which will define what is known on 
this topic in a generalisable way. 
5. To develop and refine future research questions using this synthesized literature, 
and address clinical needs in this area. 
 
Design 
Systematic appraisal and synthesis of qualitative research. 
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Sampling 
As purposive/theoretical sampling of qualitative research studies has not been 
validated, a comprehensive search of relevant databases, grey literature, hand 
searching of relevant journal and references of included studies will be completed to 
retrieve all relevant studies in this area. This approach will reduce the risk that any 
relevant data is excluded. 
 
Search Strategy  
• Electronic searches of specialist databases: EMBASE, Medline, CINAHL, PsychInfo, 
ASC, Social Science Citation Index using both database specific search terms and 
validated methods for retrieving qualitative studies.  
• Supplemented by searches of databases of grey literature, contacting other 
qualitative health researchers in relevant areas, searching reference lists of studies 
retrieved 
 
Inclusion criteria 
Papers involving all of the following will be included  
1. Studies using recognised qualitative research methods  
2. Participants are general practitioners (or any practitioner who fulfils the role of a 
GP/ primary care physician/ family physician etc.)  
3. Papers that concern multi-morbidity or multiple chronic conditions where there is 
no index condition, or one condition is not considered more important than the 
others. 
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The primary focus is to review the literature on medications management in multi-
morbidity, but papers with a broader focus are included in the search to increase 
the number of relevant papers retrieved. 
Making decisions on inclusion: Citations that are returned from our search strategy will 
be title scanned. The abstracts will be read for papers with relevant titles. Full papers 
will be retrieved for papers with relevant abstracts or potentially relevant or 
ambiguous abstracts (197). Full papers will be reviewed by two researchers.  
 
Quality assessment 
Quality assessment will performed using the CASP tool (198). The quality assessment 
will be used when evaluating the contribution of different papers to the synthesis 
findings, and to describe the range of quality that exists for the papers included. 
Quality appraisal will not be used to exclude studies that otherwise meet the inclusion 
criteria. 
 
Data Extraction 
The source material are the included texts. Data on the study design and settings, 
research methods, and main themes (participants’ quotes and authors’ interpretations) 
will be extracted. One researcher will extract data from all studies and to assess the 
reliability of this data extraction, and a second researcher will extract data from a 
selection of studies. The data (participants’ quotes and authors’ interpretations) will be 
recorded as verbatim extraction where possible to limit the loss of important detail. 
Data will be extracted from findings that are relevant to our research question rather 
than from the paper as a whole (i.e. difficult decision making/prescribing in patients 
with multi-morbidity rather than experience of multimorbidity overall).  
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Synthesis strategy 
The synthesis will be undertaken using the seven step meta-ethnographic method 
(details below) (192). An interpretive approach rather than an integrative approach will 
be used (337). Interpretative synthesis involves techniques to identify related concepts 
in the original studies, which are then reworked and reformulated to extend theory and 
develop new constructs. Integrative approaches on the other hand involve 
quantification and systemic integration of data. In this review, concepts will not be 
specified a priori, and will not be rigidly defined. As per Estabrooks et al. the review 
question is focused on similar populations (GPs) or general themes (management of 
multimorbidity) (338). Other than this, the key concepts and themes will be sought 
inductively. 
 
Data analysis/synthesis 
Meta-ethnography – the seven steps 
1. Getting started. This will involve stating the specific research question we aim 
to answer, and the contribution that it will make to current debates in this field. 
2. Deciding what is relevant to the initial interest. Noblit and Hare stated that the 
scope of a meta-ethnography is more restricted than that of a narrative review, to 
avoid making gross generalisations across disparate fields (192). It includes several 
distinct processes such as i) defining the focus; ii) locating relevant studies; iii) making 
decisions on inclusion; and iv) quality assessment. Sampling may be conducted 
theoretically until saturation is reached, but it is not possible to establish the 
population of studies from which to sample without first identifying all relevant studies. 
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3. Reading the studies. Included studies will be carefully read to identify the 
nature of the study, the type of scenarios discussed, the study setting, study 
participants, and the main findings. Studies may be grouped together according to 
shared perspectives, settings or contexts, guided by the research question. The 
different contributions of each study to the review will be examined to determine if 
some appear to have more important findings than others (in narrative synthesis this 
would be termed weighting). Quality assessment will be conducted at this stage, and 
the contribution of each study will be considered with reference to its quality, validity 
and trustworthiness.  
4. Determining how studies are related. The major themes from each study will be 
recorded in a grid. These themes will initially be generated from first order 
interpretations (FOIs) or participants’ views. Second order interpretations (SOIs) will be 
extracted as author interpretations. Comparisons will be made between studies for 
recurring concepts (which may include similar or disparate findings) and absences of 
these concepts. Overarching themes that encompass the major findings from all studies 
will be constructed. Each cell of the grid will be considered in turn to ensure that the 
main themes from each paper are encompassed in overarching themes. 
5. Translating the studies into each other (i.e. constructing a common rubric 
across studies). This involves identifying the same themes that are expressed 
differently across studies, and viewing these in relation to each other.  
6. Synthesizing translations. This step is not mechanistic: it involves interpreting 
the translated contributions from each study to the overarching themes, and assessing 
how these contributions relate to each other. The two types of translation described by 
Noblit and Hare (192) will be performed: reciprocal translation (accounts are directly 
comparable) and refutational translation (the accounts are oppositional). Third order 
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interpretations (TOIs) will be generated by combining the FOIs and SOIs across studies. 
The combination of TOIs will allow a line of argument to be constructed. The line of 
argument describes all the concepts in a paragraph; breakdown of the principal 
features of the line of argument are reflected in the third order interpretations (TOIs). 
TOIs are generally expressed as a testable hypothesis. TOIs are consistent with the 
original study results while also extending beyond them; they justify the claim the 
meta-ethnography achieves more than a traditional review, in relation to a focused 
research question.  
7. Expressing the synthesis. This depends on who we are targeting: clinicians, 
researchers or policy makers. We will take the additional step suggested by Britten et 
al. (339): to consult with the authors of included primary studies to test the validity of 
the interpretations developed during the synthesis and the extent to which they are 
supported by the primary data. This is most likely to be useful where the number of 
primary studies is small but the authors of the primary studies may have useful insights 
into the possible accuracy and generalisability of the synthesis. 
 
Expected output of research 
1. Interpretation and synthesis of qualitative research to be published in peer reviewed 
journals 
2. Comprehensive description of work that has been conducted in this area 
3. New interpretation across studies to highlight generalisable and outlying findings 
4. Direction for the next steps or the research required to improve the quality of 
medicines management in patients with multi-morbidity, and inform the next stage of 
a PhD research project. 
5. Presentations of the synthesis findings to different audiences.  
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Supplementary material 2. Search terms for systematic review 
 
Locating relevant studies  
The following databases were searched using database specific search terms and 
validated methods for retrieving qualitative studies (194-196): EMBASE (Elsevier), 
Medline (Ovid), CINAHL, PsycInfo, Academic Search Complete, SocIndex, Social Science 
Full Text (all Ebsco). For the published review, this search was last updated on 21st 
September 2012. (An updated search is available in supplementary material 27.) 
 
Supplementary search 
The database search was supplemented by searching through the references of 
included articles (this yielded one relevant article). The following grey literature 
databases were searched: WORLDCAT via the Online Computer Library Center (OCLC), 
Proquest, and PapersFirst via OCLC, ASSIA (Applied Social Sciences Index and 
Abstracts), Directory of Open Access Books (DOAB) and Ebrary. 
 
1. Search Terms for Database Embase, Platform: Elsevier  
(Qualitative search terms were taken from Walters et al. (195).) 
#1.1: interview*:ab,ti  
#1.2: 'health care organization'/exp  
#1.3:experiences:ab,ti  
#1.4:'qualitative research'/exp  
#1: #1.1 OR #1.2 OR #1.3 OR #1.4  
#2.1: comorbid*:ab,ti  
#2.2: morbid*:ab,ti  
#2.3: (multi* NEXT/3 (disease* OR ill* OR condition*)):ab,ti 
#2.4: pluripathology:ab,ti  
#2.5: (chronic NEXT/3 (disease* OR ill* OR condition* OR disorder* OR health OR medication* OR 
syndrome* OR symptom*)):ab,ti 
#2.6: multimorbid*:ab,ti  
#2.1 OR #2.2 OR #2.3 OR #2.4 OR #2.5 OR #2.6  
#2: #2.1 OR #2.2 OR #2.3 OR #2.4 OR #2.5 OR #2.6  
#3: 'prescription'/exp OR 'inappropriate prescribing'/exp OR 'clinical decision  
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making'/exp OR 'medical decision making'/exp OR 'polypharmacy'/exp OR 'clinical 
practice'/exp OR 'medical practice'/exp 
#4.1:'general practice'/exp  
#4.2:'general practitioner'/exp OR 'general practitioners'/exp 
#4.3:'family medicine'/exp  
#4.4:'family health'/exp  
#4.5:'primary health care'/exp  
#4.6: 'primary medical care'/exp  
#4.7:'ambulatory care'/exp  
#4.8:'community care'/exp  
#4.1 OR #4.2 OR #4.3 OR #4.4 OR #4.5 OR #4.6 OR #4.7 OR #4.8 
#4: #4.1 OR #4.2 OR #4.3 OR #4.4 OR #4.5 OR #4.6 OR #4.7 OR #4.8  
#5: #1 AND #2 AND #3 AND #4  
#6: #5 AND ('clinical trial'/de OR 'cohort analysis'/de OR 'controlled clinical trial'/de OR 
'controlled study'/de OR 'cross-sectional study'/de OR 'randomised controlled trial'/de 
OR 'retrospective study'/de OR 'case control study'/de OR and 'statistical model'/de) 
 
#7: #5 NOT #6 
 
 
2. Search Terms for Database CINAHL, Platform: EBSCO  
(Qualitative terms taken from Wilczynski NL, Marks S, Haynes RB.(194).) 
S1 SU multimorbidity OR TI multimorbidity OR AB multimorbidity  
S2 SU multimorbid* OR TI multimorbid* OR AB multimorbid*  
S3 SU multi# morbid* OR TI multi# morbid* OR AB multi# morbid*  
S4 
SU (multiple chronic N3 (disease* OR illness* OR condition*) ) OR TI (multiple 
chronic N3 (disease*OR illness* OR condition*) ) OR AB (multiple chronic N3 
(disease*OR illness* OR condition*) ) 
 
S5 
SU (chronic N3 (disease* OR illness* OR condition*) ) OR TI (chronic N3 
(disease*OR illness* OR condition*) ) OR AB (chronic N3 (disease*OR illness* OR 
condition*) ) 
 
S6 SU pluripathology OR TI pluripathology OR AB pluripathology  
S7 SU comorbidity OR TI comorbidity OR AB comorbidity  
S8 SU comorbid* OR TI comorbid* OR AB comorbid  
S9 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8  
S10 SU 'family medicine' OR TI 'family medicine' OR AB 'family medicine'  
S11 SU 'family practice' OR TI 'family practice' OR AB 'family practice'  
S12 SU general practice' OR TI 'general practice' OR AB 'general practice'  
S13 SU general practitioner*' OR TI 'general practitioner*' OR AB 'general practitioner*'  
S14 SU family physician* OR TI family physician* OR AB family physician*  
S15 SU primary care OR TI primary care OR AB primary care  
S16 SU primary health care OR TI primary health care OR AB primary health care  
S17 SU primary medical care OR TI primary medical care OR AB primary health care  
S18 SU ambulatory care OR TI ambulatory care OR AB ambulatory care  
S19 S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18  
S20 SU Decision making OR TI Decision making OR AB Decision making  
S21 SU health care delivery OR TI health care delivery OR AB health care delivery  
S22 SU Prescribing OR TI Prescribing OR AB Prescribing  
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S23 SU polypharmacy OR TI polypharmacy OR AB polypharmacy  
S24 
SU ((inappropriate OR appropriate OR suboptimal OR under OR over OR optimal) 
N3 (prescribing OR prescription OR medication* or drug*) ) OR TI ((inappropriate 
OR appropriate OR suboptimal OR under OR over OR optimal) N3 (prescribing OR 
prescription OR medication* or drug*) ) OR AB ((inappropriate OR appropriate OR 
suboptimal OR under OR over OR optimal) N3 (prescribing OR prescription OR 
medication* or drug*) ) 
 
S25 
SU (multi* N3 (drug* OR medication* OR prescription*) ) OR TI (multi* N3 (drug* 
OR medication* OR prescription*) ) OR AB (multi* N3 (drug* OR medication* OR 
prescription*) ) 
 
S26 SU clinical practice OR TI clinical practice OR AB clinical practice  
S27 S20 or S21 or S22 or S23 or S24 or S25 or S26  
S28 TI interview OR AB interview  
S29 SU audiorecording OR MW audiorecording  
S30 MW qualitative stud* OR TI qualitative stud* OR AB qualitative stud*  
S31 S28 or S29 or S30  
S32 TI morbidity OR AB morbidity OR MW morbidity  
S33 S9 or S32  
S34 S19 and S27 and S31 and S33  
 
3. Search terms for Database Medline, Platform OVID. 
(Qualitative search terms taken from Wong et al. (193).) 
1. interview:.mp. 
2. experience:.mp. 
3. qualitative.tw. 
4. exp Qualitative Research/ 
5. 1 or 2 or 3 or 4 
6. exp Family Practice/or exp General Practice/ 
7. exp General Practitioners/ 
8. exp Family Practice/or family medicine.mp. 
9. exp Primary Health Care/ 
10. exp Physicians, Family/ 
11. exp Physicians, Primary Care/ 
12. exp Ambulatory Care/ 
13. 6 or 7 or 8 or 9 or 10 or 11 or 12 
14. co-morbid:.ti. or co-morbid:.ab. or comorbid:.ti. or comorbid:.ab. or co morbid:.ab. 
or co morbid:.ti. 
15. morbid:.ti. or morbid:.ab. 
16. (multi: adj3 (ill: or disease: or condition:)).ab,ti. 
17. pluripathology.ab,ti. 
18. (chronic adj3 (disease: or ill: or condition: or disorder: or health or medication: or 
syndrome: or symptom:)).ab,ti. 
19. (multimorbid: or multi morbid: or multi-morbid:).ab,ti. 
20. 14 or 15 or 16 or 17 or 18 or 19 
21. exp Decision Making/ 
22. exp Professional Practice/ 
23. exp Physician's Practice Patterns/ 
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24. exp Inappropriate Prescribing/ 
25. exp Drug Prescriptions/ 
26. exp Polypharmacy/ 
27. 21 or 22 or 23 or 24 or 25 or 26 
28. 5 AND 13 AND 20 AND 27 
 
4. Search terms for Database PsycInfo, Platform EBSCO 
(Qualitative search terms taken from McKibbon et al. (196).) 
S1 SU multimorbidity OR TI multimorbidity OR AB multimorbidity 
S2 SU multimorbid* OR TI multimorbid* OR AB multimorbid* 
S3 SU multi# morbid* OR TI multi# morbid* OR AB multi# morbid* 
S4 
SU (multiple chronic N3 (disease* OR illness* OR condition*) ) OR TI (multiple 
chronic N3 (disease*OR illness* OR condition*) ) OR AB (multiple chronic N3 
(disease*OR illness* OR condition*) ) 
S5 
SU (chronic N3 (disease* OR illness* OR condition*) ) OR TI (chronic N3 
(disease*OR illness* OR condition*) ) OR AB (chronic N3 (disease*OR illness* OR 
condition*) ) 
S6 SU pluripathology OR TI pluripathology OR AB pluripathology 
S7 SU comorbidity OR TI comorbidity OR AB comorbidity 
S8 SU comorbid* OR TI comorbid* OR AB comorbid 
S9 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 
S10 SU 'family medicine' OR TI 'family medicine' OR AB 'family medicine' 
S11 SU 'family practice' OR TI 'family practice' OR AB 'family practice' 
S12 SU general practice' OR TI 'general practice' OR AB 'general practice' 
S13 SU general practitioner*' OR TI 'general practitioner*' OR AB 'general practitioner*' 
S14 SU family physician* OR TI family physician* OR AB family physician* 
S15 SU primary care OR TI primary care OR AB primary care 
S16 SU primary health care OR TI primary health care OR AB primary health care 
S17 SU primary medical care OR TI primary medical care OR AB primary health care 
S18 SU ambulatory care OR TI ambulatory care OR AB ambulatory care 
S19 S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 
S20 SU Decision making OR TI Decision making OR AB Decision making 
S21 SU health care delivery OR TI health care delivery OR AB health care delivery 
S22 SU Prescribing OR TI Prescribing OR AB Prescribing 
S23 SU polypharmacy OR TI polypharmacy OR AB polypharmacy 
S24 
SU ((inappropriate OR appropriate OR suboptimal OR under OR over OR optimal) 
N3 (prescribing OR prescription OR medication* or drug*) ) OR TI ((inappropriate 
OR appropriate OR suboptimal OR under OR over OR optimal) N3 (prescribing OR 
prescription OR medication* or drug*) ) OR AB ((inappropriate OR appropriate OR 
suboptimal OR under OR over OR optimal) N3 (prescribing OR prescription OR 
medication* or drug*) ) 
S25 
SU (multi* N3 (drug* OR medication* OR prescription*) ) OR TI (multi* N3 (drug* 
OR medication* OR prescription*) ) OR AB (multi* N3 (drug* OR medication* OR 
prescription*) ) 
S26 SU clinical practice OR TI clinical practice OR AB clinical practice 
S27 SU experience level OR TI experience level OR AB experience level 
 256 
 
S28 SU morbidity OR TI morbidity OR AB morbidity 
S29 S9 or S28 
S30 S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 
S31 S19 and S29 and S30 
S32 TI experiences OR AB experiences 
S33 TI interview* OR AB interview* 
S34 TI qualitative OR AB qualitative 
S35 S32 or S33 or S34 
S36 S31 and S35 
S37 CC 3410 (Professional Education & Training) 
S38 CC 3430 (Professional Personnel Attitudes & Characteristics) 
S39 CC 3400 (Professional Psychological & Health Personnel Issues) 
S40 S37 or S38 or S39 
S41 S30 or S40 
S42 S19 and S29 and S41 
S43 S35 and S42 
 
5. Search terms used for Academic Search Complete; Social Sciences Full Text (H.W. 
Wilson);SocINDEX with Full Text, Platform EBSCO 
S1 Qualitative research OR AB qualitative OR TI Qualitative 
S2 SU attitude* of health personnel 
S3 SU questionnaire* or AB questionnaire* OR TI questionnaire* 
S4 'nursing methodology research' 
S5 AB interview* OR TI interview* OR SU interview* 
S6 AB focus group* OR TI focus group* OR SU focus group* 
S7 SU multimorbidity OR TI multimorbidity OR AB multimorbidity 
S8 SU multimorbid* OR TI multimorbid* OR AB multimorbid* 
S9 SU multi# morbid* OR TI multi# morbid* OR AB multi# morbid* 
S10 
SU (multiple chronic N3 (disease* OR illness* OR condition*) ) OR TI (multiple 
chronic N3 (disease*OR illness* OR condition*) ) OR AB (multiple chronic N3 
(disease*OR illness* OR condition*) ) 
S11 
SU (chronic N3 (disease* OR illness* OR condition*) ) OR TI (chronic N3 
(disease*OR illness* OR condition*) ) OR AB (chronic N3 (disease*OR illness* OR 
condition*) ) 
S12 SU pluripathology OR TI pluripathology OR AB pluripathology 
S13 SU comorbidity OR TI comorbidity OR AB comorbidity 
S14 SU comorbid* OR TI comorbid* OR AB comorbid 
S15 S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 
S16 S1 or S2 or S3 or S4 or S5 or S6 
S17 SU 'family medicine' OR TI 'family medicine' OR AB 'family medicine' 
S18 SU 'family practice' OR TI 'family practice' OR AB 'family practice' 
S19 SU general practice' OR TI 'general practice' OR AB 'general practice' 
S20 SU general practitioner*' OR TI 'general practitioner*' OR AB 'general practitioner*' 
S21 SU family physician* OR TI family physician* OR AB family physician* 
S22 SU primary care OR TI primary care OR AB primary care 
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S23 SU primary health care OR TI primary health care OR AB primary health care 
S24 SU primary medical care OR TI primary medical care OR AB primary health care 
S25 SU ambulatory care OR TI ambulatory care OR AB ambulatory care 
S26 S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 
S27 S15 and S16 and S26 
S28 SU Decision making OR TI Decision making OR AB Decision making 
S29 SU health care delivery OR TI health care delivery OR AB health care delivery 
S30 SU Prescribing OR TI Prescribing OR AB Prescribing 
S31 SU polypharmacy OR TI polypharmacy OR AB polypharmacy 
S32 
SU ((inappropriate OR appropriate OR suboptimal OR under OR over OR optimal) 
N3 (prescribing OR prescription OR medication* or drug*) ) OR TI ((inappropriate 
OR appropriate OR suboptimal OR under OR over OR optimal) N3 (prescribing OR 
prescription OR medication* or drug*) ) OR AB ((inappropriate OR appropriate OR 
suboptimal OR under OR over OR optimal) N3 (prescribing OR prescription OR 
medication* or drug*) ) 
S33 
SU (multi* N3 (drug* OR medication* OR prescription*) ) OR TI (multi* N3 (drug* 
OR medication* OR prescription*) ) OR AB (multi* N3 (drug* OR medication* OR 
prescription*) ) 
S34 SU clinical practice OR TI clinical practice OR AB clinical practice 
S35 S28 or S29 or S30 or S31 or S32 or S33 or S34 
S36 S27 and S35 
S37 morbidity OR TI morbidity OR AB morbidity 
S38 S15 or S37 
S39 S16 and S26 and S35 and S38 
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Supplementary material 3. Data extraction form for systematic review  
 
Adapted from the Joanne Briggs data extraction form (199). 
 
 
 
Author  
Background of authors  
Country of study  
Year of publication  
Setting of study  
Aims (Phenomena of Interest)  
Participants 
 GPs (n) 
 Others (profession, n) 
 
Professional Orientation/Focus of GPs  
Methodology  
Methods 
Data collection 
Data analysis 
 
Main findings  
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Supplementary material 4. Table 15. ENTREQ statement 
Table 15. Enhancing transparency in reporting the synthesis of qualitative research 
(ENTREQ) statement 
No Item Guide and description 
1 Aim To synthesize the existing published literature on the perceptions of 
GPs or their equivalent on the clinical management of 
multimorbidity and determine targets for future research that aims 
to improve clinical care in multimorbidity 
 
2 Synthesis 
methodology 
Meta-ethnography 
3 Approach to 
searching 
Pre-planned comprehensive search strategies to seek all available 
studies 
 
4 Inclusion 
criteria 
Qualitative research methods (i.e. data collection and analysis) 
Population: General practitioners or their equivalent  
Topic: Clinical management of multimorbidity 
No language or year limits 
 
5 Data sources Electronic databases (EMBASE, Medline, CINAHL, PsychInfo, ASC, 
Social Science Citation Index). 
Grey literature databases included WORLDCAT via the Online 
Computer Library Center (OCLC), Proquest, PapersFirst via OCLC, 
ASSIA (Applied Social Sciences Index and Abstracts), Directory of 
Open Access Books (DOAB) and Ebrary. 
Last search update for published paper was on 21st September 
2012. 
6 Electronic 
Search 
strategy 
Literature search terms are described in detail in Supplementary 
material 1. 
 
7 Study 
screening 
methods 
The titles and abstracts of retrieved citations were scanned by one 
reviewer (CS). Full papers were ordered for all potentially relevant 
abstracts. Full papers were reviewed by two researchers (CS, CB) 
and were included if they met our inclusion criteria.  
8 Study 
characteristics 
The characteristics of the included studies are presented in Table 1. 
 
9 Study selection 
results 
The studies screened are described in brief in Figure 4 (Flow 
diagram) and in greater detail in Supplementary material 5. 
 
10 Rationale for 
appraisal 
One researcher (CS) formally assessed quality. Decisions on 
inclusion and relevance of studies to our research question was 
independently conducted by two reviewers (CS, CB) 
11 Appraisal 
items 
The CASP tool was used to appraise all included studies 
 
12 Appraisal 
process 
Quality assessment was formerly conducted by one reviewer (CS) 
 
13 Appraisal 
results 
The overall quality of the ten included studies was high, with all 
articles meeting the majority of CASP criteria. The most common 
weaknesses were related to data saturation (not reported in six 
studies) and reflexivity (not discussed in five studies). GPs with 
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academic/research affiliations were over-represented as research 
subjects in five studies, representing a potential source of bias. 
An overview of the quality appraisal is available in Supplementary 
material 6 and the quality assessments for each included paper is 
available here:  
https://drive.google.com/file/d/0BxJS5MOWiRUtQWo0ek4zaXlSaXc
/view?usp=sharing 
14 Data 
extraction 
A data extraction form was derived from the Johanna Briggs data 
extraction form (Supplementary material 3). All text under the 
headings “results /conclusions” was considered data from the 
primary studies unless it was stated to be given by a healthcare 
professional that was not a GP. This data was extracted 
electronically and entered into a computer software package to 
facilitate data management. 
15 Software NVivo 9 
 
16 Number of 
reviewers 
Three reviewers – CS, SMH, CB. 
17 Coding The meta-ethnographic approach described by Noblit & Hare 
informed coding of data. Relevant data was initially open coded, 
with in vivo coding used where possible. Axial coding was informed 
by steps 4-6 of the meta-ethnographic approach. 
18 Study 
comparison 
Overarching concepts that represented the entire dataset were 
formulated after initial readings of the included papers. The specific 
contribution of each paper to each key concept was then 
determined. 
19 Derivation of 
themes 
Themes were derived initially as key concepts representing the 
entire dataset. The contribution of each paper to each key concept 
was determined and the meaning of the key concept was modified 
based on the comparisons and synthesis of contributions to the key 
concept.  
20 Quotations Quotations from the primary studies are provided in Table 2 to 
illustrate themes/constructs. 
 
21 Synthesis 
output 
A line of argument was derived which represents a statement of 
GPs’ perception of multimorbidity. The key concepts demonstrate 
key areas that have arisen from existing qualitative work, in a 
variety of health care settings, and as such gives direction to on-
going research and intervention development in this field.  
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Supplementary material 5. Excluded studies 
Exclusions were made by applying the following criteria in this order: not qualitative 
research; not dealing with multimorbidity/focus is on index diseases; not primary 
care/GP. Once one reason for exclusion was found, no other reasons were sought. For 
foreign language titles, Google translate was used to ascertain if the title was 
applicable. Table 15 shows the number of citations returned from each database, the 
number that remained after removal of duplicates, and the number excluded on the 
basis of title or abstracts. Full text papers were retrieved for all remaining citations. 
These were read, and decisions made regarding their inclusion by two reviewers. The 
reasons for exclusion of full text papers are provided below. 
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Table 16. Reasons for excluded papers stratified by database 
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EMBASE 1121 16 1105 1082 34 577 447 24 23 0 11 7 0 4 1 19 
CINAHL 65 6 59 55 0 14 32 9 4 0 0 3 0 1 0 3 
PsycInfo 184 47 137 134 0 48 72 14 3 0 0 2 0 1 0 2 
Academic Search 
Complete 
198 58 140 137 2 67 65 3 3 0 0 2 0 1 0 2 
Medline (Ovid) 437 73 364 360 12 185 153 10 4 0 0 2 0 2 0 2 
Total  2005 200 1805 1768 48 891 769 60 37 0 11 16 0 9 1 28 
*Duplicates searched for in order of EMBASE/CINAHL/Medline/PsycInfo/ASS) 
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Detail on excluded full-texts 
EMBASE 
Full texts retrieved for 23 citations; 18 were excluded, one was only available in 
abstract form, and four were included. 
1. Ampt AJ, et al. Attitudes, norms and controls influencing lifestyle risk factor 
management in general practice. BMC Family Practice 2009,10:59. Concerns 
lifestyle modification in the management of chronic disease, but does not 
incorporate multimorbidity.  
2. Balla J, et al. Clinical decision making in a high-risk primary care environment: A 
qualitative study in the UK. BMJ Open 2012;2(1). Concerns decision making in out 
of hours care, not multimorbidity. 
3. Boyd CM, et al. Clinical practice guidelines and quality of care for older patients 
with multiple comorbid diseases: implications for pay for performance. JAMA. 2005 
Aug 10;294(6):716-24. Review of one case vignette, and application of guidelines. 
4. Davidson W, et al. Physician characteristics and prescribing for elderly people in 
New Brunswick: Relation to patient outcomes Canadian Medical Association 
Journal. 1995. 152. 8. Quantitative analysis only. 
5. Demirkol A, et al. Providing healthcare for people with chronic illness: the views of 
Australian GPs. Med J Aust. 2003 Sep 1;179(5):269.Does not focus on 
multimorbidity.  
6. Fortin M, et al. Multimorbidity's many challenges. BMJ. 2007 334(7602):1016-7. 
Editorial. 
7. Horne R, et al. Shared care: a qualitative study of GPs' and hospital doctors' views 
on prescribing specialist medicines. Br J Gen Pract. 2001 Mar;51(464):187-93. 
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Relates to GPs perceptions of shared care between primary and secondary care, 
not multimorbidity.  
8. Hudon C, et al. Patient-centered care in chronic disease management: A thematic 
analysis of the literature in family medicine. Patient Educ Couns. 2012 
Aug;88(2):170-6. Analysis of existing literature rather than primary data. 
9. Kadam U. Redesigning the general practice consultation to improve care for 
patients with multimorbidity. BMJ.2012;345:e6202. Editorial 
10. Loeb DF, et al. Primary care physician perceptions on caring for complex patients 
with medical and mental illness. J Gen Intern Med. 2012 Aug;27(8):945-52. Epub 
2012 Feb 28. Focuses on the interaction between mental and physical illness, using 
mental illness an index illness. 
11. Mangin D, et al.Beyond diagnosis: rising to the multimorbidity challenge. BMJ. 2012 
Jun 13;344:e3526. Editorial. 
12. Martin C, Rohan BG. Chronic illness care as a balancing act. A qualitative study. 
Australian family physician. 2002. Concerns models of care rather than delivery of 
care or multimorbidity. 
13. May C, et al. Framing the doctor-patient relationship in chronic illness: a 
comparative study of general practitioners' accounts. Sociol Health Illn. 2004 
Mar;26(2):135-58. Re-analysis of previously gathered qualitative data to examine 
the doctor-patient relationship.  
14. Salisbury, 2012. Editorial. 
15. Saltman, 2004. Editorial. 
16. Shepherd, 2012. Letter in response to Mercer article. 
17. Webster, 2000. Letter. 
 265 
 
18. Weiner M, et al. Perspectives of general practitioners towards evaluation and 
treatment of cardiovascular diseases among older people. J Prim Health Care. 2009 
Sep;1(3):198-206. Although reported as mixed methods, the qualitative component 
was just ‘narrative comments’ at the end of a quantitative/likert questionnaire. 
19. Abstract only: Limm B, Hughes TB, Boyd C, Rand C. Primary care providers' 
experiences of assessing and minimizing treatment burden of multimorbid older 
adults. J Am Geriatr Soc. 2012;60. Abstract from AGS 2012 annual meeting. Study 
authors contacted – Dr C Boyd – and full account not yet published. 
20. Bower, 2011: included. 
21. Smith, 2010: included. 
22. O'Brien, 2011: included. 
23. Marx, 2009: included. 
 
CINAHL 
Full texts retrieved for four citations, and three were excluded.  
1. Rashidian A, et al. Falling on stony ground? A qualitative study of implementation 
of clinical guidelines' prescribing recommendations in primary care. Health Policy, 
2008 Feb; 85 (2): 148-61. Focused on the implementation of guidelines' prescribing 
recommendations- not multimorbidity. 
2. Kupka NJ. Interactions between practitioners and patients with chronic illnesses. 
Rush University, College of Nursing, 2003; Doctoral dissertation – research. Focuses 
on the use of motivational techniques by GPs in managing chronic disease – not 
multimorbidity.  
3. Lown BA, et al. Mutual influence in shared decision making: a collaborative study of 
patients and physicians. Health Expectations. Jun 2009, Vol. 12 Issue 2, p160-174. 
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Concerns characteristics of the doctor-patient relationship and decision making- 
not multimorbidity. 
4. Fried: included. 
 
Medline 
Full texts retrieved for four citations, and two were excluded.  
1. Müller-Engelmann M, et al. Shared decision making in medicine: the influence of 
situational treatment factors. Patient Educ Couns. 2011 Feb;82(2):240-6. Concerns 
situations where shared decision making is an appropriate approach- not 
multimorbidity. 
2. Harries C, et al. Which doctors are influenced by a patient's age? A multi-method 
study of angina treatment in general practice, cardiology and gerontology.Qual Saf 
Health Care. 2007 Feb;16(1):23-7. Focuses on management of angina and has only 
one line on multimorbidity in qualitative section. 
3. Solomon: included. 
4. Luijks: included. 
 
PsycInfo 
Full texts retrieved for three citations, and two were excluded. 
1. Peters-Klimm et al. Physicians’ view of primary care-based case management for 
patients with heart failure: A qualitative study. International Journal for Quality in 
Health Care, Vol 21(5), Oct, 2009. pp. 363-371.Concerns the evaluation of the 
implementation of a case management programme for heart failure- not 
multimorbidity.  
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2. Chew-Graham CA, Hogg T. Patients with chronic physical illness and co-existing 
psychological morbidity: GPs' views on their role in detection and management. 
Primary Care Psychiatry 2002, 2:35-39. Focuses on the management and diagnosis 
of an index condition (depression) in patients with chronic physical disease. 
3. Steinman: included. 
 
Academic Search Complete / Social Science Full Text 
Full texts were retrieved for three citations, and two were excluded. 
1. Malin A, et al. GPs' decision-making--perceiving the patient as a person or a 
disease. BMC Family Practice. 2012, Vol. 13 Issue 1, p38-43. 6p. Quantitative 
analysis. 
2. Hunt LM, et al. The Changing Face of Chronic Illness Management in Primary Care: 
A Qualitative Study of Underlying Influences and Unintended Outcomes. Ann Fam 
Med. 2012. Addresses individual chronic diseases (diabetes and hypertension) but 
not the presentation of these in tandem. 
3. Schuling: included.  
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Supplementary material 6. Table 17. Quality assessments for systematic review 
This table provides a summary of the CASP quality analysis for each paper included in 
the systematic review. 
Table 17. Quality assessments for systematic review 
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Was there a clear statement of the aims of the 
research? 
Y Y Y Y Y Y Y Y Y Y 
Is a qualitative methodology appropriate? Y Y Y Y Y Y Y Y Y Y 
Was the research design appropriate to address 
the aims of the research? 
Y Y Y Y Y Y Y Y Y Y 
Was the recruitment strategy appropriate to the 
aims of the research? 
Y Y Y Y Y Y Y Y Y Y 
Were the data collected in a way that addressed 
the research issue? 
Y Y Y Y Y Y Y Y Y Y 
Has the relationship between researcher and 
participants been adequately considered? 
Y N Y N Y N N Y Y N 
Have ethical issues been taken into 
consideration? 
N Y Y Y Y Y Y Y Y Y 
Was the data analysis sufficiently rigorous? Y Y Y Y Y Y N N Y ~ 
Is there a clear statement of the findings? Y Y Y Y Y Y Y Y Y Y 
How valuable is the research? Y Y Y Y Y Y Y Y Y Y 
 Studies by Smith et al., Fried et al., Marx et al. and Schuling et al. involved 
participants that were strongly involved with academia or medical education rather 
than full time GPs. GPs in the study by Bower et al. were in a research network.  
 Data saturation not discussed by Smith, O’Brien, Steinman, Fried, Solomon or 
Anthierens. 
 Reflexivity not discussed by Bower, Schuling, Steinman, Fried, Solomon, Anthierens. 
 How qualitative quotes were chosen was not described in the studies by Luijks, 
Bower, Schuling.  
 Description of analysis in Schuling lacked detail. 
 Location for interview not given in Fried, Smith, Schuling, Luijks, 
 Deviant cases not discussed in Anthierens.  
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Supplementary material 7. Table 18. Key concepts and subthemes 
Table 18. Key concepts from the included papers and subthemes that occurred with 
each key concept 
 
Key concept 
(number of studies this related to) 
Sub-themes in each key concept 
(number of studies this related to) 
Disorganisation and fragmentation of care 
(8) 
 
Structure of primary care (6) 
Inadequate time (5) 
Fragmented care and involvement of 
secondary care (8) 
The inadequacy of guidelines and 
evidence based medicine (10) 
 
Single disease focus (5) 
Doubts on the evidence underpinning 
guidelines (5) 
Guidelines add to complexity (7) 
Queries on the relevance of disease specific 
outcomes (6) 
The use of guidelines for primary prevention 
(5) 
Using modified approaches to guidelines (5) 
Linking guidelines to physician 
reimbursement (3) 
Challenges in delivering patient-centred 
care (10) 
 
Individualising management (7) 
Taking a generalist approach (10) 
Importance of a longitudinal patient-GP 
relationship(7) 
The impact of multimorbidity and treatment 
burden (6) 
Specific complicating patient characteristics 
(6) 
Challenges in shared decision-making (10) 
 
Discussing risks and outcomes associated 
with treatment options (8) 
Using alternative models of decision-making 
(7) 
Lack of appropriate communication skills (3) 
Approaches to changing or deprescribing 
medications (6)  
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Appendix II. Supplementary data for Chapter 6. Qualitative interview study.  
The materials in this appendix are supplements to the published version of the 
qualitative interview study. 
 
Supplementary material 8. Topic guides for interviews 1, 10 and 20 showing iterative 
refinement of interview probes. 
 
Topic Guide Interview 1 
Introduction: Data shows that the management of multimorbidity can be difficult for 
GPs. I want to understand the issues that GPs experience in multimorbidity to see if we 
can target anything to make the management of these patients easier.  
 Describe my background (GP trainee and PhD student). 
 Permission to record interview. 
 No patient identifying information required. 
 Ethics approval gained from ICGP and UCC. Full confidentiality ensured, data will be 
password protected and stored only in UCC. 
 
Opening questions 
 Participant’s job title, role, qualifications. 
 Length of time in practice, how long in this practice, how many sessions per week. 
 Describe practice: size, no of GPs, practice population. 
 Any practice protocols on multiple chronic diseases? Do they work? 
 What does the term multimorbidity mean? 
 
Description of patients chosen for chart-stimulated recall 
 Patient’s gender, age, social background, diseases and current medications. 
 Describe last four consultations with this patient, beginning with fourth last. 
 
Probes 
 Organisation of care 
 Role of specialists 
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 Guidelines 
 Polypharmacy 
 Adverse drug effects 
 Goals of care 
 Patient-centredness 
 Shared decision making 
 What hindered/helped/would have helped 
 
____________________________________________ 
 
Topic Guide Interview 10 
No change in introduction, opening questions and case descriptors.  
Probes 
 Fragmentation 
o Communication with other healthcare professionals  
o Good experiences and bad experiences 
 Goals of care 
o What has influenced these? 
 Managing medications 
o What do you do when you look at a list of meds and question their 
usefulness – how do you respond to that thought?  
o Reasons to change them?  
o Stopping medications? 
o Inherited medications? 
o Other GPs have told me that they stay away from messing with these 
patients’ medicines - do you ever feel like that? Why? What would make it 
easier for you? 
o Polypharmacy – issues for the patient and/or the doctor 
o Conflicts: ideally patients would not be on these two meds, but patients are 
far from ideal….. When you were deciding to start this med, how did you 
decide to use it? 
 Are guidelines useful in multimorbidity? 
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o What ones do you use? Why?  
o What do guidelines say regarding options? 
o What makes you comfortable in not using them? 
 Shared decision-making 
o Approaching this with the patient 
 Longitudinal care  
 Negative cases: This case seems to be going well for you. Can you think of any cases 
where you found it hard to decide what to do with the medications?  
 Support for patient. Support for doctor.  
 
____________________________________________ 
 
Topic Guide Interview 20 
No change in introduction, opening questions and case descriptors. 
Probes 
 Communication with other healthcare professionals 
 Patient-centred care and goals of care  
 Managing medications 
o Not rocking the boat  
o Polypharmacy –What stops you from stopping meds? 
o Who has control of prescribing for these patients?  
o Where does the balance in prescribing decisions lie? How does this balance 
change with time (years of doctor- patient relationship)? When doctor and 
patient disagree, how is course of action decided on? 
 What helps you decide what is best practice in medical management?  
 Shared decision-making 
o Communication strategies around multiple options. 
o Patient attachment to meds 
 Longitudinal care and trust. How does this change things?  
 What combinations of conditions are challenging?  
 Informing patients of adverse drug effects: how much information should we give 
about options /interactions? 
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 Next of kin: useful or unwanted input- what would you have done if they were not 
involved? 
 Chronic disease programmes – will this change prescribing for multimorbid 
patients? 
 Any practice processes that help manage medications/safety?  
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Supplementary material 9. Table 19. COREQ statement  
Consolidated criteria for reporting qualitative research (COREQ) statement (340) 
Table 19. Consolidated criteria for reporting qualitative research (COREQ) statement 
Domain 1: Research team and reflexivity 
 
Personal Characteristics 
1. Interviewer/ 
Facilitator 
Which author conducted the 
interviews? 
CS conduced the interviews. 
2. Credentials What were the researcher's 
credentials? E.g. PhD, MD 
CS is a medical doctor, has the 
medical and GP memberships, and 
is a senior registrar in general 
practice and a PhD candidate as 
part of an academic/clinical 
fellowship programme. 
3. Occupation What was their occupation 
at the time of the study? 
Academic/clinical research fellow in 
general practice, with three days 
per week in research and two days 
per week in general practice. 
4. Gender Was the researcher male or 
female? 
Female 
5. Experience 
and training 
What experience or training 
did the researcher have? 
CS received training at the Health 
Experience Research Group, Oxford 
University; completed training in 
NVivo computer assisted qualitative 
data management; and achieved 
first class honours in Qualitative 
Research Methods in University 
College Cork, Ireland. 
Relationship with participants 
6. Relationship 
established 
Was a relationship 
established prior to study 
commencement? 
6/20 of the GPs that participated 
were tutors for the Department of 
General Practice, University College 
Cork but there was no other 
relationship established between 
the participants and the research 
team prior to commencing the 
study. 
7. Participant 
knowledge of 
the 
interviewer 
What did the participants 
know about the researcher? 
e.g. personal goals, reasons 
for doing the research 
Participants were aware that CS was 
a senior registrar in GP and a PhD 
candidate in General Practice.  
8. Interviewer 
characteristics 
What characteristics were 
reported about the 
interviewer/facilitator? e.g. 
Bias, assumptions, reasons 
and interests in the research 
topic 
As a fellow member of the 
profession of General Practice, it is 
likely that GPs may have opened up 
more to CS than a non-clinical 
researcher. However, as an early 
career GP, CS is also less likely to 
have conceptual blindness to many 
of the issues in the day to day 
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management of patients in 
multimorbidity than an established 
GP.  
Domain 2: study design 
 
Theoretical framework 
9. Methodological 
orientation and 
Theory 
What methodological 
orientation was stated to 
underpin the study? e.g. 
grounded theory, discourse 
analysis, ethnography, 
phenomenology, content 
analysis 
Grounded Theory as described by 
Charmaz (166) 
Participant selection 
10. Sampling How were participants 
selected? e.g. purposive, 
convenience, consecutive, 
snowball 
20 GPs were interviewed. GP 
participants were initially 
purposively sampled from CPD 
meetings. This method was 
complemented with snow ball 
sampling to achieve adequate 
representation of our sampling 
frame. Of 21 GPs that signed up 
from CPD groups, 14 were 
interviewed. The remaining six 
participants were snowball sampled 
to give representation of pre-
determined criteria of rural/urban, 
single/group practice and length of 
time qualified.  
11. Method of 
approach 
How were participants 
approached? e.g. face-to-
face, telephone, mail, email 
At CPD meetings for purposive and 
by contacting individual GPs for 
snowball sampling based on 
recommendations from GPs already 
enrolled and participating. 
12. Sample size How many participants 
were in the study? 
20 
13. Non-
participation 
How many people refused 
to participate or dropped 
out? Reasons? 
Of 21 GPs that signed up from CPD 
groups, 14 responded to further 
contact and all 14 were interviewed. 
The remaining six participants were 
snowball sampled to give 
representation of pre-determined 
criteria of rural/urban, single/group 
practice and length of time 
qualified.  
Setting 
14. Setting of data 
collection 
Where was the data 
collected? e.g. home, clinic, 
workplace 
In the GP participants’ surgeries or 
clinics.  
15. Presence of 
non-
Was anyone else present 
besides the participants and 
No 
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participants researchers? 
16. Description of 
sample 
What are the important 
characteristics of the 
sample? e.g. demographic 
data, date 
See Table 3: Almost have were in 
rural practice; 70% were in group 
practices and 70% were qualified as 
GPs for longer than ten years. 
Data collection 
17. Interview guide Were questions, prompts, 
guides provided by the 
authors? Was it pilot 
tested? 
Early interviews (gp1-3) were 
reviewed by MB for questions and 
interview technique. Topic guides 
were used and reviewed after every 
interview. 
18. Repeat 
interviews 
Were repeat interviews 
carried out?  
No 
19. Audio/visual 
recording 
Did the research use audio 
or visual recording to 
collect the data? 
All interviews were audio recorded. 
20. Field notes Were field notes made 
during and/or after the 
interview or focus group? 
Field notes were made during and 
immediately after the interviews, 
and were referred to during the 
early stages of analysis, and during 
refinement of the topic guides. 
21. Duration What was the duration of 
the interviews or focus 
group? 
GPs were asked to give 
approximately 30 minutes for each 
interview. The average length was 
42 minutes, range 32-65mins. 
22. Data saturation Was data saturation 
discussed? 
Yes, conceptual data saturation was 
achieved at interview 18, as 
subsequent interviews did not lead 
to further categories in coding. 
23. Transcripts 
returned 
Were transcripts returned 
to participants for 
comment and/or 
correction? 
No. 
Domain 3: analysis and findings  
 
Data analysis 
24. Number of data 
coders 
How many data coders 
coded the data? 
Four data coders coded the data. 
25. Description of 
the coding tree 
Did authors provide a 
description of the coding 
tree? 
No coding tree was developed but 
all members of the research team 
discussed and agreed on the 
grounded theory approach to 
analysis a priori.  
26. Derivation of 
themes 
Were themes identified in 
advance or derived from 
the data? 
Coding was data driven. The first 
stage involved open coding for GPs’ 
actions in multimorbidity, and the 
causes, conditions and 
consequences of these actions. 
Divergent or disconfirming cases 
were actively sought. The second 
stage of coding involved 
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categorization of the coded data 
based on thematic or conceptual 
similarity. 
27. Software What software, if 
applicable, was used to 
manage the data? 
NVivo 10 was used to facilitate data 
management.  
28. Participant 
checking 
Did participants provide 
feedback on the findings? 
No 
Reporting 
29. Quotations 
presented 
Were participant 
quotations presented to 
illustrate the themes 
/findings? Was each 
quotation identified? e.g. 
participant number 
Yes, the source GP for each quote is 
provided.  
30. Data and 
findings 
consistent 
Was there consistency 
between the data 
presented and the 
findings? 
Quotes are embedded in text so are 
used to illustrate our findings in 
participants own language as much 
as possible. 
31. Clarity of major 
themes 
Were major themes clearly 
presented in the findings? 
Major themes are presented in the 
results section. 
32. Clarity of minor 
themes 
Is there a description of 
diverse cases or discussion 
of minor themes? 
Subthemes are presented within the 
major headings. Further details are 
provided on the cases discussed in 
Supplementary material 10. 
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Supplementary material 10. Overview of cases discussed by GPs in chart-stimulated 
recall 
Age  
(years) 
Gender 
(m/f) 
List of chronic diseases provided by GP 
60 f Hypertension, hypothyroidism, type 2 diabetes mellitus, asthma, 
hiatus hernia and gastro-oesophageal reflux.  
78 m Type 2 diabetes mellitus, multiple PEs /DVTs, osteoarthritis (right 
total knee replacement), hypothyroidism, BPH, hypertension, 
glaucoma, depression, irritable bowel syndrome, deafness, 
dyspepsia, gallstones, haemorrhoids 
61 m Ischaemic heart disease (MI, recent bypass), COAD, right heart 
failure, recent PE, delirium recurrent /agitation at night, type 2 
diabetes mellitus, BPH, hyperlipidaemia 
51 f Hyperlipidaemia, hypertension, carpal tunnel syndrome, benign 
positional /recurrent vertigo, migraine, cerebrovascular disease, 
depression, medically unexplained symptoms /chronic pain query 
cause, chronic Lyme disease, hypothyroidism, dyspepsia.  
78 f Hypertension, atrial fibrillation, hyperlipidaemia, hearing loss, 
schizophrenia, depression 
50 m IHD, hypothyroidism, haemochromatosis, obesity, hypertension, 
hyperlipidaemia 
50 f Depression, anxiety, alcoholism, recurrent deliberate self-harm, 
bipolar affective disorder, seizure disorder, menorrhagia, 
hypothyroidism, diarrhoea under investigation, cerebrovascular 
disease  
60 m Type 2 diabetes mellitus, multiple sclerosis, cognitive impairment, 
lumbar disc issues with leg pain, high PSA, anaemia query cause, 
depression, hypertension 
76 f Hypertension, CKD, hyperlipidaemia, cervical cancer, chronic lower 
back pain, recent PE, schizophrenia 
84 f Recurrent DVT, IHD: recent angina, COAD, osteoarthritis with 
bilateral total hip replacements, practically blind, hypertension, 
recurrent falls with fractured distal radius, osteoporosis, glaucoma, 
constipation 
84 f Ischaemic heart disease: MI 1998, hypertension, hyperlipidaemia, 
chronic back pain due to osteoarthritis and disc disease, squamous 
cell carcinoma of skin, DVT last year, prostate cancer, metastatic 
bone disease, osteoporosis, constipation 
72 f Anxiety, depression, obesity, osteoarthritis with prior total knee 
replacement, GORD, urinary frequency, urgency & incontinence, 
recurrent UTIs, hyperlipidaemia, hypertension, gout, IHD: angina, 
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fibroids, COAD/asthma, cardiac failure, type 2diabetes mellitus, 
cognitive impairment 
77 m Polymyalgia rheumatica, multiple PEs, iron deficiency anaemia, 
Crohn’s disease, left lung lobectomy for lung cancer, type 2 
diabetes, left ventricular failure, asthma/COAD, obesity 
67 f Depression, anxiety, type 2 diabetes, non-ischaemic dilated 
cardiomyopathy with cardiac failure, alcohol abuse 
39 f Recurrent depression, chronic back pain, bilateral PEs, psychoactive 
substance abuse, post-traumatic stress disorder/neurosis 
43 m Hepatitis C, HIV, COAD /asthma, depression with psychotic 
features, anxiety, addiction /substance abuse, dyspepsia 
81 f COAD and asthma, peripheral vascular disease: left external iliac 
artery stenosis, macular degeneration with disciform scar on left 
side and visual impairment, osteoarthritis & hip replacement, 
chronic sinusitis, shortness of breath under investigation (being 
treated as IHD), stage 2 CKD, glaucoma 
86 f Anxiety, osteoporosis, stage 3 CKD, hypothyroidism, facial 
squamous cell carcinoma requiring zygoma excision, IHD: single 
vessel coronary disease with a stent in 2009, atrial fibrillation, 
cardiac failure, musculoskeletal pain: prior shoulder dislocation, left 
knee replacement, right thumb fracture, fracture left side, stress 
urinary incontinence, COAD, diverticulosis, aortic stenosis with 
valvuloplasty 2012, constipation 
75 m Cerebrovascular disease/stroke: history of a right occipital lobe 
haemorrhage with a residual left homonymous hemianopia, IHD: 
minor coronary disease, hypertension, aortic stenosis moderate, 
anxiety, irritable bowel syndrome, dyspepsia with prior duodenal 
ulcer, seizure disorder.  
75 m Morbid obesity, haemochromatosis, hypertension, dyspepsia, 
autoimmune lichen planus, type 2 diabetes mellitus, gout, 
osteoarthritis: right and left hip replacement, transitional cell 
carcinoma of the bladder in 2012 - currently in remission, CKD, 
peripheral vascular disease: prior aortic aneurysm repair, awaiting a 
femoral popliteal bypass, colonisation with MRSA undergoing 
treatment, cardiac failure, COAD, constipation. 
39 m Gender reassignment with hormonal feminization, dyspepsia, 
anaemia query cause, high risk for thromboembolic disease.   
71 m BPH, depression, IHD, hyperparathyroidism with hypercalcaemia 
79 f Type 2 diabetes mellitus, hypertension, hyperlipidaemia, 
hypothyroidism, urge incontinence/irritable bladder, 
cerebrovascular disease – prior amaurosis fugax and transient 
ischaemic attacks, psoriatic arthritis, temporal arthritis, cataracts 
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from steroids, glaucoma, osteopenia, recurrent UTIs, vulval lichen 
sclerosis  
52 f Depression, anxiety/panic, hypertension, mucinous ovarian cyst 
with recent hysterectomy, Anti –nuclear antibody positive arthritis, 
chronic lower back pain with prior cauda equine syndrome, obesity, 
acne. 
83 f Malignant melanoma, hypertension, atrial fibrillation, 
cerebrovascular disease – transient ischaemic attacks, breast 
cancer with double mastectomy, type 2 diabetes mellitus, 
dementia, pernicious anaemia, urinary incontinence, CKD, 
depression. 
75 f IHD (MIs and stents), depression, cerebrovascular disease: stroke, 
vascular Parkinson’s, dementia, type 2 diabetes mellitus, 
osteoarthritis, fibromyalgia, temporal arteritis, osteoporosis, 
recurrent UTIs, irritable bladder, cataracts with decreased vision, 
glaucoma 
62 m Ischaemic heart disease (MI with cardiac arrest in 2011, now post 
bypass surgery), recent PE, hypothyroidism, hyperlipidaemia, 
depression, type 2 diabetes mellitus 
85 f Recurrent DVTs and PEs with greenfield filter, hypothyroidism, 
hyperlipidaemia, shoulder problems and sacroiliac joint pain, 
chronic cough likely COAD, tinnitus, diverticulosis, hypertension 
60 m Anxiety, depression, urinary incontinence, COAD/asthma-mild, 
impaired glucose tolerance, hypertension, hyperlipidaemia, 
constipation, dyspepsia, learning disability 
84 f IHD, cardiac failure, hyperlipidaemia, asthma, osteoporosis, 
dizziness/vertigo, arrhythmia 2:1 heart block  
66 m Hypertension, hyperlipidaemia, hiatus hernia, CKD, anaemia of 
chronic disease, cardiac failure, IHD, obesity, type 2 diabetes 
mellitus, atrial fibrillation 
80 m Dementia, cerebrovascular disease, rheumatoid arthritis, 
osteoarthritis, postural hypotension, recurrent falls, prostatic 
cancer on chemotherapy, osteopaenia 
81 m Rheumatoid arthritis, IHD, hypertension, osteoarthritis with cervical 
spondylosis and shoulder impingement, recurrent falls. 
92 m Ischaemic heart disease, congestive cardiac failure, osteoarthritis – 
neck, hips, shoulders- with neuropathic pain from neck, Parkinson’s 
disease , stage 3 CKD, hypertension, anaemia of chronic disease, 
falls with prior fracture humerus, actinic Keratosis, possible 
squamous cell carcinoma on face, eczema 
62 f Type 2 diabetes mellitus, asthma, hypertension, osteoarthritis –
prior knee replacement, osteoporosis, diverticular disease, breast 
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cancer (2011), hiatus hernia with Barrett’s oesophagus  
61 f Ulcerative colitis with prior subtotal colectomy, retinal occlusion 
secondary to recent endocarditis – sustained visual impairment, 
mitral valve prolapse and repair, atrial fibrillation, recurrent lentigo 
maligna, renal Calculi requiring recurrent lithotripsy, osteoporosis, 
dyspepsia and prior duodenal ulcer  
77 f Rheumatoid arthritis, osteoporosis, hyperlipidaemia, anaemia of 
chronic disease, IHD (non-obstructive coronary artery disease) 
58 f Systemic lupus, chronic pain, chronic anaemia, hyperhidrosis, 
diverticular disease, GORD, osteoporosis, benign essential tremor, 
IHD, high prolactin query cause. 
76 m CKD, heart failure, osteoarthritis with prior hip replacement, 
cerebrovascular disease-prior stroke, hypercholesterolemia, COAD, 
bowel carcinoma with right hemi colectomy, atrial fibrillation, 
alcohol abuse 
69 m Gout, atrial fibrillation, alcohol abuse, type 2 diabetes mellitus, 
hypertension, hyperlipidaemia, IHD. 
40 m Peptic ulcer disease, depression, chronic pain, chronic headache, 
constipation, alcoholism, mitochondrial disorder (“never fully 
nailed down”)   
80 f Hypertension, atrial fibrillation, recurrent UTIs, chronic pain query 
cause, chronic sinusitis 
64 m Type 2 diabetes mellitus, erectile dysfunction, ischaemic heart 
disease, morbid obesity, stage 3 CKD, BPH, hypertension, 
hyperlipidaemia, recurrent UTIs and prior urinary calculus, 
recurrent GI bleeds 
59 f Breast cancer currently on chemotherapy, hyperlipidaemia, 
osteoporosis 
87 f Atrial fibrillation, lipid disorder, hypertension, osteopaenia 
79 f Type 2 diabetes mellitus, hypertension, migraine, temporal arteritis 
75 m Atrial fibrillation, PEs, prostate carcinoma, lung cancer undergoing 
radiotherapy, unclear psychiatric diagnosis   
78 m Cerebrovascular disease with prior stroke and marked spasticity, 
urolithiasis, recurrent UTIs, oesophageal cancer, dyspepsia, 
hypertension, depression, constipation, chronic pain, anaemia 
query cause.   
82 m Cerebrovascular disease, multi-infarct dementia, parkinsonism, 
bilateral subdural haematomas with bilateral frontal shunts, 
rheumatoid arthritis, right upper lobe neoplasm not for 
intervention or radiotherapy, COAD, polycythaemia rubra vera, 
gout, fragility and mobility problems, constipation 
71 f Osteoporosis with fractured right neck of femur, heart failure with 
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biventricular defibrillator, orthostatic hypotension, atrial 
fibrillation, hyperlipidaemia, irritable bowel, cerebrovascular 
disease, cognitive impairment, recurrent UTIs  
82 f Adenocarcinoma caecum- right hemi-colectomy, asthma which is 
steroid dependant, COAD in addition to asthma, glaucoma, 
hypothyroidism, chronic pain from neuralgia and osteoarthritis, 
osteoporosis with Colles fracture and fractured ankle, 
hyperlipidaemia, GORD with an oesophageal web, steroid induced 
myopathy, MI in 2005, severe diverticular disease, chronic iron 
deficiency anaemia, PE. 
 
Abbreviations: 
BPH: Benign prostatic hypertrophy  
CKD: Chronic kidney disease 
COAD: Chronic obstructive airways disease 
DVT: Deep venous thrombosis 
GORD: Gastro-oesophageal disease 
IHD: Ischaemic heart disease 
MI: Myocardial infarction 
PE: pulmonary embolism 
PSA: Prostate specific antigen  
UTI: Urinary tract infection 
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Appendix III. Supplementary data for Chapter 7. Scoping review 
The materials in this appendix are supplements to the manuscript of the scoping review 
that was submitted for publication. 
 
Supplementary material 11. Table 20. Search terms for scoping review 
Table 20. Example of search terms for scoping review 
#  Query  Limiters/Expanders  Last Run Via  
S1  TX chart-stimulated recall OR 
TX chart stimulated recall OR 
TX case-based discussion OR 
TX case-based oral  
Search modes - 
Boolean/Phrase  
Interface - EBSCOhost 
Research Databases  
Search Screen - Advanced 
Search  
Database - CINAHL Plus 
with Full Text  
S2  TX general practice AND TX 
general practitioner AND TX 
family practice AND TX family 
physician AND TX family 
medicine AND TX primary care 
AND TX primary health care 
AND TX primary medical care 
AND TX primary care physician 
AND TX family practitioner  
Search modes - 
Boolean/Phrase  
Interface - EBSCOhost 
Research Databases  
Search Screen - Advanced 
Search  
Database - CINAHL Plus 
with Full Text  
S3  TX general practice OR TX 
general practitioner OR TX 
family practice OR TX family 
physician OR TX family 
medicine OR TX primary care 
OR TX primary health care OR 
TX primary medical care OR TX 
primary care physician OR TX 
family practitioner  
Search modes - 
Boolean/Phrase  
Interface - EBSCOhost 
Research Databases  
Search Screen - Advanced 
Search  
Database - CINAHL Plus 
with Full Text  
S4  S1 AND S3  Search modes - 
Boolean/Phrase  
Interface - EBSCOhost 
Research Databases  
Search Screen - Advanced 
Search  
Database - CINAHL Plus 
with Full Text  
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Supplementary material 12. Data extraction form for scoping review of chart-
stimulated recall 
 
Author  
Year of publication  
Aims (Phenomena of Interest)   
Setting of study  
Participants: how sampled 
 GPs (n) 
 Others (profession, n) 
 
How were charts chosen  
How was topic guide developed and used  
Method of data analysis  
Main findings  
How was CSR useful in generating these findings  
Duration of interviews  
Professional background and training of interviewer  
Other issues of note (especially potential pitfalls and 
how to avoid them) 
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Supplementary material 13. Table 21. PRISMA checklist 
Table 21. PRISMA checklist for scoping review  
(341) 
Item   Page#  
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
118 
Abstract   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration 
number.  
119 
Introduction   
Rationale  3 Describe the rationale for the review in the context of what 
is already known.  
121 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
 
Methods   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
NA 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 
giving rationale.  
123-4 
Information 
sources  
7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
123-4 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
282 
Study 
selection  
9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
124 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators.  
125 
Data items  11 List and define all variables for which data were sought 
(e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
125 & 
283 
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Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this 
was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
125 & 
287 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
125 
Synthesis of 
results  
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
125 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
124 & 
287 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
NA 
Results   
Study 
selection  
17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
126 
Study 
characteristic 
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
136-6 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment (see item 12).  
287 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, 
for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot.  
NA 
Synthesis of 
results  
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
NA 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
287 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity 
or subgroup analyses, meta-regression [see Item 16]).  
128-
34 
Discussion   
Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance 
to key groups (e.g.,healthcare professionals, users, and 
policy makers).  
137 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
137 
Conclusions  26 Provide a general interpretation of the results in the context 
of other evidence, and implications for future research.  
138-9 
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Funding   
Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
systematic review.  
27 
 288 
 
Supplementary material 14. Table 22. Quality appraisal of included studies 
Table 22. Quality appraisal of studies included in scoping review of chart-stimulated recall 
Footnotes to quality appraisal of studies included in scoping review of chart-stimulated recall: 
i. The interviews in Lockyer et al. used survey type questions rather than open-ended or exploratory questions. It was difficult to see what the charts 
added here. 
Critical Appraisal Skills Programme (CASP) tool for qualitative research Ab 
 
Dee 
 
Guerra 
 
Guerra 
 
Lockyer 
 
Jennett 
 
Rochefort 
 
Sinnott 
 
1. Was there a clear statement of the aims of the research? y y y y y y y y 
2. Is a qualitative methodology appropriate? y y y y y y y y 
Detailed Questions:          
3. Was the research design appropriate to address the aims of the 
research? 
y y y y ~(i) y y y 
4. Was the recruitment strategy appropriate to the aims of the research?  y y (ii) y y y y y y 
5. Were the data collected in a way that addressed the research issue? y ~(iii) y y ~(iv) y y y 
6. Has the relationship between researcher and participants been 
adequately considered? (v) 
n n n n y n n y 
7. Have ethical issues been taken into consideration? 
-Research ethics committee approval 
-Ethical concerns (vi) 
 
y 
n 
 
n 
n 
 
y 
n 
 
y 
n 
 
n 
n 
 
n 
n 
 
y 
n 
 
y 
n 
8. Was the data analysis sufficiently rigorous? y n(vii) y y ~ (viii) ~ (viii) ~(viii) y 
9. Is there a clear statement of findings? y y y y y y y y 
10. How valuable is the research? y y y y y y y y 
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ii. Participation rates in these studies were low. In Dee et al. it took an “extensive search…considerable effort, patience and accommodation”, 6% 
agreed in Jennett et al., 20% in Guerra et al., 36% Rochefort et al. 
iii. Information was collected by Dee et al. to show what clinical questions arose on reflection. They did not demonstrate if these questions interfered 
with care, or if the doctors would have actually gone on to seek answers to them. So the findings could have been an artefact of the study rather 
than a clinical reality. 
iv. In Lockyer et al. it wasn’t clear if the physicians answered questions based on the chart of the baby that led to the interview being triggered, or 
whether their answers to the Likert scale type questions were more rhetorical or free-floating.  
v. Although the professional background of the researcher was given in the studies by Dee, Jennett, Guerra, Lockyer, Sinnott; it was only the Sinnott 
paper where there was a discussion on how this may have impacted on the interviewee and on the data. Training of the interviewer was discussed in 
Lockyer et al. Ab et al. said that interviews were non-confrontational and open-ended questions used. 
vi. While most of the studies, especially the more recent ones described ethical approval, none discussed ethical concerns specific to CSR.  
vii. Qualitative data analysis only briefly mentioned or not discussed. 
viii. The qualitative findings were not related back to the charts discussed in Rochefort et al. (i.e. quotes do not concern cases) and there are no 
qualitative findings (i.e. quotes) in Dee et al. or Lockyer et al. Overall sense that Dee were not conducted as a rigorous piece of qualitative research. 
Lockyer was evaluation of dissemination strategy using qualitative means.  
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Appendix IV. Supplementary data for Chapter 8. Cross-sectional study 
The materials in this appendix are online supplements to the published version of the 
cross-sectional study. 
 
Supplementary material 15. Table 23. STROBE statement 
Table 23. STrengthening the Reporting of OBservational studies in Epidemiology 
(STROBE) statement 
Item Recommendation Page 
# 
Title and abstract  1 (a) Indicate the study’s design with a commonly used 
term in the title or the abstract 
141 
(b) Provide in the abstract an informative and 
balanced summary of what was done and what was 
found 
142 
Introduction   
Background/ 
rationale 
2 Explain the scientific background and rationale for 
the investigation being reported 
144 
Objectives 3 State specific objectives, including any pre-specified 
hypotheses 
145 
Methods   
Study design 4 Present key elements of study design early in the 
paper 
146 
Setting 5 Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-
up, and data collection 
146 
Participants 6 (a) Give the eligibility criteria, and the sources and 
methods of selection of participants 
146 
Variables 7 Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
146-9 
Data sources/ 
measurement 
8  For each variable of interest, give sources of data 
and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than one group 
146-9 
Bias 9 Describe any efforts to address potential sources of 
bias 
(Response & recall bias addressed in methods & 
discussion section]=) 
146 
Study size 10 Explain how the study size was arrived at 
(Baseline data for primary care cohort study) 
146 
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Quantitative variables 11 Explain how quantitative variables were handled in 
the analyses. If applicable, describe which groupings 
were chosen and why 
 
146-9 
Statistical methods 12 (a) Describe all statistical methods, including those 
used to control for confounding 
149 
(b) Describe any methods used to examine subgroups 
and interactions 
150 
(c) Explain how missing data were addressed 150 
(d) If applicable, describe analytical methods taking 
account of sampling strategy.  
NA 
(e) Describe any sensitivity analyses 150 
Results   
Participants 13 (a) Report numbers of individuals at each stage of 
study—e.g. numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the 
study, completing follow-up, and analysed 
151 
(b) Give reasons for non-participation at each stage- 
discussed in prior publication, referenced in 
manuscript. 
 
Prior 
paper 
(283) 
(c) Consider use of a flow diagram.   
Descriptive data 14 (a) Give characteristics of study participants (e.g. 
demographic, clinical, social) and information on 
exposures and potential confounders 
Table 
7 
(b) Indicate number of participants with missing data 
for each variable of interest 
Table  
7 
Outcome data 15 Report numbers of outcome events or summary 
measures 
Table 
7 
Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision 
(e.g., 95% confidence interval). Make clear which 
confounders were adjusted for and why they were 
included 
151-2 
(b) Report category boundaries when continuous 
variables were categorized 
151-2 
(c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful time 
period 
NA 
Other analyses 17 Report other analyses done—e.g. analyses of 
subgroups and interactions, and sensitivity analyses 
154 
Discussion   
Key results 18 Summarise key results with reference to study 
objectives 
158 
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Limitations 19 Discuss limitations of the study, taking into account 
sources of potential bias or imprecision. Discuss both 
direction and magnitude of any potential bias 
160 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence 
160 
Generalisability 21 Discuss the generalisability (external validity) of the 
study results 
160 
Other information   
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, for 
the original study on which the present article is 
based 
27 
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Supplementary material 16. Table 24. Prevalence of chronic conditions in the 
Mitchelstown Cohort Study overall and stratified into those with or without adverse 
childhood experiences 
Table 24. Prevalence of individual chronic conditions in the overall Mitchelstown 
Cohort Study, and stratified into those with or without ACE. 
Self-reported chronic 
condtion 
Patients who 
report condition 
n=2047 
n (%) 
Patients without ACE 
with condition 
n=1457 
n (%) 
Patients with ACE 
with condition 
n=444 
n (%) 
P 
 
Low back pain 656 (33.9) 445 (32.0) 177 (42.0) <0.000 
Hypertension 567 (29.0) 401 (28.6) 131 (30.7) 0.41 
Anxiety  264 (13.9) 145 (10.6) 101 (24.9) <0.000 
Osteoarthritis 247 (13.2) 165 (12.2) 68 (16.8) 0.02 
Urinary incontinence 209 (11.0) 138 (10.1) 58 (14.0) 0.03 
Depression 205 (10.9) 101 (7.4) 90 (22.4) <0.000 
Rheumatoid arthritis 204 (10.7) 143 (10.4) 49 (12.0) 0.35 
Thyroid disease 173 (9.3) 124 (9.3) 34 (8.3) 0.544 
Asthma  165 (8.4) 111 (7.8) 46 (10.7) 0.06 
Other cardiac 115 (6.2) 73 (5.4) 38 (9.3) 0.005 
Osteoporosis 111 (5.9) 83 (6.2) 24 (5.9) 0.84 
Diabetes 101 (5.0) 69 (4.8) 22 (5.0) 0.84 
Cancer 80 (4.0) 55 (3.9) 19 (4.4) 0.65 
Bronchitis 55 (2.8) 39 (2.8) 13 (3.1) 0.74 
Angina 47 (2.4) 31 (2.2) 14 (3.3) 0.19 
Prior heart attack 49 (2.4) 36 (2.5) 12 (2.7) 0.77 
PVD 21 (1.0) 14 (1.0) 5 (1.1) 0.74 
Stroke  22 (1.1) 13 (0.9) 6 (1.4) 0.37 
Heart failure 8 (0.4) 4 (0.3) 4 (1.0) 0.07 
Aortic Aneurysm 5 (0.3) 3 (0.2) 2 (0.5) 0.37 
Any chronic 
condition 
1483 (72.5) 1036 (71.1) 361 (81.3) <0.000 
Multimorbidity 927 (45.3) 626 (43.0) 248 (55.9) <0.000 
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Supplementary material 17. Table 25. The association between subtypes of adverse 
childhood experience and multimorbidity at baseline in participants in the Mitchelstown 
Cohort Study 
 
Table 25. Adjusted odd ratios and 95% confidence intervals for the association 
between subtypes of adverse childhood experience and multimorbidity at baseline in 
participants in the Mitchelstown Cohort Study 
 
Subtypes of ACE Prevalence 
n (%) 
Odd ratios (95% CI) for 
multimorbidity in fully adjusted 
model  
   
Abuse: 
emotional, physical or sexual 
 
256 (12.5) 1.4 (1.1, 1.8)* 
Neglect: 
emotional or physical 
 
136 (6.6) 1.1 (0.7, 1.5) 
Household dysfunction: 
domestic abuse, parents divorced, 
parents in prison, parental addiction or 
mental illness  
295 (14.4) 1.4 (1.1, 1.7)* 
*p<0.05  
The models shown here are adjusted for age, gender, education, GMS status, 
behavioural factors (body mass index, diet, physical activity, smoking), depression and 
anxiety scores. 
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Supplementary material 18. Figure 15. The association between a history of any adverse 
childhood experience or subtype of adverse childhood experience, and psychiatric 
conditions in participants with multimorbidity in the Mitchelstown Cohort Study. 
 
 
Figure 15. Adjusted odds ratios and 95% confidence intervals for the association 
between a history of any ACE or subtype of ACE, and psychiatric conditions in 
participants with multimorbidity in the Mitchelstown Cohort Study. 
 
*p<0.05.  
The models shown here are adjusted for age, gender, education, GMS status, 
behavioural factors (body mass index, diet, physical activity, smoking), depression and 
anxiety scores.  
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Appendix V. Supplementary data for Chapter 9. Intervention development paper. 
The materials in this appendix are online supplements to the published version of the 
Intervention Development study.
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Supplementary material 19. Table 26. Behaviour Change Wheel Step 5: Identify intervention functions 
We found that all nine intervention functions listed in the BCW were potentially relevant to our behavioural analysis. Therefore, we used the APEASE 
criteria (171) to assess and grade each intervention function into first and second line options. The APEASE acronym stands for affordability, 
practicability, effectiveness and cost effectiveness, acceptability, side effects/safety and equity. The first line approaches were chosen for the 
intervention.  
Table 26. BCW Step 5: Identify intervention functions using APEASE criteria 
 
 
 
 
BCW 
Intervention 
Functions 
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ty
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q
u
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s 
Eq
u
it
y 
Comments 
 
 
Decision: 
First line 
Second Line 
Not 
appropriate 
Incentives       Creating an expectation of award is a crucial characteristic for the intervention, given 
the competing demands on GPs time, and the lack of remuneration for chronic disease 
management. Financial incentives are effective in changing healthcare professional 
practice (342), but care must be taken that the incentive chosen is affordable and 
widely available (equitable). As the incentive is for the behaviour of reviewing 
medications, not the outcome of stopping or reducing medications, unintended 
consequences on prescribing are unlikely. 
First line 
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Environmental 
Restructuring 
      Changing the existing social environment will be required if medication review is to be 
conducted in a safe and systematic way. Adding low cost, generalisable paper-based 
prompts to the environment is affordable, and likely to be effective if appropriate 
prompts are chosen.  
First line 
Enablement       Increasing GPs’ capability is acceptable, affordable and will be effective if existing 
barriers are addressed. 
First line 
Education  /-      Increasing GPs’ knowledge through educational programmes is practicable and 
acceptable: numerous such programmes already exist. However, delivering information 
on medication review would unlikely be implemented directly without further 
interventional support; for example, prior educational interventions on prescribing 
were only effective if consideration was given to local context (162). Also, putting 
excessive educational focus on the rationalisation of medications may lead to 
unintended consequences in prescribing. Access to educational programmes may be 
inequitable/unaffordable. Educational meetings alone are unlikely to effectively change 
complex behaviours (343). 
Second line 
Training /-     /- The myriad combinations of drugs and diseases that can occur in multimorbidity make 
it difficult to develop and deliver training programmes. Similar to education, equitable 
access and affordability cannot be guaranteed. Training in other aspects of medication 
management in multimorbidity, i.e. communication skills on deprescribing, may be 
useful for other interventions but we are focusing on the conduct of medication 
reviews. 
Second line 
Restriction      /- This function concerns using rules to increase the target behaviour (medication review) Not 
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by reducing the opportunity to engage in competing behaviours. Thus, this is not 
practicable as we are trying to encourage a behaviour that does have a direct 
competing behaviour.  
appropriate 
Coercion       In Ireland, chronic disease care is currently not remunerated under GPs contract of 
service, so it would not be possible to withhold payments etc. for it. Creating an 
expectation of punishment or limiting access to certain categories of drugs without 
evidence of medication review would not be acceptable to GPs.  
Not 
appropriate 
Persuasion       As most GPs in the qualitative study already agreed with the need for medication 
reviews, trying to further persuade them of the benefits would be unlikely to stimulate 
any sustained behaviour change.  
Not 
appropriate 
Modelling       Using local opinion leaders as an example for GPs to aspire to is inappropriate in this 
context (344), particularly considering the need for patient-centred decision-making in 
multimorbidity. 
Not 
appropriate 
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Supplementary material 20. Table 27. Behaviour Change Wheel Step 7: Identify behaviour change techniques 
This table shows the behaviour change techniques (n=32) that are associated with the three chosen intervention functions (incentivisation, 
enablement and environmental re-structuring) and were deemed potentially relevant to our intervention. The possible operationalization of each 
technique and reasons for choosing/ not choosing it are described in column three. 
 
Table 27. BCW Step 7: Identify behaviour change techniques 
Intervention 
functions  
Behaviour change techniques 
associated with this intervention 
function 
Possible operationalization of the technique based on the standard definition of the technique from Michie et 
al. (171) (in italics) and reasons for choosing it (indicated by ) or not choosing it. 
Incentivisation Self-monitoring of 
behaviour/outcome of behaviour 
Establish a method for the GP to monitor and record their conduct of medication reviews /outcomes of medication 
reviews as part of a behaviour change strategy.  
In itself and in the current climate in general practice where medication review is not a priority for GPs, this 
behaviour change technique is unlikely to motivate GPs without associated initiative or reward. 
Feedback on the 
behaviour/outcome(s) of the 
behaviour 
Monitor and provide informative or evaluative feedback on medication review /outcome of medication review.  
May be successful, as monitoring of GPs prescribing of benzodiazepines is already utilised and accepted by GPs. 
Unless there was imminent reward or punishment associated with the behaviour, it may be capturing information 
to feed back to GPs. 
Monitoring of 
behaviour/outcome of behaviour 
by others with feedback 
Observe or record medication review/outcomes of medication review with the GP's knowledge as part of a 
behaviour change strategy.  
In current climate, unlikely to motivate GPs unless there was associated reward or a threat of punishment for 
failing to conduct medication reviews.  
Material incentive or reward Inform that payment of money, or other valued objects will be delivered if and only if there has been effort and/or 
progress in performing medication reviews.  
This would likely be very successful in changing GP behaviour (e.g. QOF initiatives in UK) but is outside the scope 
of our resources. 
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Self- incentives or rewards 
 
Plan to reward self in future if there has been effort in performing medication review.  
This is deliverable in the form of continuing medical education points for engaging in medication review.  
Discrepancy between current 
behaviour and goal 
Draw attention to the discrepancies between a GP’s current behaviour regarding medication review and their 
previously set action plans, outcome or behavioural goals.  
Most GPs want to do the best by their patients regarding medications, and many believe in regular medication 
reviews for the purpose of minimizing treatment burdens as seen in the qualitative study. Given the current 
pressures on time being experienced by GP, highlighting their shortcomings in the area of medication review is a 
negative approach. In the short-term, it may dissuade GPs from becoming involved in the feasibility study of the 
intervention. 
Enablement 
 
Social support 
(unspecified/practical) 
 
Advise or provide practical help for GP for the performance of medication review (e.g. GP colleagues).  
From our date, many GPs were already engaging in informal conversation with their GP colleagues on how to 
manage challenging or complex patients, so this avenue is worth exploring as useful. 
Reduce negative emotions  Advise GPs on ways of reducing negative emotions (i.e. frustrations/stress/uncertainty) to facilitate performance 
of medication review.  
Current behaviour (maintaining the status quo) occurs to some extent because GPs are avoiding these negative 
emotions. Tackling the status quo will involve additional work for the GP which may further add to their negative 
emotions. Rather than targeting the GP’s negative emotions it would be more professionally appropriate to target 
the source of those emotions i.e. rather than targeting GPs’ fear of medico legal consequences, target reducing 
the risk of medico legal consequences. 
Conserve mental resources  To advise GP on ways of minimising demands on mental resources to facilitate medication review.  
This behaviour change technique could be applied by encouraging GPs to use guidelines to help them remember 
the role for certain drugs. However, in multimorbidity, mental resources are required to compute the possible 
interactions between drugs and diseases, and what potential changes are of value. As no one guideline is 
available for the myriad combinations of diseases in multimorbidity, facilitating use of mental resources, rather 
than conservation of mental resources is required.  
Generalisation of a target 
behaviour  
Advise GP to use their approach to medication review in non-multimorbid patients, in a situation involving 
multimorbidity.  
Given the particular difficulties relating to polypharmacy, drug-drug and drug-disease interactions reported by 
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GPs in multimorbid patients, the solution will require more than extrapolation of prescribing skills from straight 
forward ones to multimorbid ones.  
Action planning (implementation 
strategy) 
 
Prompt detailed planning of the medication review (must include at least one of time of week, number done 
together, time of day, with or without patient presentation, triggers for).  
This is important to give GPs some control over how the intervention is implemented in their practice. As the 
flexibility of implementation should be seen as an asset in our intervention, this behaviour change technique 
should be incorporated as an active component. 
Problem solving  Analyse, or prompt the GP to analyse factors influencing their ability to conduct medication reviews and generate 
or select strategies that include overcoming barriers and/or increasing facilitators.  
While GPs trying to conduct more medication reviews will have to tailor their approach for their own practice, 
they are unlikely to have the time or interest in formulating and developing the change strategy themselves. It 
may work better to develop an intervention and then ask GPs to tailor it for their practice, which is more 
implementation strategy than problem solving. 
Pros and cons  Advise the person to identify and compare reasons for wanting and not wanting to change their behaviour 
regarding medication reviews.  
The qualitative study has already identified that GPs already respect the need to do medication reviews (pros). It 
has also showed some of the down sides (cons) to medication reviews in patients with 
multimorbidity/polypharmacy which lead them to maintaining the status quo instead. The need here is to 
facilitate medication reviews, rather than just highlight its importance.  
Valued self-identity  Advise the GP to write or complete grading scales about a cherished value or personal strength as a means of 
affirming their identity as part of a behaviour change strategy.  
It is important to empower GPs and improve their sense of self-esteem as professionals in the management of 
chronic disease, and that may be a useful side effect of any intervention that we undertake. However using this as 
an active component of the intervention may be perceived by GPs as condescending and viewed with scepticism.  
Graded tasks Set the GP easy to perform tasks, making them increasingly difficult, but achievable until medication review is 
performed.  
This may be useful in an educational setting but in routine practice it is not appropriate to stagger the tasks 
required in medication review: it is important that all medications are reviewed in the context of each other, and 
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the wider bio-psychosocial context of the patient. 
Focus on past success Advise GPs to think about situations in which they previously conducted successful medication reviews.  
In many cases, these successes may have occurred in an ad hoc fashion; therefore emphasizing their success 
detracts from the need for systematic, planned medication reviews that we are trying to encourage. This 
approach may be useful once the medication reviews are underway, to consolidate on-going behaviour change. 
Goal setting: behaviour  Set or agree on a goal defined in terms of the conduct of medication review to be achieved. Unsure how much this 
will achieve, as intention is already there, but competing demands and opportunity cost too great.  
Goal setting: outcome Set or agree on a goal defined in terms of a positive outcome of the conduct of medication review. 
In some patients, there may be no change in medications required. If focus is on outcomes, and there are no 
specific outcomes apparent, this could de-motivate GPs to continue doing medication review. The focus should 
instead be on the practice of doing medication reviews, regardless of whether changes are made to medications.  
Commitment Ask the GP to affirm or reaffirm statements indicating commitment to conduct medication reviews. 
Although GPs may affirm this, they face many competing demands for their time, so alone, this behaviour change 
technique will not be effective, and may in fact cause a sense of failure if they do not enact their commitment.  
Self-monitoring Establish a method for the GP to monitor and record their medication review as part of a behaviour change 
strategy. 
This alone is unlikely to strongly motivate GPs. If it was coupled with some incentive, especially financial 
incentives, it may be useful.  
Review behavioural goals GP to review their goals for medication review jointly and consider modifying them in light of current achievement 
of these goals.  
It is unlikely that GPs will have set goals for medication review prior to this intervention. 
Review outcome goals Review the outcome of medication reviews to date jointly with another person and consider modifying goals in 
light of current achievement.  
This may be useful behaviour change techniques once the medication reviews are underway, but it is unlikely that 
GPs will have set goals for medication review prior to this intervention. 
Comparative imaginings of future 
outcomes 
Prompt or advise the imagining and comparing of future outcomes of changed (regular or structured reviews of 
medications) versus unchanged behaviour (non-systematic reviews of medications.  
Using data from the qualitative study, future outcomes here include the long-term time-saving nature of regular 
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medication reviews, the lessening of patients risk of adverse effects and less medico-legal risk. While these points 
would highlight the benefits of doing medication reviews, the imaginings would not be sustainable, and given the 
competing priorities for GPs in practice, would be unlikely to produce behaviour change. 
Environmental 
re-structuring 
Prompts/cue  
 
Introduce a stimulus with the purpose of cueing medication review, which would be used at the time of 
performance of medication review 
This could be easily implemented in the form of a checklist of things to consider. Could be written or 
computerised. 
Adding objects to the 
environment  
Add objects to the general practice environment in order to facilitate performance of medication reviews, 
involving more than verbal, visual, or written information.  
The use of Information Technology and Computer Assisted Decision Support Systems is relevant here, and is being 
researched as an intervention by other groups.  
Restructuring the social 
environment 
 
Change, or advise to change the social environment in order to facilitate performance of the medication review.  
If medication review was scheduled, and accepted within the practice as a reasonable activity for the GP to spend 
time on, this could potentially impact on number of medication reviews conducted in major way – as indicated by 
qualitative study.  
Restructuring the physical 
environment 
Change, or advise to change the physical environment in order to facilitate performance of medication review.  
May not be acceptable to alter GPs working environment physically, and as medication review is a cognitive task, 
not likely to yield great benefit. 
Associative learning Present a neutral stimulus jointly with a stimulus that already elicits the behaviour repeatedly until the neutral 
stimulus elicits that behaviour.  
No stimulus to prompt medication review already exists, so could not operationalize this. 
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Supplementary material 21. Behaviour Change Wheel Step 8: Identify mode of delivery 
using expert panel 
 
The expert panel critically reviewed the format of the emerging intervention strategy, 
the behaviour change techniques chosen, and the implementation plan. The panel 
focused on the following aspects of the intervention: 
 
1. What prompts should be used to guide medication review in MY COMRADE?? 
Many instruments are available to assess prescribing (112). The expert panel explicitly 
considered the following: 
 RCGP Prescribing Indicators (345) 
 Medication Appropriateness Index (346) 
 Welsh Medicines Support Centre questions (347) 
 Use of medicine framework: Australia tool (348) 
 Polypharmacy Guidance, NHS Scotland (349) 
 STOPP START (114 ) 
 NO TEARS (307)  
The purpose is to prompt discussion between GPs rather than prompt prolonged 
pharmacological assessment. The panel felt that a broad, generic, pragmatic checklist 
was most appropriate. Such approaches have been found to improve quality of care in 
other fields of medicine (350). The last option, NO TEARS (307), was originally designed 
as a generic checklist to underpin doctor-patient communication about medications. 
The seven letters in the acronym prompt the doctor to: review the Need and indication 
for the medication, ask Open questions to the gain the patient’s views on their 
medication, ensure appropriate Tests and monitoring have been conducted, ensure no 
changes have occurred in recent Evidence and guidelines, ensure that the patient is not 
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experiencing Adverse effects, ensure that medications are optimized for Risk reduction 
or prevention, and consider Simplification of medication to improve adherence. We felt 
this short list, which was not bound by drug or disease would allow consideration of 
the individual context of each patient, including the psychosocial issues that were 
shown to be of a greater burden in multimorbid patients in Chapter 8. To transform 
this checklist to make it fit for discussion between two GPs, rather than a GP and 
patient, the second prompt was modified. We used O to prompt GPs to review whether 
a patients need for a medication On-going. The need to discuss changes with the 
patient is not removed; it will just occur downstream from the activities targeted in this 
intervention. 
 
2. How should GPs choose which patients to review using MY COMRADE? 
As GPs cannot be expected to review all patients using the format set out in our 
intervention, they should be informed which type of patients to choose. The expert 
panel considered the following options for patient selection:  
 Patient age (i.e. >65 years) 
 Number of prescribed medications (i.e. >5 or >10) 
 Number of comorbidities (i.e. >3, >4, etc.) 
 Level of patient disability or functional impairment, including care home residence  
 Use of high risk medications such as warfarin, non-steroidal anti-inflammatories, 
diuretics etc.  
 GP choice as indicated by GPs discomfort with current medication regimen 
With specific reference to the Kings Fund report (99) co-authored by two of the expert 
panel (MD &RP), it was agreed that GPs choose patients that were prescribed ten or 
more regular medicines, or five or more medicines with another complicating factor. 
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Complicating factors include medications that are a well-recognised source of 
interactions or risk, poor adherence, impaired cognition, psychosocial complexity, or 
end-of-life or palliative care. 
 
3. How should the behaviour change technique of “action planning” be 
operationalized?  
The behaviour change technique action planning (which includes implementation 
planning) was incorporated into the intervention to allow tailoring to individual general 
practices. The expert panel concluded that while the best people to tailor the 
intervention would be the GPs themselves they must be given clear guidance on how 
to do this. Thus in order to address barriers to implementation up front, each practice 
will be asked to consider the following prior to adopting the intervention:  
1. What will make this intervention difficult? 
2. How should these difficulties be tackled, knowing your practice? 
3. What is your plan for rolling out this intervention?  
 What day? What time of day? Which office? How many at one session? 
Which GP will you involve? Anything else, specific to how your practice 
runs? 
This process will enhance GPs’ engagement with the intervention, give them autonomy 
over how it is rolled out, and highlight potential stumbling blocks before they occur. 
The practice specific implementation plans will be examined in the evaluation process.  
 
4. How should the intervention be evaluated? 
As the goal of the intervention was to change GPs behaviour from “maintaining the 
status quo” to actively reviewing medications, the expert panel agreed the primary 
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outcome for the initial evaluation would be whether medication reviews were 
performed using this approach. The evaluation will provide information on the 
implementation process, reasons for why the intervention succeeds, fails, or has 
unexpected consequences, and will identify other causal and contextual mechanisms 
associated with achieving behaviour change.  
As per the MRC framework, a single primary outcome may not make the best use of 
the data: a range of measures will be needed and unintended consequences picked up 
where possible. Therefore, secondary outcomes that will be evaluated in the future 
include:  
 Medication related 
o the number of changes recommended in each collaborative medication 
review 
o the number of changes that are subsequently made to the patients 
medications 
o the medication appropriateness scores/number of potentially inappropriate 
medications before and after the collaborative medication review 
 Process of care related 
o number of consultations that directly result from the review 
o the amount of time taken per review 
o additional workload generated by review i.e. investigations, referrals etc. 
 
 309 
 
Supplementary material 22. Validation of the chosen intervention functions and behaviour change techniques using the theoretical domains 
framework 
The theoretical domains framework (TDF) is a set of domains that each contain multiple theoretical constructs relating to theory of behaviour change 
(171, 351). It has been developed in conjunction with the COM-B and the Behaviour Change Wheel, and may also be used in intervention 
development. We applied the TDF to our empirical data to see if it led to a similar set of intervention strategies and behaviour change techniques as 
the original COM-B based approach. 
Table 28 shows the TDF domains relevant to our qualitative data.  
Table 29 shows the intervention functions related to these TDF domains: all of the intervention functions in the Behaviour Change Wheel (BCW) were 
indicated as potentially relevant for our intervention. This was also found in the COM-B behavioural analysis (described in Chapter 9). 
Table 30 shows the behaviour change techniques (BCTs) that were included in the MY COMRADE intervention (Chapter 9). We mapped these techniques to 
the TDF domains associated with them in a paper by Cane et al.(352) and on page 156 of the Guide to Designing Interventions (171). The TDF domains 
associated with the behaviour change techniques in MY COMRADE were amongst the TDF domains relevant to our qualitative data (shown in Table 28).  
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Table 28. Determination of intervention functions relevant to the empirical qualitative date using the theoretical domains framework 
COM-B 
component 
Behavioural description and interview source Potentially relevant TDF domains (constructs) 
Capability-
Psychological 
 
Pharmacological knowledge, an inadequate evidence base, conflicting practice by others, lack of 
information relevant to general practice reduces GPs capability to do medication reviews 
In some cases, GPs feel there is no available evidence for what is best in multimorbidity  
gp5 “so can we honestly say that this tablet that she has been on X number of years, that by stopping 
it that she’ll be any better? No we can’t, can we say that by stopping it that it won’t speed up her 
death? No we can’t” 
gp7 “It is very hard to justify getting rid of any of his meds, although polypharmacy is a big problem 
for him.” 
 
Existing tools/guidelines are not helpful to GPs when conducting medication reviews, and sometimes 
make things more difficult:  
gp16 “I've yet to see any really decent guidelines, I don't know if they are that useful to be honest in 
day-to-day decision-making, we prefer to kind of tailor (management) ourselves do you know”  
gp7 “with this guy, the guidelines tend to go out the window, because I think if you try to be too strict, 
if you try to completely adhere to the guidelines with any of his problems then it is going to, adversely 
affect his other morbidities.” 
 
Insufficient knowledge on new drugs  
gp3 “we are getting these pieces of information from the drug companies that are nearly impossible 
to digest, they don’t seem to have any relevance for what I am doing, I find them very hard to read 
them” 
 
Information relevant to general practice required  
gp17 “GP led education is what we will do, none of us have any interest in sitting down to a lecture by 
a nephrologist and more, you know, you don’t have to tell us they are clever” 
 
Knowledge (knowledge) 
 
Skills (skills, practice, competence) 
 
Memory/attention/decision making processes 
(attention, decision making, cognitive overload) 
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Involvement of hospital prescribers can complicate matters in multimorbidity and confuses GPs 
further 
gp6 “ our consultant hospital colleagues, they are giving the statins out - the Prosper trial seems to be 
totally ignored, the evidence from it does not seem to be taken on board.”  
gp6 “(patients)are never strictly in the right boxes; there are always the complicating factors; there’s 
always the, you know, diabetes with the gout - and you send them up to a rheumatologist they come 
back with a huge dose of steroid then, you say ‘well I could have done that’” 
gp10 “when Dr XX put her on a big whack of steroids, this women is a diabetic, and there was no 
reference to the fact that she was diabetic - the adjustments that would need to be made, you know?”  
Opportunity- 
Physical  
GPs feel they do not have adequate time resources to conduct medication reviews 
Lack of time for renewing scripts within the consultation.  
gp13 “there are times when you kind of have to say to someone when they come in ‘I’ll have to do 
some of this another day, or you’ll have to come back to me, we’ll do it in a different structure in a 
different format”  
gp1 “if I just had time to have a 30 -45 minute consultation with a patient while you don’t have the 
waiting room building up, you could actually get to the bottom of some of the stuff they’re on” 
 
Lack of systems within the practice that allocate time to the activity of medication review 
gp9 “it’s one of the old chestnuts is that you are so busy when you are working that to take the time 
to look at these things in proper, I mean if you are going to do it, you have to do it obviously properly” 
gp12 “sometimes it would be nice to start afresh and I could ask the patient to come into me instead 
of them coming to me with some big long thing or whatever they had wrong with them today; instead 
me saying to them ‘now this is what I want to talk about (sorting out medications)’” 
Environmental context and resources 
(organisational culture, resources/material 
resources, barriers and facilitators) 
 
Goals (action planning) 
Opportunity- 
Social 
GPs feel that conducting medication reviews is complicated by the lack of social convention or 
acceptability, from a patient’s perspective, of having medications removed or rationalized.  
Patient attachment to medications 
gp11 “She’s attached to them, so I haven’t, I haven’t had the heart to broach it” 
gp7 “She wasn’t keen to change her Risperdal because she had been on it for years” 
gp5- “ they say ‘oh god, doc, I want to stay on that’ even if you feel it’s doing feck all good you’ll just 
Social influences (social pressures, social norms) 
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prescribe it out again, you know- who are we to say ‘no, no we need to stop that’ do you know”  
gp9 “she would be the type of patient, I would think, where you’d maybe get a phone call the 
following week saying ‘I don’t feel as well off that tablet as I did on it’ in a lot of cases you’d end up 
putting her back on it.” 
 
Patients’ misconceptions about longstanding medications  
gp13 – “some of the stuff she is on like the domperidone and the betahistine and stuff I’m not really 
convinced that she needs it. I have talked to her about it - about whether or not it might be useful to 
take things off but she’s reluctant to take them out and as far as she is concerned they’ve been started 
at some point over the years for her for some reason, so she wants to try and keep them” 
Motivation- 
Automatic 
Reflex responses to polypharmacy in multimorbid patients, who demonstrate no obvious adverse 
drug effects, was to “maintain the status quo” in almost all interviews. This occurred due to lack of 
time in the consultation, lack of consistency in hospital prescribers, lack of convention for stopping 
medications, and lack of confidence in own prescribing.  
gp11 “she has been doing better than she has been in a long time so I’m not going to rock the boat at 
all”  
gp12 “‘look she’s on it, she’s fine, it doesn’t bother her, it’s suiting her fine” 
gp13 “largely for her I’d let it sit, I think if she is stable I don’t try and change too much” 
gp14 “there is that aspect of not rocking the boat, you know and being straight up about it as well, 
sometimes as well you can get into the routine ‘oh are you just in for the prescription?’, you just print 
it off automatically without giving due consideration to can we shorten this, can we do this that and 
the other.” 
gp18 “take the line of least resistance! Here’s another 3 months prescription!” 
gp19 “anything that complex I didn’t entertain changing because why stir up?” 
Reinforcement (rewards, incentives) 
Motivation- 
Reflective 
MOTIVATIONS AGAINST MEDICATION REVIEW 
GPs have beliefs about negative consequences of medication rationalisation such as potential 
medico-legal repercussions, negative responses from patient/next of kin, and harming the doctor-
patient relationship due to risk of patient perception of medication rationalization as withdrawal of 
care.  
Social/professional role and identity 
(Professional role & identity) 
 
Beliefs about capabilities (self-efficacy, 
empowerment, professional confidence) 
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gp9 “would be loath to stop it, again probably in that situation it’s probably medico-legal, if you stop 
it and they do get a thrombosis the next week, you will feel a bit guilty”  
gp6 “his wife or he will say ‘hang on a second I want to go on as long as I can, why are you risking me 
getting a heart attack?’ Why stop my aspirin and my statin, if there is a small risk I’ll get a heart 
attack, why not leave me on it, why are you taking me off’” 
Leaving decisions to other clinicians: gp16 “I'd prefer to have them (specialists) say yes or no, because 
that way at least if I get sued I've covered myself.” 
 
Some GPs have negative beliefs about their capabilities relative to other prescribers, and find it 
difficult to stop what others have started (low self-efficacy /empowerment) 
gp6 “I find that in some of the situations that the patient comes to you, they’ve been in hospital, 
something happens they end up in hospital but when they come out, they come out on medications 
that I would not have necessarily have started” 
gp9 “I suppose it’s deference to consultant opinion as usual, I suppose I should probably read up 
about it again and see whether I can think of reducing it.” and “the problem is, I suppose, in terms of 
cardiac stuff and in particular anti-angina stuff you have to be very brave to stop that I think, in a lot 
of ways.” 
gp13 “I’m absolutely in fear of changing these medications at all (shakily laughing)” 
 
The opportunity cost of medications reviews is using that time for other purposes, some of which 
are associated with greater gains (financial /time efficiency /delivering patient determined rather 
than doctor determined care)  
Lack of remuneration for changing medications:  
gp17 “at some point I have invested as much time as I can, in to them, and don’t forget this is all pro 
bono, and you know, sometime you say ‘will I keep doing it?” 
gp11 “she has had multiple other things going on as well, so the consultation time would be taken up 
(if medications were also reviewed)” 
gp6 “to really get him on the amount of medication he needs, we’d be seeing him almost every few 
weeks - we’d be seeing him very frequently and that has huge implications because you have so many 
 
Beliefs about consequences (anticipated regret 
or consequences) 
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patients and you can’t, if you saw everybody every few weeks, you can’t do it” 
 
MOTIVATIONS TO REVIEW MEDICATIONS:  
GPs also have beliefs about the consequences of not reviewing medications that could be used to 
motivate them to do reviews:  
Demonstrating that medications have been reviewed is important medico-legally:  
gp19 “It is your signature on the GMS prescription so if you haven’t weighed up the pros and cons, and 
made a decision yourself, even though someone else started it, if they end up addicted to such and 
such a thing, you’re responsible”  
gp10 “What is important in theory and what is actually important in practice, on the ground, are often 
two entirely different things; but medico-legally the problem is that if this guy dies of renal failure they 
are going to be looking at his medication list and you will be thinking ‘oh, crap’”  
It is good defensible practice to do and document medication reviews:  
gp10 “the longer I am in practice the longer my clinical notes are getting and the more I am 
documenting; aware of interaction, need to watch renal function but that must balance benefits 
versus risks.” 
Important to review medications in order to discuss implications of polypharmacy with patients:  
gp10“Everything interacts with everything these days and you explain to them ‘look, technically you 
are not supposed to be on that but look it’s working for you’” 
 Negative emotions about not reviewing medications, could be alleviated by reviewing them:  
gp11 “it would make you feel nervous, because obviously you wouldn’t like anything happening 
somebody, and she probably was on it too long, it would have been difficult for me to probably stand 
over it... I could have probably been in trouble myself if something had happened her” 
gp8 “He was on something else, I think it was a PPI and it was interfering with his HIV and I felt very 
bad about that after, because when he came out of hospital, i thought, oh my god” 
Increasing comfort with prescribing if reviewed systematically:  
gp17 “we try and do a three month chart review on diabetics to make sure that we have pulled all of 
them in and they are as up to date as we can get them, so the plan is that everybody has all the boxes 
ticked, so now I’m quite comfortable with diabetes, I’m quite comfortable with hypertension” 
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Table 29. Mapping the TDF domains relevant to the empirical qualitative date (Table 28) to their related intervention functions  
 
 Intervention Functions 
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Knowledge  +         
Skills   +        
Memory/attention/decision-making processes   + +   +    
Environmental context and resources   + + +  +    
Goals  +    + + + + + 
Social influences    + +  +   + 
Reinforcement   + +  +   +  
Social/professional role and identity  +      +  + 
Beliefs about capabilities +     + +  + 
Beliefs about consequences  +      +  + 
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Table 30. Mapping the behaviour change techniques in the final MY COMRADE intervention to the TDF domains associated with them  
 
 
 
Chosen intervention function  
Behaviour change techniques in MY COMRADE Related TDF domains (352) 
Environmental Restructuring Restructuring the social environment 
Prompts/cue 
Environmental context & resources  
Environmental context & resources 
Enablement Social support (practical)- 
Action planning (implementation intentions) 
Social influences 
Goals 
Incentivisation Self-reward or incentive – CME Reinforcement 
 
The links between the TDF domains and the behaviour change techniques are taken from the Guide to Designing Interventions (171) and the paper by Cane 
et al. (352)   
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Appendix VI. Supplementary data for Chapter 10. Feasibility study 
Supplementary material 23. GP information sheet 
GP participant information leaflet on a feasibility study on collaborative medication 
review for multimorbidity in primary care. 
 
Why is this study being done? 
Many patients attending GPs have multimorbidity (multiple chronic diseases). However, 
clinical guidelines generally do not take multimorbidity into account. This can lead to a 
situation where the guidelines for one condition suggest medications that may adversely 
affect a co-existing disease, or can lead to high numbers of medications or problematic 
polypharmacy. We have studied how GPs make decisions in these challenging multimorbid 
patients, and found that they often speak to their GP colleagues. In this study, we would 
like to formalize this interaction – that is examine what happens when two GPs review a 
patient’s notes together, with a view to making recommendations on the patient’s 
medication regimen. 
Who is organising and funding the study? 
The project is sponsored by the Health Research Board and the Health Service Executive. 
The research team is based in University College Cork. The principal researcher, Dr Carol 
Sinnott, is a trainee in general practice. The principal investigator and supervisor is 
Professor Colin Bradley.  
Why am I being asked to take part? 
We are asking you to take part because in the course of your everyday work, you are likely 
to be faced long and complicated prescriptions for patients with multiple morbidities. We 
want to explore how useful a new approach to medication review would be for these cases. 
This new approach involves two GPs reviewing the medications together with the help of a 
list of prompts/checklist.  
How will the study be carried out? 
This is a feasibility study. If you agree to participate, Carol will attend your practice at a 
time that suits and explain how the case review should take place- this meeting will only 
take 15 minutes.  
You will be given the checklist (includes only 7 prompting questions), which you and your 
GP colleague can refer to when you are systematically reviewing your patient’s 
medications. For the purposes of case review, we will ask you to choose 3 -5 cases from 
your practice, each with multiple chronic diseases that require 10+ medications or 5+ 
 318 
 
medications with another complicating factor. The case reviews, which can take place at a 
time that suits you and your GP colleague, will take approximately ten minutes per case. 
You can make a note of any potential changes to medications on the checklist page, and 
scan it into the patient’s notes. This will make the next review easier and is important 
medico-legally. Any potential changes to medications should be discussed with the patient 
before making the change. After you have completed the case reviews, Carol will re-attend 
your practice to explore how the process went, if any changes were made to the patient’s 
medications and if you have any recommendations on how it could be improved. We will 
not ask for any patient identifying information. However we will take details of the 
patient’s age, gender, diagnoses and list of medications. With your permission, we will 
record this second meeting, and the recorded data will be analysed for recurrent issues 
that arise for GPs in this area.  
What about confidentiality? 
All information obtained during the study will be strictly confidential. All identifiable 
information will be removed from recorded data. A study ID number will be assigned to any 
data relating to your practice, to maintain anonymity. Only investigators named on this 
information sheet will have access to the data, which will be stored securely in UCC. 
What will happen with the results of this study? 
The findings of this study will be written up for the HRB report and subsequent 
publications. The results will also be compiled and submitted as part of a PhD thesis. In all 
cases only anonymous extracts or quotes will be reported. Copies of the findings will be 
made available to participants. 
Who has reviewed this study? 
This research gained approval from the ethics committee of the CREC, UCC. If you decide to 
take part you will be asked to sign a consent form. You are free to withdraw at any time. If 
you have any questions or concerns, please do not hesitate to contact the research team 
detailed below. 
Dr Carol Sinnott Professor Colin Bradley 
GP Trainee, South East Training Scheme Professor and Head of Department 
Research Fellow, University College Cork Department of General Practice, University 
College Cork. 
csinnott@ucc.ie gp@ucc.ie 
086 3123989 021 4901572 
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Supplementary material 24. GP instruction sheet for feasibility study 
What to do 
1. Choose three patients each on which to do the medication review. Try to choose 
patients prescribed 10+ medications or 5+ medications with another complicating 
factor. 
2. Schedule a time to discuss these patients with another GP in your practice 
3. Use the attached checklist as a guide for the discussion. Make a note of any 
potential changes to medications on the page, and scan into the patient’s notes. 
4. Please try to complete the cases reviews within the next month – they take 
approximately 10mins each, but may take longer initially. 
 
Before starting, Consider 
4. What benefits would you see in this format for medication review? What might make it 
difficult?  
5. What plan would suit your practice, for trying this out?  
 What day of the week?  
 What time of day?  
 Which office?  
 How many case reviews will you do at one sitting? 
 Which GP will you involve? 
 Anything else, specific to how your practice runs? 
 
Additional points 
 Document the medication review in the patient’s notes - it will make the next 
review easier and is important medico-legally. 
 
 Highlight any potential options for medication changes -these options should be 
discussed with the patient at their next consultation, prior to making any changes. 
 
 Internal CME points apply. 
 
 For further information, please contact: Dr Carol Sinnott, Research fellow in 
General Practice, UCC. csinnott@ucc.ie 
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Supplementary material 25. Prescribing checklist 
 
Collaborative Medication Review 
Review by:  Dr. _________________  &  Dr. ___________________  
Date of review: 
Patient name & DOB: 
 
 Give your GP colleague a brief description of the case (e.g. 75 year old lady, lives 
alone, history of diabetes and arthritis).  
 Discuss each medication (or groups of medications, such as anti-hypertensives) 
using the points below. 
 Not all points will be relevant. 
 
N What is the need or indication for this medication? 
O Is this need on-going? Has the patient’s condition or life expectancy 
changed since this medication was started? Was long term treatment 
intended?  
T Is the patient getting appropriate tests and monitoring associated with 
this medication?  
E Has the evidence or guidelines changed in relation to this 
medication/condition since it was commenced? (think of big messages) 
A Are there any adverse effects with this medication? Check for 
interactions, duplications, contraindications. 
R Risk reduction and prevention: Are doses/medications optimised to 
lower the patient’s risk? 
S Can treatment be simplified to a safer /easier to use alternative? 
 
List the medications where there is potential to change /further action required: 
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Additional points 
 The medication review should be documented in the patient’s notes (e.g. 
scan in this page). It will make the next review easier. 
 Any options for medication changes should be discussed with the patient 
at their next consultation, prior to making any changes. 
 The ‘NO TEARS’ checklist is adapted from the BMJ 2004;329:434 
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Supplementary material 26. Topic guide for evaluation interviews 
 
1. Acceptability: what was your initial impression of this approach to MR? Were you 
optimistic that it would work?* Is it credible, does it have any advantages to existing 
approaches. 
2. Adoption: what was your initial plan on how to bring this into your practice?* What 
were your goals and intentions with relation to it?* 
3. Appropriateness: how fitting is this intervention to the setting of multimorbidity? How 
fitting is it to the setting of GP? Did you think it would be useful? For what?* How was 
making decisions in this format (easier or more complicated)?* What about discussing 
your practice with another GP – comfortable /uncomfortable? 
4. Feasibility: how feasible is it for you right now, to continue doing this? Is it practical 
/trialable? Were you confident that you could conduct it? Any concerns about being 
able to do it? * what are the main barriers (need link to meds info for example?) 
5. Fidelity: how did you do it? What happened in the review? Especially specific BCTs: 
social support, checklist, action planning, changing social environment, awarded CME 
points? Which features were most related to success/failure of intervention? 
6. Implementation cost: were there opportunity costs? Were there other things that you 
could not do as a result of this intervention? (i.e. house visits /seeing patients /going 
home) 
7. Coverage: how widely applicable is this to your patients on multiple meds? Are there 
many that you find this not appropriate in? 
8. Sustainability: do you think it could become routine. Incorporated in to regular 
practice? What are the incentives for you to continue (CME/safety/time saver)?* 
 
*=question adopted from the theoretical domains framework (351) 
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Supplementary material 27. Table 31. Template for Intervention Description and 
Replication (TIDIER) Checklist  
Table 31. Template for Intervention Description and Replication (TIDIER) Checklist   
Item 
no. 
Item  Where located (page #) 
Title   
1 Multimorbidity Collaborative Medication Review And 
Decision-making (MY COMRADE) 
197-8 
Why   
2 We used the results of a systematic review and 
qualitative interview together with the Capability- 
Opportunity-Motivation-Behaviour (COM-B) model of 
behaviour, the Behaviour Change Wheel approach to 
intervention development and the Behaviour Change 
Technique taxonomy to develop this intervention 
specifically to facilitate the conduct of active 
medication review. 
197-8 
What   
3 Participants were provided with an information leaflet, 
and instructions on how to implement the intervention, 
which detailed the five behaviour change techniques 
included in the intervention. They were also provided 
with copies of the prescribing checklist that was used as 
one of the behaviour change techniques. This checklist 
was a modified version of the NO TEARS tool for 
medication review.  
Provided in supplementary 
material 23, 24 and 25. 
 
4 Each pair of GPs was asked to conduct six medication 
reviews using the MY COMRADE approach (or three 
medications reviews per GP). GPs were asked to choose 
patients with multimorbidity who were prescribed 10 
or more medications or 5 or more medications with 
another complicating factor (i.e. impaired cognition, 
psychosocial complexity, poor life expectancy etc.).  
Page 198 
Who   
5 Only practicing GPs implemented the intervention Page 198 
How   
6 GPs implemented the intervention in pairs.  Page 198 
Where   
7 The intervention was implemented in the GP practice. 
The participating GPs were asked to come up with an 
action plan in which they would specify when and 
where (i.e. which office within the practice) they would 
conduct the reviews.  
Page 198 
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When and how much  
8 Each pair of GPs was asked to conduct six medication 
reviews using the MY COMRADE approach (or three 
medications reviews per GP). GPs were asked to choose 
patients with multimorbidity who were prescribed 10 
or more medications or 5 or more medications with 
another complicating factor (i.e. impaired cognition, 
psychosocial complexity, poor life expectancy etc.). 
They were asked to complete the reviews within a one 
month interval. 
Page 198 
Tailoring  
9 Participating GPs were advised that could adapt the 
action plan (when, where, how many patients to review 
in one sitting etc.) to suit their own practice. This 
adaption was captured in evaluation interviews. 
Page 198, and supplementary 
material 23 and 24. 
Modifications  
10 The only modification from the researcher perspective 
was that instead of leaving the date for follow-up 
interviews for the GPs to organize, the research team 
started to set follow-up dates from the third practice 
on.  
Page 201 
How well  
11 Intervention adherence and fidelity were assessed in 
evaluation interviews with CS, using self-report by 
participants.  
Page 206 
12 
 
Observation or recording of implementation of the 
intervention was not performed. 
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Appendix VII. Supplementary data for Chapter 11.  
Supplementary material 28. Results of updated search for systematic review. 
 
Introduction 
Given the increasing interest in the management of multimorbidity, there was a need 
to ascertain if there had been important developments in the qualitative literature 
since the systematic review and synthesis, conducted in September 2012. 
 
Aim 
 To identify qualitative literature on GPs perceptions and experiences of managing 
patients with multimorbidity published since September 2012. 
 To interpret any relevant new literature using the domains derived in the original 
review (Chapter 5). 
 To highlight new domains of importance (if any) in this field. 
 
Methods 
The original search was repeated: EMBASE, MEDLINE, CINAHL, PsycInfo, Academic 
Search Complete, SocIndex, Social Science Full Text were search from September 2012 
to November 2015 to identify literature using qualitative methods on GPs perceptions 
and experiences of managing patients with multimorbidity. Citations were screened by 
a single reviewer (CS). Full texts were read and interpreted using the lens of the four 
domains that emerged in the original systematic review. The four domains were i) 
disorganisation and fragmentation of healthcare ii) inadequacy of guidelines and 
evidence-based medicine iii) challenges in delivering patient-centred care and iv) 
challenges in shared decision-making. 
 326 
 
 
Results 
The search results are shown in the table 32. In total, there were 858 citations, which 
led to nine relevant papers. The characteristics of the nine papers are shown in Table 
33. The contribution of the nine papers to each of the four domains in the original 
review, and any notable new findings are shown in Table 34.  
 
Discussion  
While the nine new papers show much overlap with the four domains that arose in our 
original review, there are also consistent new findings. The most striking of these is the 
call for greater training and education on how to deal with challenges in patients with 
multimorbidity, suggesting that physicians are now accepting that the challenges at 
health system level and in the medical evidence base will not be addressed in the short 
term. In particular, approaches to shared decision-making are called for. The need for 
enhanced communication was a strong finding in all studies: between GPs and 
specialists, GPs and allied healthcare professionals and in one case, between the 
multiple lay carers for the patient. This brief synthesis shows the evolution of the 
qualitative literature on multimorbidity from focusing on problems to moving towards 
solutions. This change is encouraging and if the momentum continues, promises 
improvements in the provision of care to patients with multimorbidity.  
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Table 32. Results of updated search 
 
Database Number of 
citations 
Number of relevant 
papers 
Embase 562 4  
CINAHL 53 2  
PsychInfo, Social Sciences Full Text, SocIndex, 
Academic Search Complete 
131 1 
Medline 112 1 
Reference searching  1 
Total  858 9 
 
 
  
 328 
 
Table 33. Characteristics of new papers relevant to qualitative systematic review 
First author 
(reference) 
Title of study Participants and setting Data collection Data analysis 
Sondergaard 
et al. (353) 
 
Problems and challenges in relation to 
the treatment of patients with 
multimorbidity: GPs’ views and attitudes 
180 GPs attending a workshop on 
multimorbidity in Tampere, 
Finland. 
Audio recorded workshop and 76 
questionnaires 
Framework analysis 
 
Loffler et al. 
(354) 
Approaches of GPs and patients to 
multimorbidity: A qualitative study 
9 GPs and 19 multimorbid 
patients in Nordrhein-Westfalen, 
Germany. 
Narrative interviews with GPs and patients Content analysis 
Written in German – 
English abstract & 
google translate used 
here. 
Herrmann et 
al. 
(355) 
GP medication prioritisation in older 
patients with multiple comorbidities 
recently discharged from hospital: a case-
based bottom-up approach 
44 GPs in Sachsen-Anhalt, 
Germany. 
Focus group discussions and semi-
standardised interviews. Vignettes related to 
drug optimisation were discussed in the 
interviews/focus groups. 
Grounded theory 
Written in German – 
English abstract & 
google translate used 
here. 
Junius-Walker 
et al. 
(356) 
What is important, what needs treating? 
How GPs perceive older patients' multiple 
health problems: a mixed method 
research study 
9 GPs and 35 patients in 
Hannover, Germany. 
Interviews with GPs, based on how they 
prioritised the multiple issues facing their 
multimorbid patients. The lists of problems 
were provided to the GPs from a geriatric 
assessment.  
Content analysis 
Nuno-Solinis 
et al. 
(357) 
Multiple comorbidities from the 
perspective of primary care health 
professionals 
Fourteen health professionals: 6 
specialists in family medicine, 3 
hospital specialists, 4 nurses, and 
1 community pharmacist. 
Basque region, Spain. 
A co-creation workshop (12 participants) and 
10 interviews with health professionals 
Thematic analysis 
Written in Spanish – 
English abstract & 
google translate used 
here. 
Sellappans et 
al. 
(358) 
Challenges faced by primary care 
physicians when prescribing for patients 
with chronic diseases in a teaching 
hospital in Malaysia: a qualitative study 
14 family medicine trainees and 5 
service medical officers. 
Teaching primary care clinic, 
Malaysia. 
3 focus group discussions Thematic analysis 
Schoenborn et 
al. 
(359) 
Current Practices and Opportunities in a 
Resident Clinic Regarding the Care of 
Older Adults with Multimorbidity 
21 internal medicine residents and 
30 of their primary care patients. 
Johns Hopkins Bayview General 
Audio-recording of 30 clinic visits Content analysis of 
consultations 
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 Medical Clinic. 
Gill, et al. 
(360) 
 
"Where do we go from here?" Health 
system frustrations expressed by patients 
with multimorbidity, their caregivers and 
family physicians 
27 triads involving patients, their 
informal caregivers and family 
physicians. 
Family Health Team, Ontario, 
Canada. 
Semi-structured interviews Qualitative descriptive 
Kuluski et al. 
(361) 
A qualitative descriptive study on the 
alignment of care goals between older 
persons with multimorbidities, their 
family physicians and informal caregivers. 
27 triads involving patients, their 
informal caregivers and family 
physicians. 
Family Health Team, Ontario, 
Canada. 
Semi-structured interviews Qualitative descriptive 
 
Table 34. Contribution of new papers to the original domains and new findings 
 
Study author 
 
Domains arising from original review  
Other findings Disorganisation and 
fragmentation of 
health care 
Inadequacy of guidelines and 
evidence-based medicine 
Challenges in delivering 
patient-centred care 
Challenges in shared 
decision-making 
Sondergaard 
et al. 
 
Complex care pathways and 
insufficient cooperation 
between professionals involved 
in the care of multimorbid 
patients underlined the GPs’ 
impression of a fragmented 
healthcare system especially:  
• Difficulties with 
inter- and cross-sectoral 
cooperation 
• Lack of 
communication 
• Lack of mutual 
recognition 
Guidelines developed for 
single diseases were identified as 
very challenging when handling 
patients with multimorbidity, 
especially in relation to: 
• Medical complexity 
• Emerging new 
symptoms 
• Polypharmacy 
Current payment 
systems were criticized 
for not matching the 
treatment patterns of 
patients with 
multimorbidity 
• Mismatch 
between patients’ 
wishes and 
resources 
• Uncertainty about 
the GP’s role 
• Fits poorly with 
existing payment 
GPs found it challenging 
to establish a good 
dialogue and prioritize 
problems with patients 
within 
the timeframe of a 
normal consultation, 
especially if: 
• they lacked contextual 
knowledge 
• trying to prioritize 
between diseases  
• there were 
complicating 
Important role for GPs in 
diminishing health 
inequality was highlighted. 
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systems in some 
countries 
Psychosocial factors 
• they lacked time 
Loffler et al. 
 
  GPs and multimorbid patients often had relatively 
different priorities. Whereas GPs mostly focused on 
the management of diseases, patients put an 
emphasis on maintaining autonomy and a social life. 
 
 
Herrmann at 
al. 
Influences on prioritisation 
included: their own abilities 
with in the health system, 
communication between 
secondary and primary care and 
their respective influences on 
each other. 
Influences on prioritisation 
included: the evidence base. 
 Influences on 
prioritisation included: 
patient health literacy, 
patient safety, 
patient wishes, and 
quality of life. 
Focused on the influences 
on GPs as they prioritise 
medications in multimorbid 
elderly patients at the 
transition between inpatient 
and home care 
Junius-
Walker at al. 
GPs tended to view problems 
that they could not help with 
(i.e. social issues) as less 
important – and tried to direct 
responsibility for these matters 
to other agencies (family 
members or social care 
organisations) 
GP viewed problems directly 
linked with aging as less 
important than actively treatable 
medical conditions –the evidence 
base dictated what GPs 
prioritised for care. The provision 
of care is undermined by a lack 
of available treatment 
approaches for complex chronic 
illnesses and disabilities. 
GPs tend to prioritise 
treatable clinical 
conditions, that require 
active treatment or 
monitoring, or that 
induce empathy or 
awareness but cannot 
be assisted further. 
Patient empowerment 
strategies need to be 
developed to improve 
their input into the 
prioritisation of their 
illnesses.  
Relates multimorbidity to 
ageing and disability, and 
suggests that GPs’ 
perception of this overlap 
inhibits some aspects of 
how they care for 
multimorbidity. Highlights 
the need for 
multidisciplinary approach.  
Nuno-Solinis 
et al. 
Multimorbidity poses challenges 
that related to working in a 
"disease-centered" health 
system. This leads to daily issues 
in the co-ordination of care 
between healthcare settings. 
The management of 
polypharmacy is a challenge. 
There is a lack of decision-making 
tools appropriate for 
multimorbidity. 
The health system 
presents barriers to 
getting appropriate care 
for these patients. 
The patient-health 
professional relationship 
and clinical decision-
making are frustrated in 
multimorbidity due to 
health system 
structures. 
Highlights the need for 
agreement on what the 
most appropriate 
professional competencies 
in multimorbidity are, and 
training in these 
competencies. 
Sellappans 
et al. 
A lack of continuity of care and 
difficulties in prescribing for 
Difficulties in managing side 
effects caused by the patients' 
- Patients were less likely 
to follow primary care 
Focused on challenges in 
medication management 
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patients with multimorbidity 
due to a lack of communication 
among different healthcare 
professionals. Exacerbated in 
the Malaysian context due to 
rotations among family 
members of carer 
responsibilities. 
complex medication regimen, 
and identifying what the cause of 
side effects may be. 
physician’s advice on 
medications than 
specialist advice. 
Large variation in 
patients’ preferences 
and adherence made 
decision-making difficult. 
(i.e. adherence, lack of 
knowledge) and lack of 
communication within 
families that alternate caring 
for older patients.  
Schoenborn 
et al. 
Patients reacted to fragmented 
care by not attending for 
diagnostic tests or clinic visits. 
No mention was made of 
physician perceptions of 
fragmentation on the patients’ 
care. 
While medical evidence was 
occasionally discussed in 
consultations, no reference was 
made to the applicability of 
evidence to older patients with 
multimorbidity. Patients took the 
lead on stopping therapies from 
which they experienced no 
benefit. 
Physicians did not 
respond to patient 
comments on prognosis 
or life expectancy. Some 
efforts to enhance the 
clinical feasibility or 
reduce treatment 
burden were made.  
Patient preferences, if 
discussed, were mostly 
incorporated into the 
care plan.  
Found missed opportunities 
to address the guiding 
principles for the care of 
older adults with 
multimorbidity set out by 
the American Geriatrics 
Society Expert Panel.  
Gill et al. Frustrations expressed by family 
physicians 
included lack of access to 
appropriate care, poor 
communication, long wait times 
and lack of care co-ordination. 
- Physicians were unsure 
how to prioritize patient 
needs and felt that they 
lacked the appropriate 
resources to do so. 
Challenges included 
difficult symptoms, the 
inability to prevent 
crises, or diagnose 
conditions rapidly when 
these were confounded 
by other diseases, and 
lack of adherence. 
Not all physicians were 
frustrated in providing 
patient care, particularly if 
the patient was stable, or if 
the patient–caregiver unit 
organised their own care. 
Kuluski et al. Mobilising services for declining 
patients was a primary concern 
for physicians. 
- - Goals were often the 
same but discrepancies 
occurred in attempts to 
achieving those goals. 
Divergence of goals most 
likely when patients 
were less stable. 
Focused on goal-setting 
between patient, physician 
and carer 
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Appendix VIII. Research and clinical training undertaken during doctoral research 
Research training  
Sept 2015 Certificate in Professional Skills for Research Leaders 
 University College Cork and the Irish Management Institute. 
 
June 2015 Fellow on the 47th Ten Day International Teaching Seminar in 
Cardiovascular Disease and Prevention, June 2015. Hosted by 
Fiji National University and University of Cambridge 
 
Apr 2015  Postgraduate Certificate in Teaching & Learning for Higher 
Education 
  University College Cork. NFQ Level 9, 30 credits. 
 
March 2015  Development of Behavioural Change Interventions Workshop,  
  Centre for Behavioural Change, University College London 
 
Nov 2014  Health Economic Evaluation Workshop,  
  Department of Economics, University College Cork 
 
Jan 2014  Certificate in Behavioural Economics in Action, Rotman School 
of Management, University of Toronto (on-line programme) 
 
Jan 2013  Certificate in Health in Numbers: Quantitative Methods in 
Clinical & Public Health Research, Harvard School of Public 
Health, Harvard University (on-line programme)  
 
Nov 2013 Certificate in Clinical Research & Good Clinical Practice for 
Investigational Medicinal Products, Irish Clinical Research 
Infrastructure Network (ICRIN)  
 
Feb 2013  Introduction to Qualitative Interviewing,  
  Health Experiences Research Group,  
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 Department of Primary Care Health Sciences, University of 
Oxford 
 
2012  Postgraduate research training modules, University College 
Cork: 
  PG6001 Scientific Training for Enhanced Postgraduate Studies 
  PG7016 Systematic Reviews for the Health Sciences 
  PG6024 Qualitative Research Inquiry 
  EH6031 Advanced Epidemiology 
 
June 2012  Certificate in Cochrane Systematic Reviews,  
  Cochrane Review Training Course, Cork 
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Clinical training and professional development  
Nov 2015 Conferred with Membership of Irish College of General 
Practitioners 
 
July 2015  Certificate in Promoting Alcohol Reduction 
   Irish College of General Practitioners, Dublin 
 
Dec 2014  Certificate in Long-Acting Reversible Contraception (LARC)  
  Irish College of General Practitioners, Dublin 
 
Sept 2013  Certificate in Family Planning & Contraception 
  Irish College of General Practitioners, Dublin 
 
June 2013  Certificate in Methadone Treatment & the Management of Drug 
Users in General Practice 
  Irish College of General Practitioners, Dublin 
 
June 2012   Completion of Membership of the Irish College of General 
Practitioner Examinations (MICGP) 
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Appendix IX. Prizes and awards relating to doctoral research 
May 2015  Prize winner in Irish Times essay competition to celebrate 
International Clinical Trials Day 2015. Title: Clinical Trials Matter 
in General Practice. https://www.hrb-
tmrn.ie/news/competition-winners/ 
 
March 2015  Winner of the Professor William Shannon Prize, Association of 
University Departments of General Practice Annual Meeting for 
research presentation on “The association between adverse 
childhood experiences and multimorbidity” 
 
Dec 2014 Winner of the Sheppard Memorial Prize, awarded by the Royal 
College of Practitioners in Ireland for essay on “What to give the 
patient who has everything? A qualitative study of prescribing 
for multimorbidity in primary care” 
 
Nov 2014  Winner of Jacqueline Horgan Medal. Royal Academy of 
Medicine in Ireland, Section of Epidemiology & Public Health 
Medicine for research presentation on “The association 
between adverse childhood experiences and multimorbidity” 
 
Sept 2014   Early Career Researcher Award, Society for Social Medicine, 
Annual Scientific Meeting 2014, Keble College, University of 
Oxford. 
 
May 2014   Second prize winner (poster), European General Practice 
Research Network Scientific Meeting, Barcelona, 2014.  
 
June 2013  First prize winner, Irish College of General Practitioners 
Research & Audit Day, 2013. 
 
June 2012  Finalist in the Doctoral Showcase, University College Cork 
presenting thesis proposal and protocol  
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Appendix X. Dissemination of doctoral research 
Peer-reviewed publications  
Sinnott C, Mercer S, Payne R, Duerden M, Bradley C, Byrne M. Development of the 
Multimorbidit Collaborative Medication Review And Decision-making (MY COMRADE) 
intervention using the Behaviour Change Wheel. Implementation Science 2015, 10:132  
 
Sinnott C, Bradley CP. Multimorbidity or polypharmacy: two sides of the same coin? 
Journal of Comorbidity 2015;5:29–31 
 
Sinnott C, McHugh S, Fitzgerald AP, Bradley CP, Kearney PM. Psychosocial complexity in 
multimorbidity: the legacy of adverse childhood experiences. Family Practice (2015) 32 
(3): 269-275 
 
Sinnott C, McHugh SM, Boyce MB, Bradley CP. What to give the patient who has 
everything? A qualitative study of prescribing for multimorbidity in primary care. Br J 
Gen Pract. Mar 2015;65(632):e184-191. 
 
Sinnott C, McHugh S, Browne J, Bradley C. GPs' perspectives on the management of 
patients with multimorbidity: systematic review and synthesis of qualitative research. 
BMJ Open. 2013;3(9):e003610. 
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Peer-reviewed abstract publications  
Mellon L, McHugh SM, Sinnott C, Kearney PM. Adverse childhood experience and 
health service utilisation: findings from a primary care-based study. J Epidemiol 
Community Health 2015;69:A46 
 
Sinnott C, Mc Hugh S, Boyce M, Bradley C. PL02 Resolving conflicts in the multimorbid 
consultation: how do general practitioners balance diseases, drugs and the views of 
other doctors? Journal of Epidemiology and Community Health. September 1, 2014 
2014;68(Suppl 1):A3. 
 
Sinnott C, McHugh S, Bradley C. Informing intervention design in multimorbidity: An 
exploration of difficult decision making using chart stimulated recall. European Journal 
of General Practice. 2014;20(3):226. 
 
Sinnott C, Hugh SM, Browne J, Bradley CP. OP89 Challenges in Managing Multimorbid 
Patients: A Meta-Ethnography of the GPS Perspective. Journal of Epidemiology and 
Community Health. September 1, 2013 2013;67(Suppl 1):A41-A42. 
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Conference proceedings: oral presentations 
July 2015  Development of a prescribing intervention for multimorbidity. 
Society  of Academic Primary Care Annual Scientific Meeting, 
University of  Oxford, UK. 
 
June 2015  Research-led Teaching in Multimorbidity: The Power of Two.  
European Conference on the Scholarship of Teaching and 
Learning, University College Cork.  
 
May 2015  Implementing medication review for multimorbid patients.  
Global Implementation Conference (GIC) 2015,  
Conference Centre, Dublin, Ireland. 
 
March 2015   Psychosocial complexity in multimorbidity: the legacy of adverse  
childhood experiences. Association of University Departments 
of General Practice of Ireland. Winner, Professor William 
Shannon Prize 
 
March 2015  Chart-stimulated recall. A method for investigating complex care 
in primary care. Association of University Departments of  
   General Practice of Ireland. 
 
Nov 2014   More than the sum of single diseases: The association between 
   multimorbidity and adverse childhood experiences 
   Winner Jacqueline Horgan Medal meeting, Royal Academy of  
   Medicine in Ireland.  
 
Sept 2014  Resolving conflicts in the multimorbid consultation: How do GPs 
   balance diseases, drugs and the views of other doctors? 
Society for Social Medicine Annual Meeting, Oxford. 
Plenary presentation and high scoring abstract 
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July 2014  Resolving conflicts in the multimorbid consultation: How do GPs 
balance diseases, drugs and the views of other doctors?  
 Society of Academic Primary Care Annual Meeting, Edinburgh, 
Scotland. 
  
July 2014   Engaging GPs in clinical trials: Barriers and facilitators 
encountered in the Thyroid Hormone Replacement for 
Subclinical Hypothyroidism (TRUST) study. Society of Academic 
Primary Care Annual Meeting,  Edinburgh, Scotland. 
 
March 2014 A qualitative exploration of difficult decision-making in 
multimorbidity:  
Getting the pieces to fit. Association of University Departments 
of General Practice of Ireland, Annual Scientific Meeting, Cork. 
 
Sept 2013 GPs’ perspectives on the management of patients with 
multimorbidity: systematic review and synthesis of qualitative 
research. 
 Society for Social Medicine, Brighton, UK  
 
July 2013 GPs’ perspectives on the management of patients with 
multimorbidity: systematic review and synthesis of qualitative 
research. 
 Society of Academic Primary Care Annual Meeting, Nottingham, 
UK  
 
June 2013 GPs’ perspectives on the management of patients with 
multimorbidity: systematic review and synthesis of qualitative 
research. 
  First Prize Winner. Irish College of General Practitioners 
Research and Audit Conference.  
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Conference proceedings: poster presentations 
July 2015 Collaborative medication review: an approach for teaching 
multimorbid medication review in GP training. Society of 
Academic Primary Care Annual Scientific Meeting, University of 
Oxford, UK 
 
March 2015   Using Behavioral Theory To Develop A Prescribing Intervention 
   for Multimorbidity. Association of University Departments of  
   General Practice of Ireland, Belfast, Northern Ireland 
 
May 2014 Informing intervention design in multimorbidity: An exploration 
of difficult decision-making using chart stimulated recall.  
   European General Practice Research Network, Barcelona.  
       
Sept 2013  GPs’ perspectives on the management of patients with 
multimorbidity The International Training Programme on 
Ageing,  
 Trinity College, Dublin. 
 
Dec 2012  Challenges in managing multimorbidity: A meta-ethnography of 
the GPs’ experience.  
 North American Primary Care Research Group Annual Meeting, 
New Orleans, US. 
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Appendix XI. Additional academic activity during the conduct of this research 
Workshop presentations 
Nov 2015 “Why…How.. and Gim’me the Money!! Facilitating Research in 
Primary Care.” ICGP Winter Meeting, Athlone. 
 
Oct 2015 Developing behaviour change interventions for primary care. 
Annual Early Career meeting, Association of University 
Departments of Primary Care in Ireland, National University of 
Ireland, Galway. 
 
Oct 2015 Designing Behavioural Interventions in Chronic Disease, Irish 
Nephrology Society Annual Winter Meeting. Waterford Health 
Park, Waterford. 
 
Invited presentations  
Oct 2015 Invited Speaker, Irish Nephrology Society Annual Winter 
Meeting. Multimorbidity; What is it and why does it matter in 
nephrology? 
Waterford Health Park, Waterford. 
 
Sept 2015 Invited Speaker. The importance of ICD-10 coding in research 
and practice. SENATOR 4th General Assembly and Steering 
Committee Meeting, Ancona, Italy. 
 
Oct 2013 Invited speaker. Network of Establishing GPs – Cork Faculty.  
  “Opportunities and funding for research in General Practice.” 
 
Oct 2013  Invited Speaker. National Association of GP Trainees Annual  
 Meeting, Lyrath, Kilkenny. “How to get your abstract accepted 
into a research  conference.” 
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Book Chapters 
Chapter 3.13 Qualitative Interviewing Healthcare Research at a Glance. Wiley & Sons 
(in press)  
 
Research letters 
Sinnott C. Drug-disease and drug-drug interactions in "concordant" combinations. 
Response to Drug-disease and drug-drug interactions: systematic examination of 
recommendations in 12 UK national clinical guidelines. 
http://www.bmj.com/content/350/bmj.h949/rr-0 
 
Sinnott C. Clinical inertia and the role of continuity of care. Response to Depression and 
Clinical Inertia in Patients With Uncontrolled Hypertension 
JAMA Intern Med. 2014;174(5):818-819. doi:10.1001/jamainternmed.2014.115 
 
Sinnott C. Response to: Facilitated physical activity as a treatment for depressed adults: 
randomised controlled trial. http://www.bmj.com/content/344/bmj.e2758/rr/589073 
 
Sinnott C. Complexity rising? Response to Multimorbidity of chronic diseases and 
healthcare utilization in general practice. BMC Family Practice 2014, 15:61 
http://www.biomedcentral.com/1471-2296/15/61/comments 
 
Research Funding Awards 
Sept 2015 Strategic Fund Award, University College Cork 
 Awarded €980 to attend the International Training Fellowship in 
Cardiovascular Epidemiology and Prevention. 
 
Feb 2015  Irish Research Council New Foundations Award for Collaboration 
and Knowledge Exchange. Awarded €2513. 
 
May 2014 Irish College of General Practitioners’ Research Travel Bursary 
Fund  Awarded €500 
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Dec 2013  Irish Research Council New Foundations Award for 
Collaboration and Knowledge Exchange. Awarded €3868 euro. 
 
Dec 2012 College of Medicine and Health Student Doctoral Travel Bursary, 
  Graduate School, University College Cork. Awarded €1000 
 
Apr 2011 Health Research Board Ireland. Research funding for PhD 
project. Awarded €30,685 and three years of salary support. 
 
Conference organisation 
Conference title: Medication Optimisation for Multimorbidity.  
In September 2014, I hosted a conference in University College Cork, September 2014 
for the purposes of inter-disciplinary knowledge exchange on research on medication 
optimisation in multimorbidity. Researchers from the fields of pharmacy, general 
practice, health psychology and geriatric medicine were invited. The conference was 
attended by over thirty national and international researchers. I gained funding to 
support the conference from the Irish Research Council New Foundations Award. 
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Appendix XII. Links to published papers 
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complexity in multimorbidity: the legacy of adverse childhood experiences. 
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http://fampra.oxfordjournals.org/content/32/3/269.long 
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